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Summary 
 
 
The neuropeptide oxytocin (OT) plays a prominent role in the regulation of a variety of 
behavioral processes like maternal behavior, anxiety-, and stress-related behaviors as well 
as social behaviors. Due to the well-known link to psychiatric disorders associated with 
anxiety, fear, and socio-emotional dysfunctions, OT is considered a viable treatment option 
for these diseases (Neumann and Slattery, 2016). Despite the profound knowledge from 
various rodent (Blume et al., 2008; Jurek et al., 2015; Jurek et al., 2012) and human studies 
(MacDonald and Feifel, 2014; Meyer-Lindenberg et al., 2011) on the beneficial effects of 
acute or short-term OT applications, the impact of extended treatment duration on the 
behavioral outcomes and OT receptor (OTR) signaling cascades remains rather sparsely 
investigated (Neumann and Slattery, 2016). 
Thus, the thesis presented here aimed to unravel the molecular mechanisms and the 
behavioral effects that are caused by chronic OT. Intracerebroventricular infusions of a high 
dose of OT (10 ng/h) via osmotic minipumps for 14 days led to increased anxiety-related 
behavior in male rats, whereas a lower dose (1 ng/h) had no effect. Additionally, a strong 
sexual dimorphism was observable. Female rats showed increased anxiety levels induced 
by the low dose of chronic OT and a trend in the higher dose, suggesting a higher sensitivity 
of females to OT. 
On a molecular level, I identified a sex-specific signaling cascade mediating the observed 
chronic OT-induced anxiogenic phenotype. Chronic OT stimulated mitogen-activated 
protein kinase (MAPK) signaling via phosphorylation of the kinases mitogen-activated 
protein kinase kinase (MEK1/2) and the extracellular signal-regulated kinase 1/2 (ERK1/2), 
and recruited further downstream the transcription factor myocyte enhancer factor 2 
(MEF2). In more detail, dephosphorylation of the isoform MEF2A at the amino acid residue 
serine 408, a transcriptional inhibitory phosphorylation site, appeared to be the main player 
in chronic OT-induced anxiogenesis in male rats. Subsequent analysis of several stress-, 
anxiety-, and neuroplasticity-related MEF2-target genes revealed an involvement of the 
corticotropin releasing factor receptor 2 α (CRFR2α). In comparison to the CRFR1, CRFR2 
has overall anxiolytic properties, brain region- and stress-dependent anxiogenic effects 
have been previously observed, though (Dedic et al., 2018; Deussing and Chen, 2018)and 
references therein). I confirmed the anxiolytic properties of CRFR2 activity in the 
paraventricular nucleus (PVN) of the hypothalamus of male rats in an agonist/antagonist 
experiment under mild stress conditions. The close link between stress and the OT system 
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(Winter and Jurek, 2019)and references therein) was confirmed in my study, as the 
anxiogenic effect of chronic OT depended on a mild stressor 24 h prior to behavioral testing. 
The Crfr2 mRNA undergoes several alternative splicing events, resulting in two different 
isoforms in rodents (CRFR2α, CRFR2β) and an additional one in humans (CRFR2γ). I 
found changes in the expression of the brain-specific CRFR2α in male rats after chronic OT 
treatment. Not only was the expression of CRFR2α altered, but also an additional alternative 
splicing event of Crfr2α mRNA towards a shorter soluble isoform, sCRFR2α (Chen et al., 
2005; Evans and Seasholtz, 2009) could be linked to chronic OT infusions. I detected a shift 
from membrane-associated mCRFR2α expression towards cytoplasmic distribution and 
extracellular release of the soluble sCRFR2α caused by chronic OT. Manipulation of either 
mCRFR2α or sCRFR2α expression conferred anxiogenic properties to the splice variant 
sCRFR2α.  
Knockdown studies in vitro linked both the expression and alternative splicing of the 
CRFR2α to MEF2A activity. However, in females no activation of MEF2 and downstream of 
CRFR2α, and alternative splicing could be detected. Signaling via alternative MAPK targets 
is conceivable and deserves further investigation. 
Furthermore, with OT-induced changes in neuronal morphology shown in previous studies 
(Lestanova et al., 2016a; Meyer et al., 2018) as well as in this thesis, OT caused significant 
neurite retraction, and the behavioral consequences due to chronic administration of OT, 
treatment duration and dosage have to be considered carefully in a clinical context. 
The establishment of a new OTR knockout cell line by means of CRISPR-Cas9 enables 
further comparative signaling as well as morphological analysis. Here, the impairment of 
MAPK signaling and neurite retraction could be linked to the loss of the OTR. 
Overall, the presented data elucidate the differential behavioral as well as molecular 
consequences of acute versus chronic OT applications in rodents. It provides a general 
strategy for the analysis of neuropeptide effects both in vitro and in vivo and challenges the 
beneficial effects of OT and its status as a potential treatment option for psychiatric 
disorders. Treatment dosage, duration as well as the gender of the patients have to be 
taken into account. However, the newly discovered connection between anxiety and the 
soluble splice variant sCRFR2α might lead to new anamnesis and treatment approaches 
for anxiety disorders. 
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Zusammenfassung 
 
 
Das Neuropeptid Oxytocin (OT) spielt eine zentrale Rolle bei der Regulierung 
verschiedener Verhaltensabläufe. Sowohl mütterliches Verhalten, Reaktionen in 
Stresssituation als auch Sozialverhalten werden maßgeblich von OT beeinflusst (Jurek and 
Neumann, 2018). Daher rückte OT ebenfalls in den Fokus der Wissenschaft als ein 
mögliches Medikament für die Behandlung von psychischen Erkrankungen, wie 
Angststörungen (Neumann and Slattery, 2016). Der zugrundeliegende Wirkmechanismus 
von OT ist bereits gut erforscht. Zahlreiche Studien in Mäusen, Ratten (Blume et al., 2008; 
Jurek et al., 2015; Jurek et al., 2012), sowie in Menschen (MacDonald and Feifel, 2014; 
Meyer-Lindenberg et al., 2011) konnten bereits positive Verhaltenseffekte von OT zeigen. 
Die Aktivierung verschiedener Signalkaskaden, allen voran der mitogen-activated protein 
kinase (MAPK) Signalweg, konnten mit OT bereits in Zusammenhang gebracht werden. 
Allerdings haben sich bis jetzt nur wenige Studien mit den Langzeiteffekten einer OT-
Behandlung auseinandergesetzt. Das ist insbesondere von großer Bedeutung im Hinblick 
auf die potentielle Behandlung von autistischen Kindern mit OT (Neumann and Slattery, 
2016). 
Ziel der vorliegenden Arbeit war es, die Effekte einer chronischen OT-Behandlung sowohl 
auf molekularer Ebene als auch im Hinblick auf Verhaltensänderungen zu untersuchen. 
Männlichen und weiblichen Ratten wurden osmotische Minipumpen implantiert, welche 
über einen Zeitraum von 14 Tagen kontinuierlich zwei verschiedene Dosen (1 ng pro 
Stunde und 10 ng pro Stunde) OT in den Lateralventrikel abgaben. In beiden Geschlechtern 
konnte ich anschließend erhöhtes Angstverhalten in verschiedenen Verhaltenstests 
feststellen. Weibchen schienen sensitiver bereits auf die niedrigere Dosis (1 ng/h) zu 
reagieren, wohingegen in Männchen nur eine hohe Dosis OT (10ng pro Stunde) zu 
vermehrter Angst führte. Die nachfolgende molekulare Analyse der aktivierten 
Signalkaskaden zeigte auch hier geschlechtsspezifische Unterschiede. Die starke 
angstfördernde Wirkung, die die hohe Dosis in Männchen hervorgerufen hat, basiert auf 
einer Aktivierung des MAPK Signalwegs durch die Phosphorylierung der Kinasen MEK1/2 
und nachfolgend ERK1/2. Dies wurde auch bereits in Zusammenhang mit akuter OT Gabe 
gezeigt (Blume et al., 2008; Jurek et al., 2015; Jurek et al., 2012). Weiterführende 
molekularbiologische Untersuchungen zeigten dann allerdings gravierende Unterschiede 
zwischen einer akuten und einer chronischen Gabe von OT auf. Chronische OT-
Behandlung führte zur Aktivierung des Transkriptionsfaktors myocyte enhancer factor 2 
(MEF2). Dieser verfügt über verschiedene Isoformen (MEF2A, B, C und D) und kann an 
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vielfältigen Aminosäuren phosphoryliert werden, was unterschiedliche Effekte auf die 
Transkription der Zielgene hat. Je nach Phosphorylierungsstelle kann die Transkription 
entweder aktiviert oder inhibiert werden. Insbesondere ein reduzierter 
Phosphorylierungsgrad von MEF2A an der Aminosäure Serin 408 scheint an der 
Verhaltensänderung durch hochdosiertes chronisches OT beteiligt zu sein. 
Phosphorylierung an dieser Stelle führt in der Regel zur Inhibierung nachfolgender 
Transkription. In diesem Fall wird durch verminderte Phosphorylierung die Expression und 
das alternative Spleißen der corticotropin releasing factor receptor 2 α (Crfr2α) mRNA 
verstärkt. Je nachdem in welcher Gehirnregion dieser Rezeptor aktiviert wird und abhängig 
von der Stresssituation, hat er angstlösende oder angstfördernde Eigenschaften. Durch 
gezielte Aktivierung und Blockierung konnte ich eine angstlösende Funktion dieses 
Rezeptors im Paraventrikulären Nukleus (PVN) des Hypothalamus von männlichen Ratten 
feststellen. Dabei waren die Ratten leichten, kurzfristigen Stressbedingungen ausgesetzt. 
Wie bereits erwähnt, ist auch das alternative Spleißen dieses Rezeptors von chronischem 
OT betroffen. Dies hat zur Folge, dass mehr von einer löslichen, kleineren Spleißvariante 
(sCRFR2α) produziert wird, welche nicht nur im PVN, sondern auch in der zerebrospinalen 
Flüssigkeit nachgewiesen werden konnte. Bis jetzt war die Funktion dieser Spleißvariante 
weitgehend unbekannt. Durch gezielte Manipulation auf mRNA Ebene konnte ich jedoch 
ihre angstfördernden Eigenschaften nachweisen. Außerdem konnte ich durch 
weiterführende in vitro Studien die vermehrte Expression von sCRFR2α und die veränderte 
Aktivität von MEF2A direkt in Zusammenhang stellen und einen Einfluss von OT auf die 
Morphologie von Neuronen feststellen. 
Die Signalkaskade von OT über MAPK Aktivierung, reduzierte MEF2A Aktivität und 
anschließendes alternatives Spleißen konnte jedoch nur in männlichen Ratten 
nachgewiesen werden, was eine geschlechtsspezifische Regulierung nahelegt. Im Hinblick 
auf OT als mögliches Medikament für psychische Erkrankungen ist es unbedingt nötig, den 
genauen Mechanismus auch in Weibchen zu untersuchen, um optimierte 
Behandlungspläne für weibliche und männliche Patienten zu erstellen. 
Um weitere molekularbiologische Untersuchungen der Signalkaskaden zu erleichtern, 
wurde eine OTR Knockout Zelllinie generiert. Erste Analysen zeigten bereits verminderte 
Aktivität des MAPK Signalweges, als auch Verlust der charakteristischen Änderungen der 
Morphologie, die Stimulationen mit OT normalerweise auslösen. 
Zusammengefasst trägt die hier vorgelegte Arbeit zu einem besseren Verständnis sowohl 
der molekularen Signalwege als auch der Veränderungen auf Verhaltensebene bei, welche 
von chronischer OT-Behandlung hervorgerufen werden. Es zeigten sich gravierende 
Unterschiede im Vergleich zu akuter OT Behandlung, die für die weitere Entwicklung von 
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OT als Medikament für psychische Erkrankungen berücksichtigt werden müssen. Die hier 
aufgezeigte Herangehensweise zur Analyse von chronischen Effekten kann 
verallgemeinert auch als Basis für Studien an anderen Neuropeptiden herangezogen 
werden. 
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Abbreviations 
 
 
acOT acute OT 
ACTH adrenocorticotropic hormone 
ANOVA analysis of variance 
ASD autism spectrum disorder 
ASO antisense oligonucleotides 
ASV antisauvagine-30 
AVP arginine-vasopressin 
BNST bed nucleus of the stria terminalis 
bp base pairs 
BRET bioluminescence resonance energy transfer 
BSA bovine serum albumin 
CA closed arm 
CaMK Ca2+/Calmodulin activated kinase 
cAMP cyclic adenosine monophosphate 
Cas CRISPR-associated 
cDNA complementary DNA 
cFOS cellular- Finkel-Biskis-Jinkins murine osteosarcoma virus 
homologue 
cOT chronic OT 
CREB cAMP response element-binding protein 
CRF corticotropin releasing factor 
CRF-BP corticotropin releasing factor binding protein 
CRFR1/2 corticotropin releasing factor receptor 1/2 
CRISPR clustered regularly interspaced short palindromic repeats 
crRNA CRISPR-RNA 
CRTC CREB transcriptional co-activator 
CSF cerebrospinal fluid 
DAG 1,2-diacylglycerol 
DB dark box 
dbcAMP dibutyryl-cAMP 
ddH2O double-distilled H2O 
DMEM/F-12 Dulbecco’s modified eagle medium F-12 
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DSB double-strand break 
ECD extracellular domain 
ECL extracellular loop 
EDTA ethylenediaminetetraacetic acid 
e.g. exempli gratia 
EGFR epidermal growth factor receptor 
EPM elevated plus maze 
ERK1/2 extracellular signal-regulated kinase 1/2 
ERK5 extracellular signal-regulated kinase 5 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
GABA γ-aminobutyric acid 
GC glucocorticoid 
GDP guanosine diphosphate 
GFP green fluorescent protein 
GPCR G protein-coupled receptor 
GR glucocorticoid receptor 
GRK G protein-coupled receptor kinases 
GTP guanosine triphosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPA hypothalamic-pituitary-adrenal 
i.c.v. intracerebroventricular 
In/Del insertion/deletion 
i.e. id est 
IP3 inositol 1,4,5,-triphosphate 
IZ inner zone 
JNK c-Jun-N-terminal kinase 
kb kilobase 
KD knockdown 
KO knockout 
LB light box 
LDB light-dark box 
LDCV large-dense core vesicles 
MADS MCMI, Agamous, Deficiens and Serum response factor 
MAP microtubule-associated proteins 
MAPK mitogen-activated protein kinase 
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mCRFR2α membrane-bound CRFR2α 
MEF2 myocyte enhancer factor 2 
MEK1/2 mitogen-activated protein kinase kinase 
MMEJ microhomology-mediated end joining 
mRNA messenger RNA 
MSK mitogen and stress activated kinase 
MβCD methyl-ß-cyclodextrin 
NHEJ non-homologous end joining 
NLS nuclear localization sequence 
NMD nonsense-mediated decay 
NMDAR N-methyl-D-aspartate receptors 
OA open arm 
OFT open field test 
OT oxytocin 
OTR oxytocin receptor 
OtrIN Otr interneurons 
p phospho 
p38 protein 38 kDa 
PAM protospacer adjacent motif 
Pax paired box 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PFA para-formaldehyde 
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIP2 phosphatidylinositol 4,5-biphosphate 
PKA protein kinase A 
PKC protein kinase C 
PLC phospholipase C 
PPT polypyrimidine tract 
PTC premature termination codon 
PVN paraventricular nucleus of the hypothalamus 
Rab4/5 Ras-related in brain 4/5 
Ras rat sarcoma 
RNP ribonucleoprotein 
rpm revolutions per minute 
RSK ribosomal protein S6 kinase 
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RT room temperature 
RT-PCR reverse transcription PCR 
S serine 
SCP stresscopin 
scr scrambled 
sCRFR2α soluble CRFR2α 
SEM standard error of the mean 
siRNA small interfering RNA 
SNARE soluble N-ethylmaleimide-sensitive factor attachment receptor 
snRNP small nuclear RNP 
ssDNA single-stranded DNA 
TALEN transcription activator-like effector nuclease 
TBS tris(hydroxymethyl)aminoethane-buffered saline 
TBST TBS supplemented with 0.1 % Tween-20 
TGOT Thr⁴, Gly⁷-OT 
Th tyrosine hydroxylase 
Thr 
TMD 
threonine 
transmembrane domain/helix 
TMH transmembrane helix 
tracrRNA trans activating CRISPR-RNA 
TRPV2 transient receptor potential vanilloid type-2 Ca2+ 
TSB target site blocker 
UCN urocortin 
VEH vehicle 
VGCC voltage-gated Ca2+ channels 
ZFN zink finger nuclease 
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Introduction 
 
 
1. Anxiety 
 
“What is an emotion?” This fundamental question was already asked by William James 135 
years ago (James, 1884); however, there are no scientific concepts that directly match the 
totality of all facets of emotions. This variety requires various models to approach the 
complexity and the components of emotions. From an ethological perspective, anxiety is a 
highly adaptive and complex response. Only appropriate conditions and correct stimuli 
guarantee the desired intensity and persistence of the behavior in various vertebrate 
species. Anxiety-related behaviors require time and effort for the successful reaction to the 
plethora of threats living organisms have to face. Dysregulations in intensity, persistence, 
or response to an incorrect stimulus are some of the sources for insufficiency in anxiety 
systems (Blanchard et al., 2008). 
In humans, the Diagnostic and Statistical Manual of Mental Disorders (DSM V, American 
Psychiatric(Association, 2013) defines 12 subtypes of anxiety disorders, namely separation 
anxiety disorder, selective mutism, specific phobia, social anxiety disorder (social phobia), 
panic disorder, panic attack specifier, agoraphobia, generalized anxiety disorder, 
substance/medication-induced anxiety disorder, anxiety disorder due to another medical 
condition, other specified anxiety disorder, and unspecified anxiety disorder. Despite the 
high prevalence and burden of anxiety disorders (Wittchen et al., 2011), treatment remains 
relatively elusive. Research on the molecular and neurocircuit background of anxiety 
disorders has progressed substantially, nevertheless no mechanistically new treatment 
options have been brought to the market within the last two decades. Standard first-line 
treatments are selective serotonin-reuptake inhibitors and serotonin-norepinephrine 
reuptake inhibitors. Second line and other treatments include tricyclic antidepressants, like 
Clomipramine, monoamine oxidase inhibitors, benzodiazepines, and anticonvulsants 
(Hoffman and Mathew, 2008; Murrough et al., 2015). Other viable candidates for the 
medication of anxiety disorder that emerged are neuropeptides, like the corticotropin 
releasing factor (CRF,(Baldwin et al., 1991; Dunn and File, 1987; Holsboer, 1999; Holsboer 
and Ising, 2008), the neuropeptide Y (Heilig, 2004; Sorensen et al., 2004) or the 
endocannabinoid system. Here, several new “druggable” targets are investigated for the 
alleviation of anxiety disorders. For review see (Patel et al., 2017). The neuropeptide 
oxytocin (OT) is well known for its anxiolytic, antistress, reproductive, and prosocial effect. 
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The impact on anxiety and the treatment of anxiety disorders will be discussed in more 
detail in the following chapters (see 2. The oxytocin system,(Neumann and Slattery, 2016). 
 
 
1.1. Animal models to study anxiety 
To fully understand the fundamentals of anxiety from neural circuits to molecular signaling, 
appropriate animal models are indispensable. In this context, rodents like mice or rats have 
proven to be suitable model organisms (reviewed in(Calhoon and Tye, 2015). Classical 
assessment of anxiety-related behavior includes approach-avoidance assays, like the 
elevated plus maze (EPM;(Pellow et al., 1985; Pellow and File, 1986), the open field test 
(OFT;(Hall and Ballachey, 1932) or the light-dark box (LDB;(Ambrogi Lorenzini et al., 1984). 
These tests are based on the conflict between the innate drive of the animals to explore 
new contexts and the impulse to avoid bright, open and exposed areas. Other approaches 
to measure anxiety-related behavior are active-avoidance tests like the shock probe burying 
and the marble burying test. Hyponeophagia, measuring the amount and latency of food 
intake in a novel environment, can be addressed by the novelty-suppressed feeding test 
(Deacon, 2011). Concluding, social behaviors are assessed by social tests like ultrasonic 
vocalization and social interaction (for detailed review see(Blanchard et al., 2008). 
In this study, anxiety and the effects of OT and manipulation of the CRFR2α on anxiety 
were assessed by EPM, LDB, and OFT. To investigate the social component of the 
treatments, social preference (Lukas et al., 2011) was additionally measured. 
 
 
1.2. Molecular underpinnings of anxiety and anxiety disorders 
To fully understand the formation of anxiety disorders, knowledge of the underlying genetic 
and environmental factors is crucial. In recent years, several genes involved in the 
regulation of anxiety were identified (Hovatta and Barlow, 2008). Although anxiety and other 
psychiatric disorders are most likely triggered by the combination of a large number of 
common and rare variants with only small effect size, several risk factors are standing out 
(Sokolowska and Hovatta, 2013). Just to mention few of them, variants of the glutamic acid 
decarboxylase 2 have been associated with panic and phobic anxiety (Lydiard, 2003; 
Smoller et al., 2001), regulator of G protein signaling is related to anxiety, introversion 
personality traits, and panic disorder (Okimoto et al., 2012; Sokolowska and Hovatta, 
2013)and references therein), and peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha emerged as a novel candidate gene for anxiety disorders (Hettema et 
al., 2011). Studies in mice revealed that glyoxalase 1 expression was increased in anxious 
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mouse strains (Hovatta et al., 2005). In addition to these factors, genes encoding for various 
neuropeptides are involved in the regulation of anxiety, like CRF (Maras and Baram, 2012), 
neuropeptide Y (Giesbrecht et al., 2010), neuropeptide S (Ionescu et al., 2012),  arginine-
vasopressin (AVP), and OT (Neumann and Landgraf, 2012). Acute treatment with OT has 
well studied beneficial effects on anxiety-like behavior (Blume et al., 2008; Jurek et al., 2015; 
Jurek et al., 2012; Martinetz et al., 2019; Neumann et al., 2000c; Okimoto et al., 2012; 
Pedersen and Boccia, 2002; Slattery and Neumann, 2010; Sobota et al., 2015; Waldherr 
and Neumann, 2007). However, profound knowledge on the intracellular signaling 
downstream of the OT receptor (OTR) induced by chronic OT treatment remains elusive 
and is the major part of the work presented here. 
 
 
 
2. The oxytocin system 
 
The neuropeptide OT and the closely related AVP were first described in 1895 as extracts 
of the pituitary gland with vasopressor and uterine-contracting properties. Due to these 
properties, OT was named after the Greek words for “quick birth” (reviewed in(Jurek and 
Neumann, 2018). The nonapeptide OT consists of the amino acids Cys-Tyr-Ile-Gln-Asn-
Cys-Pro-Leu-Gly (Fig. 1) and is synthesized in the magno- and parvocellular neurons of the 
hypothalamic paraventricular nucleus (PVN), the supraoptic nucleus, and the accessory 
nuclei (Mohr et al., 1988; Sofroniew, 1983). As a secondary structure, OT forms a loop via 
a disulfide bond between the two cysteine amino acids (Busnelli et al., 2016). After storage 
in large-dense core vesicles (LDCV), distribution and release occur via axonal projections 
(Knobloch et al., 2012) as well as local dendritic release and diffusion (Gimpl and 
Fahrenholz, 2001; Jurek and Neumann, 2018; Landgraf and Neumann, 2004; Meyer-
Lindenberg et al., 2011). Release from axon terminals is mediated by exocytosis, requiring 
depolymerization of F-actin and the soluble N-ethylmaleimide-sensitive factor attachment 
receptor (SNARE) complex to open the fusion pore. Exocytosis during axon terminal as well 
as dendritic release of OT is Ca2+ dependent which originates from various sources to 
trigger dendritic release. Extracellular Ca2+ can enter the cell via voltage-gated Ca2+ 
channels (VGCCs), ionotropic glutamate receptors including N-methyl-D-aspartate 
receptors (NMDARs), or intracellular Ca2+ levels are directly supplied from intracellular Ca2+ 
stores and Ca2+ buffering mechanisms (Ludwig et al., 2016; Ludwig et al., 2002). 
Additionally, recruitment of intracellular Ca2+ also occurs via OT-OTR binding and the 
subsequent activation of transient receptor potential vanilloid type-2 Ca2+ channels 
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(TRPV2,(van den Burg et al., 2015). Depending on the stimulus, OT either acts as a rapid 
neurotransmitter released from axon terminals (Dabrowska et al., 2011) or as a 
neuromodulator which is released from dendrites, soma, or non-terminal axonal regions 
(Tobin et al., 2012). In contrast to fast neurotransmission, OT can reach and bind nearby or 
remote receptors via diffusion through the extracellular fluid and thereby exert its effects 
(Neumann and Landgraf, 2012). However, recent studies support a new model of OT 
actions via focused axonal release (Chini et al., 2017)and references therein). 
Despite broad evidence for a coordinated central and peripheral release of OT, plasma 
levels are only of limited suitability as a global biomarker for the activity of the central OT 
system, mainly due to the separation by the blood-brain barrier. However, diffusion between 
extracellular fluid and the ventricular cerebrospinal fluid (CSF) allows conclusions from CSF 
OT levels to central release (Landgraf and Neumann, 2004; Neumann and Landgraf, 2012). 
 
 
 
Figure 1. Structure of the nonapeptide OT, consisting of a cyclic part of six amino acids that are being 
connected with a disulfide bridge between cysteine 1 and cysteine 6. The linear part consisting of a prolin, 
leucine and glycine is terminated by an amidated COOH terminus (Jurek and Neumann, 2018). 
 
 
In both rodents and humans, OT plays a key role for the regulation of social behaviors 
including pair bonding, sexual behavior, maternal care as well as the ability to form normal 
social attachments (Bosch et al., 2005; Carter et al., 1992; Kosfeld et al., 2005; Waldherr 
and Neumann, 2007; Young et al., 2001). Moreover, several studies have proven that acute 
OT applications show anxiolytic and stress-protective effects in rodents and humans (Jurek 
and Neumann, 2018). In this regard, the pharmacogenetic manipulation of the brain OT 
system in rats and mice attenuates the response of the hypothalamic-pituitary-adrenal 
(HPA) axis, reduces anxiety, and improves stress-coping (Amico et al., 2004; Neumann et 
al., 2000a; Neumann and Landgraf, 2012; Windle et al., 1997). The brain regions involved 
in mediating those effects are within amygdala and septal regions, the raphe nucleus, and 
the hypothalamic PVN (Guzman et al., 2013; Jurek et al., 2012; Knobloch et al., 2012; 
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Neumann et al., 2000a; Yoshida et al., 2009). In summary, OT exerts a plethora of central 
actions, like anxiolytic and antidepressive effects, and peripheral actions, including milk 
ejection, uterine contractions, parturition, and lactation (Ludwig et al., 2016; Neumann and 
Landgraf, 2012). In humans, intranasal application of OT for pharmacological and 
therapeutic reasons is thought to have effects on e.g. fear, anxiety, trust, rejection, empathy, 
and pro-social effects have been documented as well (Veening and Olivier, 2013). 
Additionally, cardiovascular effects of OT have been described, resulting in e.g. nitric oxide 
stimulation and therefore cardioprotective effects (Jurek and Neumann, 2018; MacDonald 
and Feifel, 2014). 
 
 
2.1. Oxytocin and anxiety 
Because of the widespread occurrence of psychosocial stress in modern societies causing 
somatic diseases, depression, and anxiety-related disorders (reviewed in(Jurek and 
Neumann, 2018) on the one hand, and the missing spectrum of treatment options on the 
other hand, novel approaches are desperately needed, for which neuropeptides like OT are 
viable candidates. As already mentioned above, OT is involved in the regulation of anxiety 
and has been linked to the treatment of anxiety disorders in several studies (reviewed 
in(Neumann and Slattery, 2016). Apart from the effects of the endogenous OT system on 
anxiety during lactation or sexual activity (Neumann and Slattery, 2016), acute 
administration of synthetic OT into various brain regions, including PVN exerts a robust 
anxiolytic phenotype (Blume et al., 2008; Jurek et al., 2012). In the prefrontal cortex, OTR 
interneurons (OtrIN) expressing the CRF binding protein (CRF-BP) are responsible for 
sexually dimorphic anxiety-related behavior. Activation of OtrIN in male mice was anxiolytic, 
whereas in females it had a prosocial effect. Li and coworkers identified the underlying sex-
specific molecular mechanism, explaining the behavioral differences between males and 
females (Li et al., 2016). Not only these brain regions play a critical role in the regulation of 
anxiety-related behaviors, anxiety cells in the ventral CA1 region of the hippocampus were 
recently shown to be activated by anxiogenic stimuli. These cells project to the lateral 
hypothalamic area and thereby control anxiety-related behavior. Learned fear remained 
unaffected as anxiety cells displayed no projections to the basal amygdala (Jimenez et al., 
2018). A recent study in prairie voles illustrated the close relationship between OT and 
stress, as OT infusions prior to a stressful situation inhibited stress activation of the HPA 
axis by the activation and release of γ-aminobutyric acid (GABA) in the PVN (Smith et al., 
2016). 
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Chronic treatment with exogenous OT, however, exerts differential effects. The first studies 
on continuous central infusions of OT via osmotic minipumps revealed decreased OTR 
binding throughout the brain (Insel et al., 1992) as well as enhanced social interactions of 
male rats treated with chronic OT for 10 days and female stimulus animals (Witt et al., 1992). 
With regard to anxiety-related behavior, chronic OT for 5 days at 3 different concentrations 
(1, 10, or 100 ng/h) had no effect on female ovariectomized rats unless a mild stressor was 
applied on the day of testing on the EPM; the highest dose of OT (100 ng/h) in combination 
with the mild stressor was then anxiolytic (Windle et al., 1997). Furthermore, chronic OT is 
also able to attenuate the stress response. 30 min restraint-induced release of 
adrenocorticotropic hormone (ACTH), corticosterone, and the increase in Crf, and cFos 
mRNA was reduced in female rats infused with 1 or 10 ng/h intracerebroventricularly (i.c.v.) 
OT for 5 days (Windle et al., 2004). In rats specifically bred for high anxiety, a high dose of 
chronic OT (10 ng/h over 6 days) attenuated the level of anxiety in female, but not male rats 
(Slattery and Neumann, 2010). Consequently, these rather neutral to beneficial effects of 
chronic OT seem to be highly time dependent as short-term (up to 7 days) treatment 
regimens seem to be less adverse. In detail, 7-day chronic OT treatment (10 ng/h) did not 
alter anxiety-like behavior in the OFT or EPM in male rats (Havranek et al., 2015), whereas 
an extended treatment duration of 14 days increased anxiety-like behavior in male mice 
(Peters et al., 2014). The behavioral and molecular consequences of such long-term 
treatment have not been assessed in male and female rats so far, and are the main subject 
of this thesis. 
 
 
2.2. Oxytocin and stress 
Stress and the OT system are very closely linked, as parvocellular OT neurons, projecting 
towards the brainstem, the spinal cord, or the supraoptic nucleus, belong to neuronal 
circuits interacting with CRF neurons in the PVN. Stress-induced CRF release and the 
subsequent activation of the HPA axis are likely to be accompanied by OT release. 
However, the exact dynamics of stress-induced OT release are less clear (Ebner et al., 
2005; Wotjak et al., 1998). As an example, CRF-induced ACTH synthesis is potentiated by 
OT (Engelmann et al., 2004; Gibbs, 1986; Gibbs et al., 1984; Lang et al., 1983; Suh et al., 
1986). Then, ACTH induces the synthesis and release of glucocorticoids (GCs) which are 
able to cross the blood-brain barrier, where they bind to glucocorticoid receptors (GR) in the 
PVN or hippocampus. By nuclear translocation, the GC-GR complex binds to its responsive 
element in the CRF promoter region and thereby reduces CRF gene transcription 
(Jeanneteau et al., 2012; Winter and Jurek, 2019). In that way, OT dampens the stress 
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response by amplification of the HPA-axis’ inherent negative feedback loop. OT also has a 
direct impact on CRF gene expression, in more detail it was found to delay Crf gene 
transcription induced by restraint stress. CREB transcriptional co-activator (CRTC3), a 
cofactor of the cyclic adenosine monophosphate (cAMP) response element-binding protein 
(CREB) is translocated to the nucleus following stressful stimuli, to stimulate Crf 
transcription. OT was shown to interfere with CRTC3 translocation, whereas CREB and 
CRTC2 activation remain unaffected by OT (Jurek et al., 2015). A second, indirect 
regulation of CRF neuronal activity is constituted by GABAergic inhibition that occurs under 
basal conditions and silences CRF neurons. The synaptic interaction of magnocellular OT 
neurons with parvocellular CRF neurons enhances this effect, resulting in oxytocinergic 
inhibition of Crf mRNA levels in the PVN (reviewed in(Winter and Jurek, 2019). This effect 
was shown in prairie voles, where the OT-induced anxiolysis is triggered by promoted 
GABAergic inhibition of CRF neuronal activity (Smith et al., 2016). The reciprocal 
expression of OTR-CRF and OT-CRFR in distinct neuronal populations of the PVN, and the 
bed nucleus of the stria terminalis (BNST) underscores the close connection between the 
OT- and the CRF-system (Dabrowska et al., 2011; Dabrowska et al., 2013). CRF is not the 
only member of the CRF family interacting with OT. For the CRF-BP a sexually dimorphic 
mechanism was proposed, as expression of the CRF-BP on OtrIN inhibits the activation of 
2/3 pyramidal cells in the prefrontal cortex of male mice only, causing anxiolysis (Li et al., 
2016). CRFR1 activation was shown to be anxiogenic in lactating and virgin female rats 
accompanied by the release of OT in the hypothalamic preoptic area (Klampfl et al., 2018). 
For the CRFR2, differential effects could be observed depending on the brain region 
involved, and stress-levels experienced (Bale et al., 2002b). In addition, release of OT in 
the dorsolateral BNST is modulated by CRFR2 activity (Martinon and Dabrowska, 2018). In 
this thesis, I provide evidence for the so far unknown impact of OT on PVN CRFR2 
expression and activity under mild stress conditions. 
 
 
2.3. Oxytocin receptor signaling 
All effects of OT described in the previous chapters are consequences of interaction of OT 
with its receptor and further downstream signaling. The OTR is located on chromosome 3 
with 4 exons and 3 introns with an overall length of 17 kilobases (kb), encoding for a 388-
amino-acid polypeptide (Inoue et al., 1994; Kimura et al., 1992). Two different transcripts 
were identified in breast tissue (3.6 kb), and in ovary, uterine endometrium, and 
myometrium (4.4 kb,(Kimura et al., 1992). Detailed splicing patterns within the brain remain 
to be investigated. The precise gene structure has been described for various species 
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including humans (Inoue et al., 1994), mice (Kubota et al., 1996), and rats (Rozen et al., 
1995). The receptor belongs to the G protein-coupled receptor (GPCR) family and ranks 
among the rhodopsin-type (class I) receptors and consists of seven transmembrane α-
helices connected by 3 extracellular and 3 intracellular loops (Fig. 2,(Gimpl and Fahrenholz, 
2001; Jurek and Neumann, 2018). 
 
 
 
Figure 2. Schematic representation of the OTR structure. 
The OTR is a seven-transmembrane helix (TMH1–7) receptor with three extracellular loops (2–7) and three 
intracellular loops (1–6, adapted from(Jurek and Neumann, 2018). 
 
 
Factors that regulate OTR expression include transcription factors, estrogens, 
progesterone, OTR promoter methylation, micro RNAs, and, with limited evidence, ligand 
availability. The OTR is widely distributed in diverse brain areas (reviewed in(Jurek and 
Neumann, 2018). 
Multiple pathways have been shown to be linked to OTR signaling. Basis of all OTR-
mediated effects is classical G (guanine nucleotide-binding) protein-coupled signaling. 
OTRs are coupled to 3 G proteins, namely the Gα and Gβ/γ subunit, whose activation is 
mediated by the exchange of guanosine diphosphate (GDP) to guanosine triphosphate 
(GTP). A recent study identified the connection between OT concentrations and the 
activation of different G protein subunits. The development of a BRET-based biosensor 
enabled the determination of the EC50 values for the different G proteins. Low 
concentrations of OT (2 nM) activate Gq proteins, whereas high ligand concentrations of 90 
nM activate GoB as shown in Figure 4 (Busnelli and Chini, 2018; Busnelli et al., 2012). 
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Figure 3. Concentration-dependent G protein-coupling of the OTR. 
Depending on ligand availability, the OTR couples to different G-proteins. Those G-proteins induce either 
activating (Gq, GoA/B) or dampening (Gi1,2,3) signaling cascades, with ligand concentrations ranging from 2 to 90 
nM. Higher concentrations likely cross-activate the vasopressin receptor too (Busnelli and Chini, 2018). 
 
 
Ligand availability but more importantly the duration of stimulation are crucial factors in 
GPCR-mediated signaling. Upon agonist stimulation, OTRs undergo desensitization and 
internalization processes, in which almost 85 % of OTR return to the cell surface within 4 h 
(Conti et al., 2009). The first step in this process is the uncoupling from G proteins after 
phosphorylation by GPCR kinases (GRK). Binding of β-arrestins mediates the removal from 
the plasma membrane by endocytosis. In the case of resensitization, the receptors are 
recycled to the cell surface, whereas degradation leads to downregulation (Conti et al., 
2009; Gimpl and Fahrenholz, 2001; Grotegut et al., 2011). For the OTR, a complete 
internalization was observed within 30 min after agonist application. Longer exposure time 
up to 18 h leads to a loss of 50 % of high-affinity receptors on the cell surface. Recycling 
was mediated via the “short cycle” involving proteins called Ras-related in brain 4/5 
(Rab4/Rab5,(Conti et al., 2009). Internalization of OTR occurs mostly via a clathrin-
dependent pathway. In more detail, phosphorylation by GRK2 protein kinase promotes 
subsequent binding to β-arrestin and endocytosis via clathrin-coated pits (Conti et al., 2009; 
Gimpl and Fahrenholz, 2001). However, agonist (Carbetocin)-binding can also induce β-
arrestin-independent internalization of the OTR (Passoni et al., 2016), which leads to 
differential downstream cascade activation. Due to the structural similarities between AVP 
and OT, binding of OT is not limited to the OTR but also occurs at AVP receptors (Akerlund 
et al., 1999), whereby differences in signaling could be attributed to flexible receptor 
interactions. Another well-known agonist to study specific receptor-mediated effects is Thr⁴, 
Gly⁷-OT (TGOT,(Lowbridge et al., 1977). 
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One pathway includes two Gα isoforms Gαq and Gα11 which are, together with Gβ/γ, both able 
to activate phospholipase C-β (PLC) subunits, causing the hydrolysis of phosphatidylinositol 
4,5-biphosphate (PIP2), which results in two products, inositol 1,4,5,-triphosphate (IP3) and 
1,2-diacylglycerol (DAG). Finally, protein kinase C (PKC) is stimulated by DAG, whereas 
IP3 enhances Ca2+ release from intracellular stores. Ca2+-dependent signaling includes, 
among others, downstream cascades like calmodulin-dependent protein kinases (CaMKII, 
CaMKIV) and Calcineurin (Busnelli and Chini, 2018; Gimpl and Fahrenholz, 2001; Jurek 
and Neumann, 2018)and references therein). The second pathway involves the Gi/Go 
family, consisting of Gαi1, Gαi2, Gαi3, GαoA, and GαoB. Gαi activates phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) as well as the mitogen-activated protein kinase (MAPK) 
pathway via the inhibition of adenylyl cyclase and the reduction of cAMP levels (Busnelli 
and Chini, 2018; Busnelli et al., 2012). In more detail, MAPK activation occurs via 
transactivation of the epidermal growth factor (EGFR,(Blume et al., 2008), followed by 
recruitment of the membrane-associated proto-oncoprotein GTPase Rat sarcoma (Ras). 
Ras via Ras proto-oncogene serine/threonine-protein kinase (Raf-1) triggers a chain 
reaction to ultimately fully activate the MAPK pathway. The three main kinases are 
extracellular signal-regulated kinase (ERK1/2), p38, and c-Jun NH2-terminal kinase 
(JNK1/2/3), the latter not being affected by OTR signaling. ERK1/2 phosphorylation occurs 
upon mitogen-activated protein kinase kinase (MEK1/2) activation in a cell- and tissue-
specific manner, however, evidence also suggests other MEK1/2 targets, independent of 
the canonical ERK1/2 pathway (Jurek et al., 2012), including PPARγ, MyoD, PI3K, or 
LIMKinase 1 (Brandt et al., 2010; Burgermeister et al., 2007; Jo et al., 2011). Other ERK 
substrates include mitogen and stress activated kinases (MSK) and the ribosomal protein 
S6 kinase (RSK,(Jurek and Neumann, 2018). 
Well-known downstream targets of MAPK signaling are the transcription factors myocyte 
enhancer factor 2 (MEF2, for more details see chapter 5.) and CREB with its cofactors 
CRTC2/3 (Jurek et al., 2015; Tomizawa et al., 2003). However, the pathways mentioned 
here cannot be considered independently, as inhibition of OT-induced Ca2+ influx has 
deleterious effects on MAPK signaling in hypothalamic cells (van den Burg et al., 2015), 
indicating an initial role of Ca2+ for further second messenger signaling. For an overall 
summary of OTR signaling, both proven as well as hypothetical see Figure 4. 
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Figure 4. Schematic summary of neuronal OTR signaling. 
The 7 transmembrane GPCR OTR (shown here as OXTR) transactivates the TRPV2 cation channel and the 
EGFR, leading to Ca2+-dependent and -independent signaling. Kinases translocate from the cytoplasm to the 
nucleus and activate a set of transcription factors, which orchestrate transcription as a complex. Kinases and 
transcription factors in blue represent cascades that have been proven to be coupled to the neuronal OTR, 
kinases in gray are hypothetical or shown to be coupled to peripheral OTRs (adapted from(Jurek and Neumann, 
2018). 
 
 
In summary, OT concentration, G protein expression, OTR membrane availability, and as 
a last factor OTR affinity states that are addressed in the next chapter determine the quality 
and quantity of OTR-mediated signaling. 
 
 
2.4. Impact of cholesterol on oxytocin receptor activity 
OTR receptors occur in two different affinity states, the low-affinity state (Kd > 100 nM) and 
the high-affinity state (Kd < 1-5 nM,(Gimpl et al., 1995). Transitions between those affinity 
states are reversible and depend on cholesterol content in the plasma membrane (Gimpl et 
al., 1995; Klein et al., 1995). In general, membranes in cellular systems are known to appear 
as lipid bilayers. The “fluid mosaic model”, as originally suggested by Singer and Nicholson, 
has become, with minor modifications, the standard model of membrane structure (Singer 
and Nicolson, 1972). Specific areas within membranes, so-called “lipid rafts” are dynamic 
microdomains that are capable of moving within the fluid bilayer. Those rafts are 
                                                                                                                            Introduction 
34 
 
sphingolipid- and cholesterol-enriched and contain ordered aggregations of membrane-
bound signaling proteins. The whole complex represents a membrane-bound anchor, which 
plays an important role during signal transduction as “transduction platform” (Simons and 
Ikonen, 1997; Simons and Toomre, 2000). Cholesterol, as one of the most abundant 
components of membranes (Liscum and Underwood, 1995), is of great significance for the 
integrity of lipid microdomain structures like caveolae and the already mentioned lipid rafts 
(Incardona and Eaton, 2000; Simons and Toomre, 2000). OTR agonist binding affinity 
states s strongly depend on cholesterol contents in the membrane (Gimpl and Fahrenholz, 
2000; Reversi et al., 2006; Wiegand and Gimpl, 2012). 
On the one hand, OT inhibits cell growth and proliferation in a PI3K-dependent MAPK 
cascade activation, when the majority of OTRs are excluded from lipid rafts and caveolae. 
On the other hand, strong PLC-independent mitogenic effects appear when OTRs are 
located within caveolae, induced by fusion to caveolin-2, a resident raft protein (Reversi et 
al., 2006; Rimoldi et al., 2003). Upon removal of cholesterol from the membrane via methyl-
ß-cyclodextrin (MßCD), the OTR was found to be shifted to the low-affinity state, whereas 
high-affinity binding states could be regained by cholesterol enrichment via cholesterol- 
MßCD. Interestingly, restoring could not be achieved by other steroids, suggesting a 
specific and direct dependency of the OTR on cholesterol (Klein et al., 1995). Additionally, 
OTR stability and conformation is strongly influenced by the location in cholesterol-rich 
domains (Muth et al., 2011). 
 
 
 
3. The CRF system 
 
Stress is a major environmental factor contributing to the formation of psychiatric disorders. 
The 3 physiologists Claude Bernard, Walter B. Cannon, and Hans Selye are considered as 
the pioneers of stress biology. Their work was the basis for the concept of 
neuroendocrinology, including the autonomic nervous system and the HPA axis as the key 
players in the stress response. While the ANS represents the rapid response towards a 
stressor, the HPA-axis modulates this response in duration and frequency (reviewed 
in(Deussing and Chen, 2018). 
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3.1. CRF family members 
The primary structure of the master regulator of the HPA axis, CRF was first identified in 
1981 as a 41 amino acid peptide (Vale et al., 1981), while the evidence for an ACTH 
releasing mediator already existed since 1955 (Selye, 1955). CRF is synthesized in 
parvocellular neurons of the hypothalamus and triggers the release of ACTH into the 
systemic circulation (Rivier and Vale, 1983; Smith and Vale, 2006; Vale et al., 1981). Upon 
ACTH release, synthesis, and secretion of GCs from the zona fasciculata of the adrenal 
cortex are promoted. GCs are then responsible for the regulation of a variety of physiological 
adaptations when binding to their cognate intracellular receptors (Bamberger et al., 1996; 
Munck et al., 1984; Smith and Vale, 2006). Furthermore, CRF regulates the ANS-mediated 
stress response and is also able to directly modulate behavioral stress responses (Deussing 
and Chen, 2018)and references therein). CRF and a group of 3 related proteins called 
urocortins (UCN), UCN1, UCN2 (also called stresscopin-related peptide), and UCN3 (also 
called stresscopin) elicit their function via binding to two different class B family of G-protein 
coupled receptor subtypes, the corticotropin releasing factor receptors 1 and 2 (CRFR1, 
CRFR2,(Hillhouse and Grammatopoulos, 2006; Lewis et al., 2001; Reyes et al., 2001; 
Vaughan et al., 1995). These receptors contain a large extracellular domain at the N-
terminus and are able to bind large peptide ligands (Deussing and Chen, 2018). CRF and 
UCN1 preferentially bind to the CRFR1, while UCN2 and UCN3 bind the CRFR2 with higher 
affinities (Hillhouse and Grammatopoulos, 2006). CRFRs mainly signal via coupling to Gs 
proteins, followed by the activation of protein kinase A (PKA) and MAPK-ERK pathways 
and the mobilization of Ca2+. Activation of ERK1/2 via PLC and for example Gqα is also 
possible. Internalization and desensitization of CRFR1 and CRFR2 is mostly β–arrestin-
mediated. Additionally, receptor activity can be modulated by carboxy-terminal PDZ-domain 
interactions. Binding to PDZ-domains regulates the cellular location of the receptors and 
attributes them to larger signaling complexes (Henckens et al., 2016)and references 
therein). In rodents, there are two isoforms of CRFR2 (α and β) and three in humans (α, β, 
and γ) arising from separate promoters and 5´ exons which splice to a common set of 
downstream exons (Chen et al., 2005; Kostich et al., 1998). The CRF-BP regulates the 
activity of CRF and UCN1 by the binding between both factors. It represents a regulatory 
capturing function that might partially act in a CRFR2-dependent manner, however, the 
precise mechanism is unknown (Deussing and Chen, 2018; Eckart et al., 2001; Huising et 
al., 2008; Karolyi et al., 1999). 
Both receptors and ligands are widely distributed throughout the brain (Fig. 5). High levels 
of CRFR1 are found in the anterior pituitary, olfactory bulb, cerebral cortex, hippocampus, 
and cerebellum. The mammalian brain variant CRFR2α is located in the lateral septum, 
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BNST, ventral medial hypothalamus, raphe nuclei, and choroid plexus (Chalmers et al., 
1995; Lovenberg et al., 1995; Van Pett et al., 2000). 
 
 
 
 
 
Figure 5. Distribution of CRF, UCN1-3, CRFR1, CRFR2, and CRF-BP mRNA expression in the rodent 
brain. Scheme taken from Deussing and Chen, 2018. Please note that in the lower scheme, PVN expression 
of CRFR2 seems to be absent, however, the data presented in this thesis and the according manuscript (Winter 
et al, in preparation) proves CRFR2 expression in the PVN. 
 
 
3.2. Ligand-receptor interaction 
Binding affinities of the CRFR1 and CRFR2 are different for CRF and the related UCNs 
(Fig. 6). These differences are mainly determined by the extracellular domain (ECD) of the 
receptors, but also the extracellular loops (ECL) and the transmembrane domain (TMD) 
contribute to the specificity of interactions. Within the N-terminus, amino acid residues 43-
50 and 76-84 play an important role in ligand binding specificity. The ECD and the TMD are 
linked by an amino acid segment close to the first TMD that is also essential for ligand 
Ligand distribution 
Receptor distribution 
                                                                                                                            Introduction 
37 
 
binding. Furthermore, interactions with the ECLs determine ligand binding specificity, as 
Arg189 mediates binding within the first ECL for the CRFR1, whereas His189 mediates binding 
to the CRFR2. 
Additionally, glycosylation influences both ligand binding specificity and signal transduction 
for the CRFR1 as well as the CRFR2. The highly specific interaction between UCN2/UCN3 
and the CRFR2 is attributed to several amino acid residues. For example, Pro11, Ala35, and 
Ala39 are uniquely found in those ligands specifically binding to the CRFR2. In general, 
active ligands consist of 3 main parts. The N-terminal domain, important for receptor binding 
and activation, the central binding domain, where the CRF-BP interacts, and the C-terminus 
that mediates ligand affinity and specificity (Deussing and Chen, 2018)and references 
therein). For both CRFR1 and CRFR2, several splice variants have been identified 
however, only one functional splice variant of the CRFR1 is expressed in the central nervous 
system. Alternative splicing of the CRFR2 is further described in Chapter 4. The importance 
of the CRFR1 for stress-related behavior was supported by several knockout (KO) studies. 
Loss of CRFR1 causes chronic GC deficiency, accompanied by reduced anxiety-related 
behavior and impairments in remote fear memory consolidation. Additionally, conditional 
KO of the CRFR1 in the forebrain lessens stress-induced dendritic remodeling and spine 
loss (reviewed in(Dedic et al., 2018). 
 
Figure 6. Interactions between CRFR1, CRFR2, and the ligands CRF, UCN1, UCN2, and UCN3. 
The potential role of the CRF-BP as a CRF/UCN1-capturing protein is also depicted (adapted from(Deussing 
and Chen, 2018). 
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3.3. The CRFR2 and its role in anxiety 
Studies on the deletion of CRFR2 yield a less clear picture compared to CRFR1. The first 
3 conventional CRFR2 KO mouse models revealed normal development of the HPA axis 
but a hypersensitive response of the HPA axis to stress. Anxiety-like behavior was 
increased compared to wild-type mice. Both Ucn and Crf mRNA levels were elevated in the 
Edinger-Westphal nucleus and central amygdala, respectively (Bale et al., 2000). The effect 
of CRFR2 deletion or antagonism on baseline anxiety appears the be sex-specific, as the 
anxiogenic phenotype only occurred in male CRFR2 KO mice but not in females (Kishimoto 
et al., 2000). Despite the normal development of the HPA axis, CRFR2 is involved in the 
maintenance of the HPA axis drive and the recovery phase of the HPA response. CRFR2 
KO mice display elevated corticosterone levels up to 90 min after stress, in contrast to an 
early termination of ACTH release (Coste et al., 2000). Impaired stress recovery was also 
seen in a triple KO mouse, lacking UCN1, UCN2, and UCN3 (Neufeld-Cohen et al., 2010). 
A more recent study demonstrated that the anxious phenotype of those KOs depends on 
stress levels. CRFR2 KO mice display increased anxiety-like behavior 24 h after acute 
restraint stress. However, there were no immediate effects after acute restraint stress as 
well as after chronic stress in KO compared to wild-type males (Issler et al., 2014). 
Furthermore, stress-levels, ligand dosage, and brain region are crucial for the impact of 
CRFR2 activity on anxiety (Bale et al., 2002a; Todorovic et al., 2007). Under low-stress 
conditions, only a relatively high dose of UCN2 in the septum increased anxiety-like 
behavior, whereas under high-stress conditions, also lower doses induced anxiety-like 
behavior (Henry et al., 2006). CRFR2-positive cells in the lateral septum exert GABAergic 
projections to the anterior hypothalamus. These outputs enhance stress-induced anxiety 
and promote persistent anxious behaviors, representing a LS circuitry that promotes stress-
induced persistent anxiety (Anthony et al., 2014). Antagonism of the CRFR2 with 
antisauvagine-30 (ASV) also causes differential anxiety-related phenotypes (Hammack et 
al., 2003; Takahashi et al., 2001). The precise dosage of ASV is essential, as high 
concentrations might trigger non-CRFR2-mediated effects (Zorrilla et al., 2013). 
As already mentioned, UCN2 (Hammack et al., 2003; Valdez et al., 2002) or UCN3 (Valdez 
et al., 2003) administration and the subsequent activation of the CRFR2 has anxiolytic 
effects in mice and rats. Moreover, CRFR2 activity is also thought to be related to the 
serotonergic system (Hammack et al., 2003; Pernar et al., 2004). Application of UCN2 into 
the dorsal raphe nucleus increased cFOS expression in a subpopulation of serotonergic 
neurons. However, the precise mechanism behind the effects of UCN and CRFR2 within 
the serotonergic system remains elusive (Dedic et al., 2018). The serotonergic system is 
also important for stress-recovery. The CRFR2 mediates the proper functioning of serotonin 
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(5-HT1A) receptors, as the KO attenuates 5-HT receptor responses in the dorsal raphe 
nucleus (Issler et al., 2014). In addition to the consequences for anxiety-like behavior, 
CRFR2 activity also affects social behaviors. KO of either CRFR2 or UCN3 in mice 
decreases the preference for novel conspecifics and impairs their ability to cope with 
socially challenging situations (Shemesh et al., 2016). Members of the CRF family, like 
UCN3, also exhibit in combination with OT, profound effects on long-term potentiation in the 
rat medial amygdala (Frankiensztajn et al., 2018). Furthermore, blocking of CRFR1 
signaling disrupts stress-induced hippocampal tau phosphorylation, a key factor of 
Alzheimer’s disease development. On the contrary, loss of CRFR2 promotes these effects 
(Rissman et al., 2007). 
The generation of different CRFR1 and CRFR2 subforms is mediated by alternative 
splicing. A mechanism that is found throughout eukaryotes and provides extensive protein 
diversity. 
 
 
 
4. Alternative splicing 
 
Alternative splicing is one of many processes that regulate gene expression, and therefore 
leads to increased protein diversity. In eukaryotes, genes contain protein-coding sequences 
(exons) interrupted by non-coding segments (introns,(Berget et al., 1977; Chow et al., 1977; 
Sharp, 1994, 2005). The removal of introns or alternative exons is mediated by a large 
ribonucleoprotein (RNP) complex, called the spliceosome. The spliceosome mediates RNA 
cleavage and ligation which are the crucial steps of splicing (Lee and Rio, 2015; Wahl et 
al., 2009; Will and Luhrmann, 2011). With a number of almost 25.000 genes in the human 
genome, but around 90.000 proteins being expressed, alternative splicing represents an 
essential mechanism for diversity in humans, and generally, in mammals (International 
Human Genome Sequencing, 2004). In fact, around 95 % of human genes undergo 
alternative splicing. Originally discovered simultaneously with constitutive splicing itself 
(Gilbert, 1978), there are various types of alternative splicing known today. The most 
important one for my study is exon skipping, where one so-called cassette exon is either 
included in the final mRNA or alternatively skipped. This mechanism is based on the 
formation of the spliceosome, consisting of small nuclear RNAs and small nuclear 
ribonucleoprotein particles (snRNP). The spliceosome machinery (U1, U2, U4, U5, and U6) 
assembles on the mRNA, particularly at the 5’ splice site (GU), the 3’ splice site (AG), and 
the branch point, upstream of the polypyrimidine tract (PPT). First, U1 forms a base-pairing 
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interaction with the 5’-splice site, whereas U2 base-pairs with the branch-point. Then, a tri-
snRNP complex containing U4, U5, and U6 associates with the forming spliceosome, 
removing U1 and U4. This leads to two transesterification reactions and joins the exons, 
excluding the intermediate exon (Fig. 7,(La Cognata et al., 2014). 
In addition to exon skipping, various other patterns of alternative splicing contribute to the 
variety of mature mRNA variants. In more detail, alternative 5′ splice sites are additional 
donor sites and thereby enable different exon lengths at the 3’ end. Alternative 3’ splice 
sites function as additional acceptor sites changing the 5’ end of the exon. Alternative 
promoters and alternative 3′ exons lead to different mature mRNA variants by altering the 
first and last exons, respectively. In the last exon, 3’ untranslated regions of different lengths 
can be created by alternative polyadenylation (Li et al., 2007; Vuong et al., 2016). These 
mechanisms are the basis for the different transcripts of the OTR gene as well as for the 
generation of CRFR1 and CRFR2 splice variants. In sheep, alterations in mRNA sequence 
of the OTR can be observed and are most likely due to alternative use of polyadenylation 
sites. This represents the first link between alternative splicing and the OTR (Feng et al., 
2000). 
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Figure 7. Basic principle of splicing in eukaryotes. 
(A) The 5’ splice site (donor sequence) is attacked by the 2’OH group of the adenosine at the branching point. 
(B) The released 3’OH group attacks the downstream 3’ splice site (acceptor sequence). The intron forms a 
lariat RNA structure. (C) 5’ and 3’ exons are joined, the intermediate intron is released into degradation (adapted 
from(Seyffert, 2003). 
 
 
4.1. Alternative splicing of the CRFR2α 
The CRFR2 exists as multiple splice variants as described in chapter 3.3. Additional to 
CRFR2α and CRFR2β (in rodents), and CRFR2γ (humans), another splice variant was 
discovered recently. It derives from the CRFR2α pre-mRNA, which is translated into a 143-
aa soluble protein, consisting of the first ECD of the CRFR2α followed by a unique 38-aa 
hydrophilic C-terminus. The loss of exon 6 causes a frameshift that leads to a premature 
termination codon (PTC) in exon 7, ahead of sequences encoding for the transmembrane 
domain (Fig. 8). Hence, the protein is hypothesized to be released in a soluble form, called 
sCRFR2α. The sCRFR2α is hypothesized to function as a decoy receptor, however proper 
                                                                                                                            Introduction 
42 
 
endoplasmic reticulum translocation and trafficking requires expression of the first TMD 
(Rutz et al., 2006). Evans and Seasholtz confirmed the efficient translation of sCrfr2α 
mRNA. However, the sCRFR2α protein is not trafficked via the secretory pathway but rather 
released by free diffusion through the nucleus pores (Evans and Seasholtz, 2009). 
Major sites of cellular expression, as shown by immunohistochemistry, include the olfactory 
bulb, cortex, midbrain, and the pituitary. Moderate expression of sCRFR2α was found in the 
PVN of the hypothalamus, while major sites of CRFR2α expression include the lateral 
septal-, midbrain raphe-, ventromedial hypothalamic-, and medial amygdaloid nuclei (Chen 
et al., 2005). Due to the intact ECD1, ligand binding activities remained functional. 
Interaction studies of sCRFR2α with ligands from the CRF family revealed binding of UCN2 
and UCN3 with low affinities, whereas binding of CRF and UCN1 occurred with nanomolar 
affinities, inhibiting the cAMP response to CRF and UCN1 in a dose-dependent manner, 
and the phosphorylation of ERK1/2 by UCN1 (Chen et al., 2005). 
 
 
 
Figure 8. Genomic structure of the Crfr2 gene. 
The Crfr2 consists of 14 exons (upper panel), gray boxes represent translated segments and white boxes 
indicate untranslated regions. The middle panel depicts the mRNA for the alternative splice variant CRFR2α, 
including exon 3 to exon 14. sCrfr2 mRNA consists of exon 3 to exon 7, with a PTC in exon 7, and a unique C-
terminal end (figure adapted from(Evans and Seasholtz, 2009). 
 
 
Alternative splicing is not only a mechanism to increase proteomic diversity, but also a 
potent on- and off switch in gene expression by causing reading frameshifts or the 
introduction of PTCs. Both events would normally lead to the degradation of the mRNA by 
nonsense-mediated decay (NMD), as alternative splicing and NMD have shown to be 
closely linked (da Costa et al., 2017). However, the sCRFR2α mRNA is not targeted for 
NMD, leading to the synthesis of a functional protein (Evans and Seasholtz, 2009), which 
has also been shown for other mRNA variants containing a PTC (Denecke et al., 2004; 
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Dreumont et al., 2005; Ge et al., 2016). This thesis and other studies contribute to the 
investigation of the function of the sCRFR2α and why its mRNA escapes NMD. 
 
 
4.2. Neural splicing regulatory networks 
Apart from its specific role in sCRFR2 expression, alternative splicing plays an important 
role in the central nervous system as it is involved in neurogenesis, the regulation of 
neuronal migration, synaptogenesis, cell survival, the regulation of synaptic function, and 
has been further linked to neurodegenerative disorders (Vuong et al., 2016). An important 
splicing factor, nSR100, regulates expression of target genes by inclusion of a neural-
specific exon in the transcription factor REST/NRSF. Studies on the knockdown (KD) of 
nSR100 have revealed impaired neurite outgrowth and neurodevelopmental defects (Raj 
and Blencowe, 2015; Raj et al., 2011). So far, no studies have assessed the significance of 
alternative splicing for OTR expression. However, different transcripts found in breast and 
ovary tissue (Kimura et al., 1992), and alternative polyadenylation patterns (Feng et al., 
2000) indicate a link between OTR and alternative splicing. 
Other factors linked to splicing/alternative splicing are transcription factors. Interestingly, 
splicing and alternative splicing can occur co-transcriptionally, meaning all splicing 
processes are tightly coupled to RNA polymerase II transcription (Kornblihtt et al., 2004). 
All steps are influenced by each other and coordinated by transcription (Proudfoot et al., 
2002). Notably, in neural cells and tissues so-called microexons of 3- to 15 nucleotides 
length have higher inclusion frequencies compared to standard alternative exons. For 
example, by the inclusion of microexons, members of the transcription factor family MEF2 
are converted into more potent transcriptional activators during neurogenesis (Raj and 
Blencowe, 2015). 
 
 
 
5. MEF2 family of transcription factors 
 
MEF2s are a group of transcription factors (Edmondson and Olson, 1989) belonging to the 
MADS-box family of transcription factors, whose name is ascribed to the initials of the 
originally identified members MCMI, Agamous, Deficiens, and Serum response factor 
(Shore and Sharrocks, 1995). Originally discovered in muscle cells, MEF2 occurs in 4 
different isoforms, namely MEF2A, B, C, and D, which share high homology in both the 
amino-terminal MADS domain that mediates DNA binding and the MEF2-specific domain. 
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This domain affects the affinity of DNA binding and the interaction with cofactors. In contrast 
to that, C-terminal transcription activation domains of the MEF2 factors exhibit more 
sequence variation (Fig. 9,(Black and Olson, 1998; Brand, 1997). The consensus DNA 
binding sequence for MEF2 is CTA(A/T)4TAG/A, where MEF2 proteins can bind as homo- 
or heterodimers (Andres et al., 1995; McKinsey et al., 2002; Molkentin and Olson, 1996; 
Potthoff and Olson, 2007). 
The regulation of MEF2 activity is orchestrated by multiple phosphorylation-, sumoylation-, 
and acetylation sites. Phosphorylation sites of direct transcriptional activation include 
MEF2A Threonine 312 (Thr312) and Thr319 as well as MEF2C Serine 387 (S387). In 
contrast, phosphorylation at MEF2A S408 promotes sumoylation, which prevents 
acetylation and is ultimately transcriptional inhibitory. Also, phosphorylation of MEF2C at 
S396 induces sumoylation at Lysine 391 and thereby inhibits transcriptional activity. 
Phosphorylation at MEF2C S59 enhances DNA binding activity (Molkentin et al., 1996b). 
Tissue-specific alternative splicing and tissue-specific expression patterns of the 4 different 
MEF2 isoforms provide highly specific gene activation in different cell types and tissues 
(reviewed in(Brand, 1997). Locations of the highest MEF2 expression include striated 
muscle and brain tissue (Edmondson et al., 1994). 
 
 
 
Figure 9. Structure of MEF2 with protein interaction domains indicated (adapted from(McKinsey et al., 
2002). The MADS domain defines the protein as a member of the MEF2 family and is evolutionary highly 
conserved. The MEF2 domain defines the MEF2 variant as either A, B, C, or D. The transcription activation 
domain is highly variable among species (less than 7% similarity between H. sapiens and C. elegans) and MEF2 
variants (McKinsey et al., 2002). 
 
 
5.1. MEF2 signaling cascades 
MEF2 is known to be a central regulator of the three major routes of a cell: cell division, 
differentiation, or death. The activation of diverse genetic programs involved in 
differentiation, proliferation, morphogenesis, survival, and apoptosis is influenced by MEF2. 
Signaling towards MEF2 is derived from two main pathways, the MAPK pathway and 
calcium signaling (Potthoff and Olson, 2007). MEF2 is a well-studied downstream target of 
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the MAPK pathway, interacting with p38 and ERK pathways (Dodou and Treisman, 1997; 
Kato et al., 2000; McKinsey et al., 2002). Most prominently, MEF2C is presumed to be a 
p38-binding protein (Han et al., 1997), but there are also known interactions between MEF2 
proteins and the extracellular signal-regulated kinase 5 (ERK5(Devost et al., 2008; Kato et 
al., 2000; Yang et al., 1998) as well as ERK1/2 (Meyer et al., 2018). One mechanism that 
mediates calcium signaling is the phosphorylation of class II histone deacetylases (HDACs) 
by several calcium-regulated protein kinases, including CAMKs. In turn, phosphorylation of 
class II HDACs regulates MEF2 activity (Lu et al., 2000; McKinsey et al., 2002; Potthoff and 
Olson, 2007). Another calcium-dependent effector is calcineurin, which activates MEF2 via 
recruitment of NFAT proteins (Blaeser et al., 2000). In neurons, calcineurin was shown to 
dephosphorylate MEF2A at S408, which causes a switch from sumoylation to acetylation 
at Lysine 403 (Flavell et al., 2006; Mao and Wiedmann, 1999) and is also involved in OT-
induced neurite retraction (Meyer et al., in preparation). Furthermore, expression of MEF2A 
(Ramachandran et al., 2008) and MEF2C (Wang et al., 2001) itself is controlled by 
autoregulation. 
MEF2 signals then act on a variety of tissues and cell types, like smooth muscle, skeletal 
muscle, cardiac muscle, neural crest cells, endothelial cells, chondrocytes, lymphocytes, 
and neurons (Fig. 10). 
 
 
Figure 10. MEF2 signal inputs and downstream effects in various tissues and cell types (Potthoff and 
Olson, 2007). 
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5.2. MEF2 functions in the brain 
Regions of highest MEF2 expression in the brain are the cerebellum, the cerebral cortex, 
and the hippocampus (Potthoff and Olson, 2007). MEF2 is involved in synapse regulation 
and neuronal survival (Mao et al., 1999), dendrite morphogenesis, controlling excitatory 
synapse formation in hippocampal neurons during development (Flavell et al., 2006; Flavell 
et al., 2008), and in memory formation and learning-induced spine formation (Barbosa et 
al., 2008; Cole et al., 2012; Vetere et al., 2011). Furthermore, it was identified as a risk-
gene for autism spectrum disorder (ASD(Li et al., 2008; Morrow et al., 2008), but not anxiety. 
The loss of MEF2 proteins exhibits severe effects on synapse number. This was shown for 
MEF2C, where deletion of MEF2C during postnatal development of mice significantly 
increased the number of spines in the hippocampus. Learning and memory, however, were 
not affected (Adachi et al., 2016). The balance between excitatory and inhibitory neurons 
during development also relies on MEF2C. Conditional deletion of MEF2C during 
embryogenesis promotes inhibitory synaptic transmission, causing a severe reduction in 
cortical network activity (Harrington et al., 2016). A brain-specific triple knock out mouse for 
MEF2A, C, and D led to decreased brain size, impaired synaptic plasticity and increased 
neuronal apoptosis causing an early death (Akhtar et al., 2012; Akhtar et al., 2009). 
However, double KO of MEF2A and D neither affected neuronal survival nor altered anxiety-
related behavior in the OFT, indicating a partially complementary role of MEF2A and C (Li 
et al., 2008; Molkentin et al., 1996a). 
 
 
5.3. Interplay between MEF2 and oxytocin 
All MEF2 isoforms are subjected to controlled phosphorylation by MAPK signaling (Han et 
al., 1997; Kato et al., 2000; Zhao et al., 1999), which is activated by OT (Jurek and 
Neumann, 2018). OTR activation and MEF2 were linked by the dependency of MEF2 
activation by ERK5 (Devost et al., 2008). Furthermore, MEF2 is downstream of MEK1/2 as 
mentioned above and is phosphorylated by OT in vitro (Meyer et al., 2018). Having 
established that MEF2 is involved in synapse regulation and neuronal survival, in the 
regulation of excitatory synapses, in memory formation and learning as well as a risk-gene 
for ASD (for references see chapter 5.2.), it is interesting to note that each of these 
phenomena have also been linked to OT activity. For example ASD (Parker et al., 2014), 
spatial memory formation during motherhood (Tomizawa et al., 2003), anti-apoptotic 
functions, proliferation, and neural differentiation (Jafarzadeh et al., 2014; Leuner et al., 
2012; Raymond et al., 2006) or control over GABA synapse development during delivery 
(Tyzio et al., 2006) are closely connected with the OT system. OT-induced neurite retraction 
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is mediated by the dephosphorylation of MEF2A at S408 via MEK1/2 activity as well as 
calcineurin signals, bridging the gap between OTR signaling, MEF2 activity, and neuronal 
morphology (Meyer et al., 2018; Meyer et al., in preparation). The behavioral impact of OT-
activated MEF2 signaling and a more detailed analysis of downstream signaling of MEF2 
was the main focus of this thesis. 
 
 
 
6. Neuronal morphology and its regulation 
 
To understand the function and structure of the nervous system, knowledge of neuronal 
morphology and functional connectivity is essential (Luo, 2002). Changes in neuronal 
morphology exert their impact from intracellular signaling to complex emotional behavior. 
 
 
6.1. Definition of neuronal morphology 
Neurons possess two different types of neurites: axons and dendrites, which are 
morphologically and functionally distinct. Axons extend over long distances and form 
presynaptic terminals originating from their growth cones. Dendrites extend over shorter 
distances and often undergo extensive branching, generating so-called dendritic trees. 
Dendrites interact with axons at their presynaptic terminals and thereby create functional 
synapses. Small protrusions on dendrites are called spines, forming mostly excitatory 
synapses in the mammalian brain. Changes in the cytoskeleton are the basis for changes 
in neuronal morphology. Navigation of neuronal processes is mediated by actin 
microfilaments, whereas microtubules are responsible for neurite growth. Dynamics of 
microtubules responsible for neurite growth are regulated by the microtubule-associated 
proteins (MAPs), in the mammalian brain mostly MAP2 (Goldberg, 2003; Luo, 2002; 
Mandelkow and Mandelkow, 1995). Intermediate filaments support proliferation and 
differentiation (Lin and Szaro, 1995), one important factor here is nestin (Hendrickson et al., 
2011; Lestanova et al., 2016b). 
 
 
6.2. Neuropeptides and the regulation of neuronal morphology 
Growing evidence suggests the involvement of neuropeptides in the regulation of neuronal 
growth, neurite extension, and retraction. Neuropeptide signaling via GPCRs acts on the 
organization of the neuronal cytoskeleton by activating PKC pathways as well as by Ca2+-
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mediated signaling (reviewed in(Lestanova et al., 2016a). GPCR activity, mediated by all G 
proteins is involved in the regulation of neurite extension and retraction (Karunarathne et 
al., 2013). OT has emerged as an outstanding effector for neuronal morphology. OT leads 
to neurite retraction in the rat hypothalamic cell line H32 in a time- and dose-dependent 
manner. Neurite retraction is under the control of MAPK signaling, as a MEK1/2 inhibitor 
abolished the OT-induced effect. Further downstream, the transcription factor MEF2A and 
reduced phosphorylation at S408 account for the morphological effects (Meyer et al., 2018). 
Interestingly, sex differences in OT effects can be traced back to cellular levels. In human 
cells derived from a female donor, OT causes neurite elongation in comparison to male 
Be(2)M17 cells. SH-SY5Y cells have significantly longer neurites after long-term treatment 
with OT and higher nestin expression levels, whereas MAP2 expression remained 
unchanged (Lestanova et al., 2016b). OT and OTR ligand exposure have regulatory effects 
on both MAP2 and nestin expression, indicating a potential role for OT as growth factor for 
neuronal cells (Bakos et al., 2013). However, these effects appear to be not only sex- but 
also cell-type specific (Meyer et al., 2018; Zatkova et al., 2018b). In SH-SY5Y cells, the 
impact of intracellular Ca2+ on neuronal morphology was confirmed. OT increases Ca2+ 
levels, whereas antagonism of Ca2+ channels reduces neurite length OT-independently. 
Other proteins involved are SHANK1 and the autism-associated SHANK3 (Zatkova et al., 
2018a; Zatkova et al., 2018b). Not only the morphology of single neurons is affected by OT, 
but also connections between neuronal cells are reinforced by OT stimulations, as the 
expression of synaptic cell adhesion molecules including neurexins and neuroligins was 
enhanced (Zatkova et al., 2019). 
OT also exhibits profound effects on neuronal morphology in vivo. Repeated OT treatment 
promotes cell proliferation, differentiation, and dendritic complexity of newborn hippocampal 
neurons (Sanchez-Vidana et al., 2016). Additionally, chronic i.c.v. infusions of OT enhances 
MAP2 levels in the hippocampus of adult male rats, whereas nestin remains unaffected, 
suggesting a regulatory role for OT in brain plasticity (Havranek et al., 2015). More in vitro 
and in vivo OT-mediated effects in the hippocampus were discovered by Ripamonti and 
colleagues. OT contributes to the development of hippocampal excitatory neurons and 
thereby supports the balance between excitation and inhibition in the hippocampus. 
Dysregulations in the connectome of neurons have been linked to several psychiatric 
disorders including autism (Ripamonti et al., 2017). 
Another prominent neuropeptide involved in the regulation of neuronal morphology is CRF. 
Apart from being a regulator of stress responses, CRF also functions as a differentiating 
factor. It has been linked to neurite extension and the promotion of growth cones in a cAMP 
and MAPK-dependent manner (Cibelli et al., 2001). Furthermore, CRF and UCN execute 
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differential effects on Purkinje cell dendritic outgrowth and differentiation of Purkinje cells. 
Short-term treatment promotes dendritic outgrowth, whereas long-term exposure had 
inhibitory effects (Swinny et al., 2004). 
As shown for MEF2A in H32 cells (Meyer et al., 2018), transcription factors fundamentally 
influence neurite outgrowth but it remains a challenge to characterize the interplay between 
DNA binding factors and cell-surface and cytoskeletal proteins responsible for the 
morphological shape of neurons (reviewed in(Santiago and Bashaw, 2014). 
 
 
 
7. The CRISPR-Cas system: a toolbox for investigating the oxytocin system 
 
A comparative analysis of OTR signaling cascades requires the generation of receptor KO 
cell lines. The CRISPR-Cas system provides the perfect tool and has clear advantages over 
other techniques, like transient small interfering RNA (siRNA)-mediated KD. The creation 
of a human OTR KO cell line was an important part of this thesis and therefore, I established 
the in vitro use of the CRISPR-Cas system in our laboratory. 
 
 
7.1. CRISPR-Cas – the immune system of bacteria 
Clustered regularly interspaced short palindromic repeats (CRISPR) and the CRISPR 
associated (Cas) proteins are encoded in the genome of bacteria and archaea as direct 
repeats with a length of ~28–40 base pairs (bp), separated by a unique sequence of ~25–
40 bp. These so called CRISPR arrays occur as tandems with up to 100 elements (Jansen 
et al., 2002).  
Already discovered in 1987 in Escherichia coli (Ishino et al., 1987) and since then identified 
in various other species of bacteria and archaea (Ishino et al., 2018; Makarova et al., 2015), 
it took until the early 2000s to unravel the actual function of CRISPR structures: CRISPR-
Cas systems represent the acquired immune system of bacteria and archaea against 
invading nucleic acids, occurring during horizontal gene transfer or conjugation as well as 
attacking viruses and phages (Bolotin et al., 2005; Mojica et al., 2005; Pourcel et al., 2005). 
Cas proteins containing functional domains characteristic for nucleases, helicases, 
polymerases and nucleotide-binding proteins are the mechanistical basis for CRISPR-Cas 
systems (Haft et al., 2005; Makarova et al., 2006). In type II systems including the Cas9 
system, transcription of the precursor CRISPR RNAs (crRNAs) from the CRISPR locus 
occurs with the support of a trans-activating RNA (tracrRNA,(Deltcheva et al., 2011). 
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tracrRNA and crRNA form a complex together with Cas9 and ultimately, the pre-crRNA is 
cleaved by the endogenous RNase III (Wright et al., 2016). In the last step, interference, a 
similar complex of mature crRNA, tracrRNA and Cas9 is formed to cleave the target DNA 
(Jinek et al., 2012). In detail, cleavage of the target strand of the DNA is mediated by the 
HNH nuclease domain of the nuclease lobe, the RuvC-like nuclease domain mediates 
cleavage of the non-target strand and contains an intervening α-helical lobe, a HNH domain, 
and a C-terminal protospacer adjacent motif (PAM)-interacting domain (Anders et al., 2014; 
Jinek et al., 2012; Wright et al., 2016). PAM-recognition is the important initial step before 
the helicase subunit starts unwinding the DNA in the seed region, in direct proximity to the 
PAM sequence (Sternberg et al., 2014). After unwinding, cleavage of both strands of the 
target DNA starts. 
 
 
7.2. Genome engineering with CRISPR-Cas9 and more 
Programmable nucleases have been employed as efficient tools in genome editing since 
1996 (Kim et al., 1996). However, techniques like the zink finger nucleases (ZFNs) and the 
transcription activator-like effector nucleases (TALENs) have several disadvantages 
including the expenditure of time, costliness and difficulties in protein design and synthesis. 
With the discovery of the CRISPR-Cas system, many drawbacks of these techniques could 
be circumvented. The technology that is used to date in genome editing is the CRISPR-
Cas9 system deriving from the class 2 type II system of bacteria, more precisely 
Streptococcus pyogenes, due to its simple mechanism with only one effector protein 
required. The system only involves the Cas9 protein and a target-specific guide RNA, either 
as one single-guide RNA molecule or as a complex of crRNA and tracrRNA. Multiplexing 
with the use of several guide RNAs is facilitated compared to ZFNs or TALENs (Doudna 
and Charpentier, 2014). Manipulation of the genome is achieved by the response of the 
cellular DNA repair mechanism to DNA double-strand breaks (DSB) with non-homologous 
end joining (NHEJ) or microhomology-mediated end joining (MMEJ) which are highly error-
prone, frequently resulting in insertion/deletion (In/Del) and frameshift mutations and 
represent an efficient tool for the generation of KOs (Cubbon et al., 2018; Heidenreich et 
al., 2003). NHEJ has recently been utilized for the integration of fluorescent tags in a 
technique called CRISPaint (CRISPR-assisted insertion tagging,(Schmid-Burgk et al., 
2016). Furthermore, NHEJ is the basis for the so-called VIKING-system, where 
manipulation of the repair mechanism aims to increase incorporation of the donor DNA into 
the cut site (Sawatsubashi et al., 2018). Targeted insertions are classically enabled by the 
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delivery of donor sequences containing homology arms and subsequent homology-directed 
repair (HDR,(Fig. 11,(Cubbon et al., 2018). 
 
 
 
Figure 11. Mechanism of genome editing with CRISPR-Cas. 
A site-specific double-strand break is introduced by a nuclease (Cas9, Cas12a, etc.) guided by either sgRNA or 
crRNA/tracrRNA complex. The cellular DNA repair mechanism reacts with NHEJ or MMEJ, causing a KO, or in 
the presence of a donor sequence, with HDR leading to a targeted mutation or insertion (adapted from(Doudna 
and Charpentier, 2014). 
 
 
Cas9 is far from being the only CRISPR-associated protein playing an important role in 
genome editing approaches. Cas12a, formerly known as Cpf1, has recently been 
discovered to not only cut double-stranded DNA but also single-stranded DNA (ssDNA) 
molecules (Chen et al., 2018). Cas proteins targeting RNA include for example proteins 
from the Cas13 family (Abudayyeh et al., 2016). Difficulties in delivery of Cas9, especially 
via viral transduction, can be now addressed with smaller RNA-guided DNA endonucleases 
like CasX (Liu et al., 2019) or saCas9 from Staphylococcus aureus (Ran et al., 2015). 
Furthermore, engineered Cas proteins like catalytically deactivated Cas9 (dCas9) to 
mediate transcriptional activation or down-regulation, or Cas9 D10A nickases to introduce 
single-strand DNA nicks opened further possibilities for genome engineering with CRISPR-
Cas9. 
Genome editing without double-strand breaks is enabled by base editing, where a C-G bp 
is converted into a T-A bp without breaking the DNA double-strand and can be employed 
for the introduction or correction of point mutations (Komor et al., 2016). The system, called 
base editor, consists of a cytidine deaminase enzyme coupled to a catalytically inactive 
Cas9 protein. So far, base editors of the fourth generation have been engineered yielding 
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up to 50 % editing efficiency (Komor et al., 2016; Komor et al., 2017) and are even further 
developed via phage-assisted continuous evolution, short BE-PACE (Thuronyi et al., 2019). 
Despite the great advances in the technique since the start of the CRISPR era, especially 
in molecular and behavioral neuroscience, there are still obstacles that need to be 
overcome, like brain region-specific delivery of CRISPR components (Heidenreich and 
Zhang, 2016). In a study from 2017, Staahl and colleagues developed a system for efficient 
editing in post-mitotic neurons in vivo using an engineered version of Cas9 fused to multiple 
SV40 nuclear localization sequences (NLS). Cas9 with four N-terminal and two C-terminal 
NLS (4xNLS-Cas9-2xNLS) reached the highest cell penetration and editing efficiencies, 
making it a promising approach for virus- and chemical carrier molecule-free delivery of 
CRISPR RNPs into the brain (Staahl et al., 2017). Another step forward was the 
development of a CRISPR-dCas9 activation system optimized for neurons. Here, dCas9 
was fused to a robust transcriptional activator, protein and guide RNA were successfully 
delivered using a dual lentiviral approach and led to specific activation of the target gene 
(Savell et al., 2019). Taken together, the CRISPR-Cas system enables fundamental 
research on cellular function, animal behavior and human neurological disorders. Despite 
the great efficiency and on-target specificity, off-target editing has to be considered. In 
addition to easy-to-use off-target detection platforms like DISCOVER-Seq and GUIDE-Seq 
(Wienert et al., 2019), the development of engineered Cas proteins with minimal off-target 
cleavage activity has progressed substantially (Ribeiro et al., 2018). 
In addition to classical DNA cleavage activity, on-target mRNA dysregulations have been 
discovered upon CRISPR-Cas9-based introduction of In/Dels. Aberrant mRNA production 
caused by In/Del mutation can lead to the promotion of internal ribosomal entry, alternatively 
spliced mRNAs and the induction of exon skipping when exon splicing enhancers are 
disrupted (Tuladhar et al., 2019). 
Taken together, the CRISPR-Cas system harbors the potential for targeted manipulation of 
alternative splicing and the capability of a directed shift of the ratio between behaviorally 
relevant splice variants and the corresponding full-length protein, such as the CRFR2α and 
its soluble variant sCRFR2α. Furthermore, comparative studies on OTR signaling cascades 
are enabled by the relatively simple generation of KO cell lines. 
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8. Aim of the thesis 
 
Treatment of psychiatric disorders, including anxiety-related disorders remains rather 
difficult. With a lifetime prevalence of 30 %, anxiety disorders rank among the most common 
psychiatric disorders which demonstrates the urgent need for effective treatment but also 
anamnesis options. The neuropeptide OT as an efficient anxiolytic and antistress factor is 
a viable candidate and has already been applied in several clinical trials (Neumann and 
Slattery, 2016). In animal models, the impact of an acute OT bolus on anxiety-related 
behavior has been assessed and revealed stable anxiolytic effects (Blume et al., 2008; 
Jurek et al., 2012). However, fundamental knowledge on the molecular background of OT’s 
mode of action is required, especially with regard to repeated and long-term treatment as it 
would be prescribed to anxiety patients. 
The overall aim of this thesis was to identify the signaling cascades involved both in acute 
and chronic OTR activation, as well as the systemic consequences of such treatment. To 
achieve this goal, I conducted comparative in vivo studies in male and female rats, whose 
OT system was manipulated by either acute, local OT administration, or the central long-
term administration of OT via osmotic minipumps, and assessed possible behavioral 
changes in several behavioral tests, such as EPM, LDB, OFT, and social preference test. 
As already shown in mice (Peters et al., 2014), chronic treatment with OT for 14 days 
increases anxiety-related behavior. Based on the previous studies mentioned above, I 
aimed to reveal the involvement of MAPK signaling in chronic OTR activation. Upon 
successfully doing so, my next aim was to elucidate the further downstream signaling 
cascade by which chronic OT exerts its anxiogenic effects. I was able to identify the 
transcription factor MEF2 as a downstream target of OTR-MAPK signaling and furthermore, 
I identified a link to alternative splicing of the CRFR2α. The behavioral role of OT-induced 
alternative splicing via a newly identified MAPK-MEF2 signaling pathway will be described 
in the first part of the thesis presented here. 
In the second part of my thesis, I will present my efforts to establish the CRISPR-Cas9 
system for differential analyses of OTR-mediated signaling. I was able to create two 
different KO cell lines, including deletion of the OTR and MEF2A. Cell culture studies of 
signaling cascades are a viable tool for the reduction of experimental animals needed. My 
goal was to develop a neuronal in vitro system that mimics chronic OT treatment. 
Stimulations with OT for 12 to 24 h delivered reproducible and reliable results with regard 
to signaling, alternative splicing, as well as changes in neuronal morphology (Meyer et al., 
2018). 
                                                                                                                            Introduction 
54 
 
Overall, the data presented here contribute to a better understanding of the molecular 
effects of OTR activation with the focus on clinically relevant chronic administration. They 
demonstrate an approach for the investigation of treatment duration and dosage and can 
be potentially applied also for other neuropeptides studied in the context of psychiatric 
disorders. 
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Material and Methods 
 
 
1. In vivo experiments 
 
1.1. Animals and husbandry 
Adult female and male Wistar rats (200-300 g body weight at the beginning of the 
experiments) were housed under standard laboratory conditions in groups of four (12h light-
dark cycle, 22 – 24 °C, lights on at 07.00 h, food and water ad libitum). All animal 
experiments were performed between 08:00 – 11:00 h and were approved by the 
Government of Unterfranken, Germany. Furthermore, experiments were performed 
according to the Guide for the Care and Use of Laboratory Animals of the Government of 
Oberpfalz, the ARRIVE guidelines (Kilkenny et al., 2010), and recommendations from the 
National Institutes of Health. Group sizes were estimated upon power analysis, based on 
results from previous publications (Jurek et al., 2012; Peters et al., 2014). Animals were 
randomly assigned to experimental groups, complying with equal mean body weight 
between groups. Additionally, blindness of the experimenter to the treatments in all in vivo 
experiments was ensured (Blume et al., 2009). All male rats were obtained from Charles 
River, Sulzfeld, Germany. Female rats originated from our own breeding at the University 
of Regensburg. 
 
 
1.2. Surgical procedures 
For the delivery of substances of interest, animals either underwent stereotaxic surgeries 
for cannula placement, microinfusions, or osmotic minipumps implantation. Prior to surgical 
procedures, all animals received a subcutaneous injection of Buprenovet as analgesic 
(Bayer, 0.05 mg/kg Buprenorphine). Surgeries were conducted under isoflurane anesthesia 
and sterile conditions (Neumann et al., 2000a). Following surgery, the animals received a 
subcutaneous injection of antibiotics, Baytril, (Bayer, 10 mg/kg Enrofloxacin) and were 
single-housed in observation cages (38 cm x 22 cm 35 x cm) and monitored daily. 
Osmotic minipumps (Alzet, model 1002, flow rate of 0.25 µl/h for 14 days) filled with 40 µM 
or 4 µM OT (equals 10 ng/h or 1 ng/h OT) were implanted subcutaneously in the abdominal 
region via a 1 cm long incision from the head to the neck of the rat. The pumps were 
connected to i.c.v. cannulas with a silicone tubing (0.5 x 0.9 mm, Reichelt Chemietechnik 
GmbH + Co., Heidelberg, Germany). After the implantation, kallocryl (Spree-Dental, Groß 
Köris, Germany) was used for fixation of the cannula and to close the skin. Rats were 
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monitored daily and weighed on days 1, 8, and 13 of infusion, as well as 4 days after the 
infusion ended in the respective experiment. 
I.c.v. cannulae (21-G, 12 mm) were stereotaxically placed 2 mm above the lateral ventricle 
(+1.0 mm bregma, +1.6 mm lateral, 2.0 mm below the surface of the skull). For acute local 
injections into both the left and right PVN of the hypothalamus, 23-G guide cannulae (12 
mm) were implanted stereotaxically 2 mm above the PVN (-1.4 mm bregma, -1.8 or +2.1 
mm lateral, 6.0 mm below surface of the skull; angle 10°,(Paxinos, 1998). In both cases, 
cannulae were closed using stylets, animals recovered for 1 week with daily handling and 
cleaning of the stylet to reduce a non-specific stress response by substance injections on 
the day of experiment. 
For OT treatments, oxytocin acetate salt (Bachem, Bubendorf, Switzerland) dissolved in 
Ringer (B. Braun Melsungen AG) was used at a concentration of 0.01 nmol/0.5 µl per side 
for local intra-PVN infusions and at a concentration of 0.1 nmol/5µl for lateral i.c.v. infusions. 
Anxiety-related behavior was assessed 10 min after injections (Blume et al., 2008; Jurek et 
al., 2012). To study the effects of CRFR2α activity on anxiety in the PVN, the antagonist 
ASV (Tocris Bioscience, Bristol, UK) was dissolved in Ringer (0.28 nmol/µl equals 280 µM 
per side and animal) was injected 10 min prior to behavioral testings. The CRFR2 agonist 
stresscopin (SCP, Phoenix Pharmaceuticals, Inc., Burlingame, USA) was applied at a 
concentration of 3 µg/0.5 µl in Ringer per side and animal, the behavior was assessed 25 
min after injections. Ringer solution in corresponding quantity was used as control 
substance (VEH) in all experiments. 
Locked nucleic acid target site blockers (TSB) and GapmeRs (0.5 nmol/0.5 µl per side and 
animal dissolved in 0.01 M phosphate-buffered saline (1 x PBS; pH 7.4, in vivo ready with 
a 5’-FAM labeling for transfection control; Exiqon/Qiagen, sequences in table 1) were 
applied by intra-PVN microinfusions using the following coordinates: -1.7 mm bregma, -0.3 
mm lateral, 8.2 mm below surface of the skull (Paxinos, 1998). Glass capillaries (VWR, 
Radnor, USA) for microinfusions with an inner diameter of 0.3 mm, delivering 70 nl per mm, 
were pulled to create a long narrow shank. The infusion site was closed with sutures and 
rats were allowed to recover for 7 days. 
 
Table 1. Sequences of TSB, GapmeR and scrambled (scr) control antisense oligonucleotides (ASOs). 
TSB/GapmeR Sequence (5’ – 3’) 
CRFR2-SA6-2 56-FAM-TTCCTCTGCTGGACA 
CRFR2-SD7-1 56-FAM-TGGACTCACCGCAGCAC 
CRFR2_RAT_SJ5,6_1 56-FAM-TACTTCCTCTGCTTG 
NEGATIVE CONTROL A (scr) 56-FAM-ACGTCTATACGCCCA 
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1.3. Behavioral testings 
Anxiety-related behavior was assessed via EPM, LDB, and OFT according to the design 
depicted in figure 12. These tests are based on the natural conflict between the explorative 
drive and the innate fear of open, bright and exposed areas of rodents. Animals are 
considered more anxious the more time they spend in dark and unexposed areas of the test 
setting, e. g. dark box (DB), closed arm (CA) or outer zone (reviewed in(Lezak et al., 2017). 
 
             acute infusions                                                chronic infusions 
 
 
Figure 12. Experimental setup for acute and chronic infusions of OT. 
 
 
1.3.1. Elevated plus maze 
To assess the behavioral impact of acute OT infusions (i.c.v. and intra-PVN) animals were 
tested for 5 min on the EPM as described previously (Pellow et al., 1985; Pellow and File, 
1986; Waldherr and Neumann, 2007). Briefly, testing occurred on a plus-shaped maze 
elevated 70 cm above the floor. Rats were placed in the central neutral zone (10x 10 cm) 
facing a closed arm and were free to enter both closed (50 x 10 x 40 cm, 10 lux) and open 
arms (OA, 50 x 10 cm, 100 lux). Behavior was recorded with an overhead camera and 
analyzed by an observer blind to the treatment by NOLDUS (EthoVision XT 12 version 12, 
NOLDUS information technology, Wageningen, Netherlands). The percentage of time spent 
on the OA relative to the time spent on all arms was considered an indicator of anxiety-
related behavior. The number of entries into the closed arms reflected locomotor activity. 
 
 
1.3.2. Light-dark box 
The LDB test was performed on day 14 of chronic OT or 10 min after acute infusions as 
previously described (Peters et al., 2014; Slattery and Neumann, 2010; Waldherr and 
Neumann, 2007). Only SCP-treated animals underwent LDB testing 25 min after substance 
application (Klampfl et al., 2014). For LDB testing, the rats were initially placed in the light 
box (40 cm x 50 cm, 100 lux, LB) facing the DB (40 cm x 30 cm, 0 lux) and allowed to move 
freely for 5 min. Transitions between the boxes were enabled by a small connection (7.5 
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cm x 7.5 cm). Distance moved and percentage of time spent in LB and DB were recorded 
from a top view and analyzed by NOLDUS (EthoVision XT 12 version 12, NOLDUS 
information technology, Wageningen, Netherlands) by an observer blind to the treatment. 
The percentage of time spent in the LB relative to the entire test duration was considered 
an indicator of anxiety-related behavior. Distance moved and velocity reflected locomotor 
activity. 
 
 
1.3.3. Open field test 
For the third test of anxiety-like behavior, rats were placed in the center of the open field 
box and allowed to move freely for 5 min. The floor of the box (80 cm x 80 cm, 130 lux in 
the inner zone (IZ): 40 cm x 40 cm) was divided in squares (10 cm x 10 cm). In a separate 
cohort of animals social preference was assessed as described previously with 
modifications (Lukas et al., 2011). First, rats were placed in an open field box and allowed 
to move freely for 5 min. After this phase of habituation, an empty cage (non-social stimulus) 
was placed into the inner zone of the box for 5 min. The empty cage was then replaced by 
a cage with a conspecific (social stimulus) for another 5 min. Duration of direct contact 
(sniffing) was measured and compared to the investigation time of the non-social stimulus. 
Distance moved and percentage of time spent in the zones were recorded from a top view 
and analyzed by NOLDUS (EthoVision XT 12 version 12, NOLDUS information technology, 
Wageningen, Netherlands) by an observer blind to the treatment. 
 
 
1.3.4. Acute mild stress paradigm 
24 h prior to substance infusion (for chronic OT d13) and the main behavioral testing (EPM, 
LDB, OFT), all animals underwent a 5 min period of mild stress (novel environment). 
Stressing occurred either on the OA of the EPM, without access to the CA, or on a circular 
elevated platform (12 cm diameter, 100 cm height,(Blume et al., 2008; Neumann et al., 
2000b). 
 
 
1.4. Collection of trunk blood, brains, tissue, and CSF 
Immediately after behavioral testing conscious rats were decapitated, trunk blood was 
collected in EDTA-coated microtubes (Sarstedt, Nümbrecht, Germany), and centrifuged at 
4 °C (5000 g, 10 min). The plasma supernatant was removed and stored for later RIA 
analysis of plasma OT levels (RIAgnosis, Regensburg). For RNA and protein analysis, PVN 
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and control regions were directly punched from freshly removed brain tissue and stored at 
-80 °C in RNAlater (Invitrogen by Thermo Fisher Scientific, Waltham, USA). In selected 
experiments, CSF was collected before decapitation. For this purpose, rats underwent 
urethan anesthesia (1.2 g/kg, 25 %, Sigma Aldrich, Darmstadt, Germany). CSF was then 
recovered via the cisterna magna using a 25-G cannula and directly frozen on solid CO2. 
 
 
1.5. Perfusion and brain slicing 
Animals used for the verification of microinfusions of 5’ FAM-labelled ASOs were 
anesthetized with ketamine (10 %, 1 ml/kg, WDT, Wertingen, Germany) and xylazine (2 %, 
0.5 ml/kg, Bernburg) and transcardially perfused with 150 ml 1 x PBS and 500 ml 4 % 
paraformaldehyde (PFA, Sigma Aldrich, Darmstadt, Germany; pH 7.4) in 1 x PBS on ice. 
Perfusion occurred immediately after the last behavioral test and was performed at a speed 
of 20 ml/min. After perfusion, removed brains were post-fixed for 24 h in 4 % PFA solution 
and incubated in 30 % sucrose in 1 x PBS at 4 °C for 3 days for cryoprotection. Processed 
brains were frozen in ice-cold 2-methylbutane (Sigma Aldrich, Darmstadt, Germany) on dry 
ice and stored at -80 °C until cryosectioning. 
Cannula placement was verified with 40 µm thick Nissl-stained coronal cryosections with 
the aid of the rat brain atlas (Paxinos, 1998). For verification of correct microinfusions as 
well as for subsequent immunohistochemical stainings, 40 µm unstained coronal 
cryosections were used. 
 
 
 
2. Cell culture 
 
2.1. Cell lines and cultivation 
All cell lines were cultured in 75 cm² cell culture flasks with Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham (DMEM/F-12, Sigma Aldrich, Darmstadt, Germany). 
The medium was supplemented with 10 % heat-inactivated fetal bovine serum (FBS, 
Capricorn, Germany), and either 1 % Penicillin-Streptomycin (Gibco™, Thermo Fisher 
Scientific, Waltham, USA) for the rat hypothalamic cell line H32 (Mugele et al., 1993) and 
the murine N2a cell line (ATCC® CCL-131™), or 1 % MEM non-essential amino acid solution 
and 0.2 % gentamycin (both Invitrogen, Germany) for human Be(2)-M17 cells (European 
Collection of Cell Cultures, #95011816). The cells were incubated in humidified atmosphere 
containing 5 % CO2 at 37 °C. Passaging was performed weekly by gentle trypsinization 
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(Trypsin-EDTA solution, 0.25 %, Sigma, Darmstadt, Germany). Primary hypothalamic 
neurons were obtained as described previously (Jurek et al., 2015), isolation and cultivation 
of primary cells were performed by Dr. Benjamin Jurek. Briefly, fetal rats were rapidly 
removed from 18 days pregnant rats after CO2 sedation and decapitation. Then, fetal 
hypothalamic tissue was dissected and collected in ice-cold buffer (pH 7.4, containing 
137mM NaCl, 5mM KCl, 0.7 mM Na2HPO4, 25 mM HEPES buffer, and 100 μg/ml 
gentamycin). Collagenase type 2 (1 mg/ml; Worthington Biochemical Corporation, 
Lakewood, USA) was dissolved in the buffer mentioned above, supplemented with 1 mg/ml 
glucose, 4 mg/ml bovine serum albumin (BSA, Sigma Aldrich, Darmstadt, Germany), 0.2 
mg/ml deoxyribonuclease, and used for digestion for 1.5 h. The cell suspension was filtered 
through a 40-μm cell strainer (BD Falcon, Heidelberg, Germany) and centrifuged at 200 g 
for 10 min. Cells were washed twice in dispersion buffer and once in plating medium 
(DMEM/F-12, 100 μg/ml gentamycin and 10 % heat-inactivated FBS) before seeding them 
in six-well plates coated with poly-L-lysine (1 x 106 cells/well). Cells were allowed to grow 
in the presence of serum for 24 h. Afterward, culture maintenance was performed for eight 
additional days in neurobasal medium containing B27 supplement (Life Technologies, Inc., 
Invitrogen). Glial cell proliferation was prevented by using cytosine arabinoside (Sigma 
Aldrich, Darmstadt, Germany) at a final concentration of 5 μM from day 4 on. After another 
6 days, cells were maintained in supplement-free neurobasal medium containing 0.1% BSA 
(Sigma Aldrich, Darmstadt, Germany; protocol adapted from(Liu et al., 2008). 
 
 
2.2. Stimulations 
To investigate signaling pathways activated by OT, several stimulation protocols were 
performed for subsequent RNA, protein and morphological analyses (for details see 
chapters below). For protein analysis, H32 cells were seeded at a density of 3 x 106 cells in 
100 mm culture dishes 24 h prior to experiments and Be(2)-M17 cells were seeded at a 
density of 6 x 106 cells per dish. Stimulations were performed in normal growth medium 
using OT concentrations of 10 nM and 100 nM. Both acute (10 min to 2 h) and chronic 
effects (12 h to 24 h) on protein expression and phosphorylation were assessed. Both the 
OTR specific agonist TGOT as well as AVP were used at a concentration of 100 nM. RNA 
isolation and morphological analyses required lower cell densities, in detail, 1 x 106 H32 
and N2a cells, and 2 x 106 Be(2)-M17 cells were plated on 50 mm culture dishes. For 
immunocytochemical analyses, between 1 x 104 and 5 x 104 cells were plated on chamber 
slides (BD Falcon, Heidelberg, Germany) 24 h prior to experiments. For methodological 
details, see chapter 3.4. Immunohistochemistry and immunocytochemistry. 
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2.3. Differentiation and morphological analysis 
Neuronal morphology was assessed according to previous studies (Meyer et al., 2018). As 
mentioned above, cells were grown in 50 mm culture dishes and cultured in normal growth 
medium that was complemented with 10 nM or 100 nM OT for 24 h. Afterward, the cellular 
membrane was stained with Green CellMask (Thermo Fisher Scientific, Waltham, USA) and 
nuclei were stained with Hoechst 33342 (2 µg/ml, Thermo Fisher Scientific, Waltham, USA). 
In short, Hoechst 33342 was applied to the cells and incubated for 30 min at 37 °C. After 
20 min a dilution of 1 x CellMask was subjoined to the medium and incubated for at least 
further 10 min at 37 °C. After two 1 x PBS washing steps, the cells were fixed with 4 % PFA 
and images were taken at the ZOE Fluorescent Microscope (Bio-Rad). 
As Be(2)-M17 cells are undifferentiated neurons, a preceding differentiation protocol was 
required to enable neurite length measurements. Therefore, either 10 mM dibutyryl-cAMP 
(dbcAMP, Tocris, Cat. No. 1141) for 48 h or neurobasal medium (10% FBS and 0.2% 
gentamycin) supplied with forskolin (Tocris, Bristol, UK) and retinoic acid (Tocris, Bristol, 
UK) were applied for 5 consecutive days. After differentiation, cells were recovered in 
growth medium for 24 h and corresponding stimulations were performed. 
 
 
2.4. Manipulation of cholesterol content in cellular membranes 
The cholesterol content of membranes is a crucial factor for the stability of OTRs (Gimpl 
and Fahrenholz, 2000, 2002). Low affinity-state receptors in cholesterol-poor membranes 
can be converted to high-affinity state by the addition of cholesterol and vice versa (Gimpl 
et al., 1995). Thereby, signal transduction and functional activity of the receptor can be 
manipulated. Cholesterol enrichment and depletion were performed according to the 
protocol of Prof. Dr. Gerald Gimpl, Mainz. After cholesterol enrichment and depletion, 
corresponding stimulations were performed as represented in the results section. 
 
 
2.4.1. Cholesterol enrichment 
For the in vitro enrichment of cellular membranes with cholesterol, a cholesterol-MßCD 
solution was prepared. For that, a cholesterol stock (Sigma Aldrich, Darmstadt, Germany) 
was pre-dissolved in 2-Propanol (3 mM final concentration) and MßCD (Sigma Aldrich, 
Darmstadt, Germany) was dissolved in double-distilled water (ddH2O) to 40mg/ml. As 
cholesterol is not soluble in polar solvents, incubation at 80 °C overnight was necessary, 
whereby MßCD forms a complex with cholesterol and resulted in a clear solution. 
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Cellular membranes were then enriched for 30 min at 37 °C using a 0.3 mM cholesterol-
MßCD solution diluted in DMEM/F-12 with 0.1 % BSA (Sigma Aldrich, Darmstadt, 
Germany). 
 
 
2.4.2. Cholesterol depletion 
To deplete cellular membranes from cholesterol, a 200mM MßCD stock solution was 
prepared (2.67g/10ml ddH2O). Cells received DMEM/F-12 with 0.1 % BSA (Sigma Aldrich, 
Darmstadt, Germany) containing MßCD in a final concentration of 10 mM for 30 min at 37 
°C. 
 
 
2.4.3. Filipin staining 
Filipin III (Sigma Aldrich, Darmstadt, Germany) is a polyene macrolide antibiotic, isolated 
from Streptomyces filipinensis and is widely used to visualize cholesterol in plasma 
membranes due to its ability to bind to sterols (Beknke et al., 1984). Either cholesterol-
enriched, -depleted, or VEH treated Be(2)-M17 cells were stained with filipin (100µg/ml in 1 
x PBS) under light protected conditions for 2 hours at room temperature (RT). For mounting, 
p-phenylenediamine (Sigma Aldrich, Darmstadt, Germany) was dissolved in ProLong® Gold 
Antifade Reagent (Cell Signaling Technologies) to a final concentration of 1 mg/ml. Images 
were acquired using the SP8 Leica confocal microscope with an x20 objective at an 
excitation of 415-500 nm and subsequently analyzed with ImageJ Fiji software (Rueden et 
al., 2017; Schindelin et al., 2012). 
 
 
2.5. Plasmid-mediated oxytocin receptor overexpression 
Transient overexpression of the OTR was achieved by the transfection of a plasmid, 
containing the human OTR coding sequence. The RC211797 OTR plasmid from Origene 
was delivered into cells via cationic lipid delivery using Lipofectamine™ 3000 and P3000 
Reagent (Invitrogen, Carlsbad, USA) according to the manufacturer’s protocol. Plasmid 
construction was based on a pCMV6-Entry vector and contained a myc-DDK tag for target 
antibody-independent confirmation of expression. Stimulations with OT were performed 3 
days after transfection. 
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2.6. CRISPR-Cas9 
Genome editing using the CRISPR-Cas9 system was applied to generate KO cell lines as 
well as to enable tag-mediated detection of endogenous protein expression. 
 
 
2.6.1. Otr knockout 
For KO of the Otr gene in human Be(2)-M17 cells, Oxytocin-R Double Nickase Plasmids (h, 
Santa Cruz Biotechnology, Dallas, USA) were transfected. Cationic lipid delivery with 
Lipofectamine™ 3000 and P3000 Reagent (both Invitrogen, Carlsbad, USA) was applied to 
deliver the plasmids to the cells. Expression of a green fluorescent protein (GFP) on the 
CRISPR plasmids enabled immediate visual confirmation of transfection efficiency. To 
obtain single-cell colonies, pre-selection of transfected cells, expressing the antibiotic 
resistance gene, with a puromycine antibiotic treatment (Puromycin dihydrochloride, Santa 
Cruz Biotechnology, Dallas, USA) was performed for 5 days at a concentration of 5µg/ml. 
Afterward, cells were diluted and seeded in 96-well plates at a density of 1 cell per well and 
re-cultured for several weeks. The genotype of the cell lines acquired was assessed by 
means of western blot, qPCR, and sequencing. 
 
 
2.6.2. Mef2a knockout 
The Alt-R® CRISPR-Cas9 system (IDT, Coralville, USA) was used to create a Mef2a KO 
H32 cell line. RNP complexes were transfected by cationic lipid delivery using 
Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, USA) and Opti-
MEM (Gibco). Transfected complexes consisted of the functional gRNA duplex, containing 
the sequence-specific crRNA (sequences in table 2) and the ATTO 550-labeled tracrRNA 
in nuclease-free duplex buffer, and the S. p. Cas9 Nuclease 3NLS. Transfected single-cells 
were acquired 2 h after transfection by cell sorting (see chapter 2.6.5.) and re-cultured for 
several weeks. The genotype was assessed by means of western blot, qPCR, and 
sequencing. 
 
Table 2. Sequences of crRNA for Mef2a KO. 
Name Sequence (5’ - 3’) 
Rn.Cas9.MEF2A.1.AA CAGGACGAACTCGGATATTG 
Rn.Cas9.MEF2A.1.AB GCTTTGTCGTACACTAACCC 
Rn.Cas9.MEF2A.1.AC ACAGACCTCACGGTACCAAA 
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2.6.3. HiBiT 
Membrane-bound CRFR2α was visualized using the Nano-Glo® HiBiT Extracellular 
Detection System (Promega, Mannheim, Germany). Therefore, a HiBiT-containing 
Ultramer® ssDNA donor sequence was introduced directly upstream of exon 6 of the 
CRFR2α gene. H32 cells were transfected with Alt-R® CRISPR-Cas9 complexes as 
described above; the HiBiT donor sequence was applied together with the RNP complex 
transfection mixture. Sequences of crRNAs and HiBiT donors are listed in table 3. Single-
cell isolation occurred again via fluorescence-activated cell sorting (FACS, see chapter 
2.6.5.). After re-culturing for several weeks, the genotype was assessed by means of 
western blot, qPCR, and sequencing. 
 
Table 3. Sequences of crRNA and donor ssDNA for HiBiT-tagging of the CRFR2α. 
Name Sequence (5’ - 3’) 
Sequence 1 GCAGGTCATACTTCCTCTGC 
Sequence 2 ACTTCCTCTGCTGGACAGAC 
Sequence 3 TGCTGGACAGACAGGCAGAC 
Linker sequence Ggatcatcaggaggatcatcagga 
HiBiT-encoding sequence GTGAGCGGCTGGCGGCTGTTCAAGAAGATTAGC 
 
 
For the detection of membrane-bound CRFR2α, cells were seeded in 96-well plates at a 
density of 1 x 104 cells per well and stimulated with 100 nM OT for 24 h. During incubation 
with 1:2 LgBiT Protein/HiBiT Extracellular Substrate in Nano-Glo® HiBiT Extracellular Buffer 
and serum-free (0.1 % BSA Sigma Aldrich, Darmstadt, Germany) DMEM/F-12 (Sigma 
Aldrich, Germany), the complementary polypeptide LgBiT binds to the HiBiT tag and 
reconstitutes the luminescent NanoBiT enzyme (Schwinn et al., 2018). Luminescence was 
measured at the GloMax Explorer (Promega, Mannheim, Germany). 
 
 
2.6.4. Sequencing 
Successful genome editing was confirmed via Sanger sequencing performed by Macrogen 
(Seoul, South Korea). Sequencing results were analyzed and compared to Be(2)-M17 
genome using Serial Cloner 2.6.1 software (serialbasics.free.fr/Serial_Cloner.html). For 
sequencing, corresponding DNA segments containing the CRISPR cutting sites were 
amplified via PCR and purified using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, 
Germany). 
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2.6.5. Cell sorting 
Single-cell sorting of cells transfected with CRISPR components mentioned above (2.6.2. 
and 2.6.3.) was performed at the 'Central FACS Facility' (CFF) at the Regensburger 
Centrum für Interventionelle Immunologie (RCI, PD Dr. Petra Hoffmann). The FACS Aria 
IIu cell sorter (BD Biosciences, San Jose, USA) at the Institute of Immunology of the 
University Hospital Regensburg was used, sorting was performed by Irina Fink. 
 
 
 
3. Molecular techniques 
 
3.1. Protein isolation 
Standard western blot analysis was performed with RIPA buffer-isolated whole-cell protein 
samples. Briefly, tissue or cells were harvested, resuspended in ice-cold RIPA buffer 
(Sigma Aldrich, Darmstadt, Germany) supplemented with 1 x Halt™ Protease & 
Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, USA), and incubated 
for 1 h at 4 °C with vortexing every 10 min. After centrifugation for 15 min at 13.000 
revolutions per min (rpm) and 4 °C, the supernatant containing the proteins was recovered. 
All samples from in vitro stimulations were purified with RIPA buffer. For simultaneous 
retrieval of in vivo protein and RNA samples, the NucleoSpin® RNA/Protein Kit (Macherey-
Nagel, Düren, Germany) was used and samples were processed according to the 
manufacturer’s protocol. The Nuclear Extract Kit (Active Motif, Rixensart, Belgium) was 
used for both whole-cell protein extraction and preparation of nuclear and cytoplasmic 
fractions from cells and freshly punched tissue. Analysis of OTR protein expression required 
gentle cell lysis with EDTA lysis buffer, containing 0.5 mM EDTA (0.02 % Sigma Aldrich, 
Darmstadt, Germany), 250 mM NaCl, 50 mM HEPES (Sigma Aldrich, Darmstadt, 
Germany), 0.05 % Igepal (Sigma Aldrich, Darmstadt, Germany and 1 x Halt™ Protease & 
Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, USA). Resuspended 
cells (Be(2)-M17 and H32) were incubated for 1 h at 4 °C with vortexing every 10 min. After 
centrifugation at 13.000 rpm and 4 °C for 15 min, the protein supernatant was transferred 
to a fresh 1.5 ml cup. 
Protein concentrations in all samples were determined using the Pierce™ BCA Protein 
Assay Kit (Thermo Fisher Scientific, Waltham, USA) and compared to the BSA standard 
curve provided with the kit. 
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3.2. SDS PAGE, western blot, and dot blot 
Protein expression and phosphorylation levels, basal as well as after stimulations or after 
in vivo treatment, were assessed by means of western blot. For all experiments, between 
15 and 30 µg protein were loaded onto Mini-PROTEAN® TGX Stain-Free™ Precast Gels or 
Criterion™ TGX Stain-Free™ Precast Gels (Bio-Rad, Munich, Germany) and separated by 
their molecular weight at 140 V for 1 h. As band size marker, the prestained protein ladder 
from Fermentas, Inc. (Glen Burnie, USA) was used. After electrophoretic separation, the 
gels were placed in Trans-Blot® Turbo™ Mini or Midi Nitrocellulose Transfer Packs and 
blotted in the Trans-Blot® Turbo™ Transfer System for 7 min. To block all non-specific 
binding sites, membranes were preincubated in either 5 % BSA (Sigma Aldrich, Darmstadt, 
Germany) in Tris-buffered saline with Tween20 (1 x TBST; pH 7.4) or in 5 % milk powder 
(Roth, Karlsruhe, Germany) in 1 x TBST buffer. Antibody solutions were prepared according 
to table 4 and incubated overnight at 4 °C. The next day, membranes were washed with 1 
x TBST and incubated with HRP-labeled secondary antibodies at RT for 1 h. Following three 
washing steps with 1 x TBST, the membrane was incubated for 5 min with Clarity Western 
ECL (Bio-Rad, Munich, Germany), or Super Signal West Dura Extended Duration Substrate 
(Thermo Fisher Scientific, Waltham, USA), and the protein/antibody complexes were 
visualized via a chemiluminescent reaction captured by the ChemiDoc XRS+ Imager (Bio-
Rad, Munich, Germany). All images were analyzed with Image Lab software (Bio-Rad, 
Munich, Germany). To consecutively visualize multiple proteins on one membrane, 
membranes were stripped following visualization to remove bound antibody complexes 
using Restore™ Western Blot Stripping Solution (Thermo Fisher Scientific, Waltham, USA). 
Afterward, membranes were blocked for 5 to 30 min with the respective blocking solution, 
a primary antibody was applied and the protocol was performed as mentioned above.  
To assess non-denatured sCRFR2α content in CSF (undiluted) and plasma samples (1:10 
dilution), 10 µl each were spotted onto a nitrocellulose membrane (0.45 µm, Bio-Rad, 
Munich, Germany). After complete drying of the dots, unspecific binding was avoided by 
incubation in 5 % BSA (Sigma Aldrich, Darmstadt, Germany) blocking solution for 1 h. 
Following this, the membrane was incubated with primary sCRFR2 antibody (gift from Prof. 
Dr. Alon Chen) for 30 min at RT and washed three times for 1 min in 1 x TBST. Afterward, 
the secondary HRP-labeled anti-rabbit antibody (1:1000 in 1 x TBST, #7074, Cell Signaling 
Technology, Danvers, USA) was applied for 30 min. Prior to development in Clarity Western 
ECL (BioRad, Munich, Germany), membranes were washed again three times for 1 min in 
1 x TBST. Images were acquired using the ChemiDoc XRS+ Imager (Bio-Rad, Munich, 
Germany) and analyzed with ImageJ Fiji software (Rueden et al., 2017; Schindelin et al., 
2012). 
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Table 4. List of antibodies used in western blot and dot blot with according dilutions and approximate 
band size. 
Antibody Cat # and Company Dilution Band size 
sCRFR2 rabbit polyclonal Gift from A. Chen 1:10000 30 kDa 
MEF2A S408 rabbit polyclonal CusAb PA000728 1:2000 50 kDa 
pMEF2A Thr312 rabbit polyclonal Abcam ab30644 1:2000 55 kDa 
pMEF2A Thr319 rabbit polyclonal OriGene TA325686 1:2000 55 kDa 
pMEF2C S396 rabbit polyclonal OriGene TA326044 1:1000 55 kDa 
pMEF2C S59 rabbit polyclonal Santa Cruz sc-13919-R 1:1000 50 kDa 
pMEF2 (B-11) mouse monoclonal Santa Cruz sc-377535 1:1000 70 kDa 
MEF2A total rabbit polyclonal Acris AP06372PU-N 1:2000 55 kDa 
MEF2C total rabbit polyclonal OriGene TA326189 1:2000 55 kDa 
CRFR2 rabbit polyclonal Millipore ABN 433 1:1000 50 kDa 
pMEK1/2 (41G9) rabbit monoclonal Cell Signaling 9154 1:1000 45 kDa 
MEK1/2 rabbit polyclonal Cell Signaling 9122 1:1000 45 kDa 
pERK1/2 rabbit polyclonal Cell Signaling 9101 1:5000 42,44 kDa 
ERK1/2 rabbit polyclonal Cell Signaling 9102 1:2000 42,44 kDa 
CREB rabbit monoclonal Millipore 04-218 1:2000 43 kDa 
pCREB rabbit polyclonal Millipore 06-519 1:5000 43 kDa 
p90RSK1 Santa Cruz sc-231 1:1000 90 kDa 
pp90RSK1 rabbit polyclonal Cell Signaling 9344 1:2000 90 kDa 
pELK-1 rabbit polyclonal Cell Signaling 9181 1:1000 47 kDa 
pMSK1 rabbit monoclonal Abcam ab81294 1:2000 90 kDa 
pp38 rabbit polyclonal Abcam ab32557 1:1000 42 kDa 
OTR rabbit monoclonal Abcam EPR12789 1:2000 55 kDa 
 
 
3.3. TransAM® MEF2 transcription factor activation assay 
Whole-cell protein extraction from chronic OT treated rats was performed using the Nuclear 
Extract Kit (Active Motif, Rixensart, Belgium). After protein concentration determination via 
BCA assay (Thermo Fisher Scientific, Waltham, USA), 20 µg protein were applied to the 
oligo-coated 96-well plate and either incubated with a MEF2A or MEF2C subform specific 
antibody (OriGene, Rockville, USA) according to the manufacturer’s instructions. 
Developing solution was incubated for 10 – 15 min and fluorescence was determined at 
450 nm in a plate reader (FluoStar Optima, BMG LABTECH, Ortenberg, Germany). 
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3.4 Immunohistochemistry and immunocytochemistry 
For the verification of ASO (TSB and GapmeR) infusions, 40 µm thick cryosections 
containing the PVN were generated and stained according to the following protocol. In 
addition to 5’-FAM-labeled ASOs, OT-neurons in the PVN were stained using the OT-
Neurophysin I antibody (PS38, 1:400, gift from H. Gainer). 40 µm thick cryo cut sections 
containing the PVN were permeabilized, blocked (1 x PBS supplemented with 2 % BSA, 1 
% glycine and 0.3 % TritonX-100 (Sigma Aldrich, Darmstadt, Germany), 1 h at RT). After 
the staining with PS38, the sections were gently transferred to SUPERFROST® glass slides 
(Thermo Fisher Scientific, Waltham, USA) and mounted with Surgipath Premier cover slips 
using ProLong Glass Anti-Fade Reagent with DAPI (Thermo Fisher Scientific, Waltham, 
USA). 
Immunocytochemical stainings were performed in primary cells. 0.05 x 106 primary 
hypothalamic cells were seeded in BD Falcon Chamber slides (Poly-D-Lysine coated), fixed 
in 3 % glyoxal, rinsed in 1 x PBST (0.1% Triton X-100), and blocked with blocking solution 
(1 x PBS, 2% BSA, and 0.5 % Triton X-100, 1 % glycine, 0.5 % cold water fish gelatin, all 
chemicals were obtained from Sigma Aldrich, Darmstadt, Germany) for 1 h followed by 
primary antibody (see table 5) incubations in 1 x PBST. Cells were mounted with ProLong 
Glass Anti-Fade (Thermo Fisher Scientific, Waltham, USA) and High Precision cover glass 
(24, 50, #1.5; CG15KH Thor Labs, Newton, USA). Image acquisition was performed at the 
Leica TCS SP8 confocal microscope and the Leica DM5000B. 
 
Table 5. List of antibodies used in immunocytochemistry with according secondary antibody and 
dilution used. 
Antibody Cat # and 
Company 
Secondary antibody Dilution 
sCRFR2 rabbit 
polyclonal 
provided by Salk 
Institute 
Alexa Fluor 594 donkey 
anti-rabbit 
1:2000 
GFAP mouse 
monoclonal 
Sigma G3893 Cy3 AffiniPure goat anti-
mouse IgG Jackson Labs 
1:400 
OT mouse 
monoclonal 
Gift from H. Gainer Cy3 AffiniPure goat anti-
mouse IgG Jackson Labs 
1:400 
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3.5. RNA and DNA isolation 
For analysis of messenger RNA (mRNA) expression of target genes in specific brain 
regions, freshly punched tissue from PVN, hippocampus and prefrontal cortex was taken 
and kept in RNAlater at -80 °C for before further processing according to the instruction 
manual of the NucleoSpin® RNA/Protein Kit (Macherey-Nagel, Düren, Germany). In a 
second approach, punched rat brain tissue was frozen in 1 ml peqGold TriFast Gold (VWR 
Life Science, Radnor, USA), carefully thawed on ice, homogenized by pipetting, and RNA 
was isolated according to the protocol provided by the manufacturer with some 
modifications as described previously (Jurek et al., 2015; Meyer et al., 2018). 
To isolate RNA from the stimulated cells, the medium was aspirated off, cells were washed 
with warm 1 x PBS, and RNA was isolated using both methods described above. RNA 
content was measured at a spectrophotometer (ND-100, NanoDrop, Thermo Fisher 
Scientific, Waltham, USA). 
Sanger sequencing of BeJ(1) and Be(2)-M17 required high amounts of genomic DNA. 
Isolation from cultured cells was performed using the DNeasy Blood & Tissue Kit (Qiagen, 
Hilden, Germany). Subsequent extraction of amplified gene fragments from agarose gels 
required purification using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). 
 
 
3.6. mRNA analysis 
Prior to polymerase chain reaction (PCR) and quantitative PCR analysis, 300 ng of total 
RNA per sample were reverse transcribed into complementary DNA (cDNA) using the 
SuperScript IV first-strand synthesis system for reverse transcription PCR (RT-PCR, 
Invitrogen, Carlsbad, USA) according to the manufacturer’s protocol. A total amount of 100 
ng cDNA was used for PCR analysis. 
 
 
3.6.1. Polymerase chain reaction 
The amplification of the Otr gene gene (primer sequences in table 6) was carried out using 
the Fermentas Dream Taq™ Green PCR Master Mix (Thermo Fisher Scientific, Waltham, 
USA). The PCR protocol started with an initial 3 min denaturation step at 95 °C. The 
amplification cycle consisted of a 30 sec denaturation step at 95 °C followed by 45 sec of 
primer annealing at 58 °C and an extension step at 72 °C for 1 min. The reaction was 
concluded with an elongation step at 72 °C for 10 min. Analysis of the PCR products was 
performed by agarose gel electrophoresis in 1 x tris acetate EDTA buffer at 140 V for 1 h. 
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Table 6. Primers for OTR sequencing. 
Target Sequence 5’ – 3’ 
Oxtr_hum_seq_for#3 ATGTTCGCCTCCACCTAC 
Oxtr_hum_seq_rev#3 GAAGAAGAAAGGCGTCCAG 
 
 
3.6.2. Quantitative polymerase chain reaction 
Relative quantification of MEF2A, sCRFR2α, and CRFR2α mRNA levels was performed 
using the QuantiFast SYBR® Green PCR Kit (Qiagen, Hilden, Germany), using ribosomal 
protein L13A (Rpl13A) as housekeeping gene (Bonefeld et al., 2008). Primer efficiency for 
each primer pair was calculated by serial dilution of test cDNA using the Pfaffl method 
(Bustin et al., 2009; Pfaffl, 2001). Specificity of the qPCR was assured by omitting reverse 
transcription and by using ddH2O as template. Cycling conditions consisted of an initial 
denaturation step of 5 min at 95° C, followed by 50 cycles of denaturation at 95° C for 10 s, 
and annealing/extension at 60° C for 45 s. At the end of the protocol, a melting curve was 
generated, and PCR products were analyzed by agarose gel electrophoresis to confirm the 
specificity of the primers (see table 7 for primer sequences). All samples were run in 
triplicate. 
 
Table 7. Rat primer sequences for the detection and quantification of target genes via qPCR. 
Target Sequence 5’ – 3’ 
MEF2A (NM_001014035.1) Fwd: AAT GGG GCG AAA GAA AAT AC 
Rev: GCT GGC GTA CTG AAA CAA CT 
CRFR2α (NM_022714.1) Fwd: ACA TCC GAG ACC ATC CAG TA  
Rev: GGA CTG CAG GAA AGA GTT GA  
sCRFR2α Fwd: CCC ATT TTG GAT GAC AAG GAG TA 
Rev: GGA TGA AGG TGG TGA TGA GGT T 
Rpl13A (NR_073024) Fwd: ACA AGA AAA AGC GGA TGG TG 
Rev: TTC CGG TAA TGG ATC TTT GC 
 
 
3.6.3. Polymerase chain reaction array 
RNA samples for PCR array analysis were processed using the NucleoSpin® RNA/Protein 
Kit (Macherey-Nagel, Düren, Germany). Reverse transcription into cDNA was performed 
with the RT2 First Strand Kit (Qiagen, Hilden, Germany). The custom RT2 PCR array 
(330171 CLAR25389) was purchased from Qiagen and pipetted according to the 
                                                                                                             Material and Methods 
73 
 
manufacturer’s protocol. Calculations are based on the ΔΔCT method, ACTB, B2M, HPRT1 
and LDHA were used as housekeepers. 
 
 
 
4. Statistical analyses 
 
Data were analyzed using SigmaPlot (version 11.0.0.75, Systat Software). Behavioral and 
molecular experiments were statistically analyzed performing parametric one-way (factor 
treatment) or two-way (factors treatment x time) analysis of variance (ANOVA), followed by 
Holm-Sidak post hoc correction if appropriate (other post hoc corrections are indicated in 
the corresponding figure legend). For non-parametric data, the Kruskal-Wallis ANOVA on 
ranks and the Tukey test were applied (other post hoc corrections are indicated in the 
corresponding figure legend). To compare two groups, separate parametric t-tests or non-
parametric Mann-Whitney U tests were performed. Statistical significance was accepted at 
p < 0.05. For behavior, n represents number of animals, for cell culture experiments, n 
represents number of wells or dishes. In morphology experiments n represents the number 
of single-cells. As indicated in the figure legend, data are represented as mean ± or + 
standard error of the mean (SEM). Statistical analysis for normal distribution and equal 
variance was performed; However, due to consistency, all data are represented as mean. 
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Results 
 
 
1. Differential effects of acute and chronic oxytocin on anxiety-like behavior 
in rats 
 
Previous studies (Blume et al., 2008; Jurek et al., 2012; van den Burg et al., 2015) 
demonstrated that acute local intra-PVN infusions of OT reduce anxiety in male rats on the 
EPM 10 min after substance application. I was able to reproduce the anxiolytic effect of 
acute OT, validating my experimental setup. 
Male rats injected with 0.1 nmol/0.5 µl OT bilaterally into the PVN spent significantly more 
time investigating the OA (39.3 % ± 5.1 % time on the OA) compared to VEH treated animals 
(18.6 % ± 3.9 % time on the OA), indicating decreased anxiety-like behavior (Fig. 13A). This 
effect occurred only when OT was injected directly into the PVN, i.c.v. infusions did not alter 
anxiety-related behavior tested on the EPM (66.5 % ± 14.5 % time on the OA for VEH, 58.04 
± 13.6 % time on the OA for OT treatment, Fig. 13B). However, the anxiolytic effect of OT 
converted, when OT was administered over a longer period of time. In detail, chronic i.c.v. 
OT infusions for 14 days at a high dose of 10 ng/h reduced the time the rats spent in the 
light compartment to about 20% (18.7 % ± 2.6 %, Fig 13C). Notably, the anxiogenic 
phenotype depended on a mild stressor (elevated platform stress,(Neumann et al., 2000a) 
24 h prior to LDB testing. Omission of exposure to this stressor but treatment with chronic 
OT (39.73 % ± 2.8 % time spent in LB) was not capable of altering anxiety levels compared 
to VEH treatment (37.52 % ± 2.2 % spent in LB, Fig. 13C). While the low dose of 1 ng/h of 
chronic OT had no impact on anxiety-related behavior in male rats, it significantly reduced 
the time female rats spent in the LB from 57.3 % ± 4.0 to 42.8 % ± 4.1 %. Females treated 
with the high dose also spent less time in the LB (48.7 % ± 2.7 %), however, this effect did 
not reach statistical significance (Fig. 13D). 
Despite the profound impact on anxiety, both acute and chronic OT-induced effects were 
transient. I assessed the permanence of acute OT 3 h after intra-PVN infusion and for 
chronic OT after additional 5 days. In both cases, animals did not display altered anxiety-
related behavior (Fig. 13E and F). 3 h after acute treatment animals spent between 76.8 % 
± 14.2 % and 48.7 ± 18.2 % time in the LB (Fig. 13E). After the recovery phase for 5 days 
after chronic OT, the time spent in the LB ranked between 26.7 % ± 4.2 % and 31.4 % ± 
11.0 % (Fig. 13F). Locomotion was not affected in any of the behavioral tests performed in 
this thesis (data not shown). 
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Figure 13. Effects of acute (acOT) and chronic (cOT) OT treatment on anxiety. Due to shortage of space, 
the abbreviations acOT and cOT are exclusively used in the figures and corresponding legends. 
(A) Mean percentage of time male rats spent on the OA of the EPM 10 min after intra-PVN infusions of either 
VEH (Ringer) or acOT (20µM, corresponding to 0.1nmol/0.5µl per side), representing anxiety-like behavior. Male 
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rats treated with acOT spent significantly more time on the OA, indicating an anxiolytic effect of OT. Mann-
Whitney rank-sum test, * p = 0.006; number of animals: VEH = 8; acOT = 9. (B) Anxiety-like behavior 
represented as mean percentage of time male rats spent on the OA of the EPM 10 min after i.c.v. VEH or acOT 
(20 µM, corresponding to 0.1 nmol/5µl) infusions. No statistically significant differences in anxiety-like behavior 
were observable, Mann-Whitney U statistic = 17.000, p = 0.937; number of animals: VEH/acOT= 6. (C) Anxiety-
like behavior represented as mean percentage of time male rats spent in the LB of the LDB after 14 days of 
i.c.v. infusions of VEH (Ringer) or cOT (1 ng/h or 10 ng/h, corresponding to 4 or 40 µM OT dissolved in Ringer, 
0.25 µl/h). Animals treated with 10 ng/h cOT spent significantly less time in the LB. One way ANOVA, F(3;59) = 
9.577; p < 0.001, Holm-Sidak post hoc test, * p < 0.001 vs VEH; number of animals: VEH = 15, treatment groups 
= 18, 10 ng/h cOT –s = 9. (D) Anxiety-like behavior represented as mean percentage of time female rats spent 
in the LB of the LDB after 14 days of i.c.v. infusions of VEH (Ringer) or cOT (1 ng/h or 10 ng/h, corresponding 
to 4 or 40 µM OT dissolved in Ringer, 0.25 µl/h). Rats treated with 1 ng/h cOT spent significantly less time in 
the LB, indicating increased anxiety-like behavior. One way ANOVA on Ranks, H = 7.525 with 2 degrees of 
freedom, p = 0.023. All Pairwise Multiple Comparison Procedures (Dunn's Method), * p < 0.05 vs VEH; number 
of animals: VEH = 6, treatment groups = 7. (E) Anxiety-like behavior represented as mean percentage of time 
male rats spent in the LB of the LDB 3 h after intra-PVN infusions of either VEH or OT (20µM, corresponding to 
0.1nmol/0.5µl per side). No statistical significant differences, Mann-Whitney U Statistic= 17,000, p = 0.383; 
number of animals: VEH/treatment group = 7. (F) Anxiety-like behavior represented as mean percentage of time 
male rats spent in the LB of the LDB after 14+5 days of i.c.v. infusions of VEH (Ringer) or cOT (1 ng/h or 10 
ng/h, corresponding to 4 or 40 µM OT dissolved in Ringer, 0.25 µl/h). The anxiogenic effect of cOT was transient 
and vanished 5 days after end of infusions. One way ANOVA, F(2;14) = 0.0621, p = 0.940; number of animals: 
VEH/treatment groups = 5. 
 
 
 
2. Downstream signaling of chronic and acute oxytocin 
 
Due to the profound differential behavioral effects of OT, I investigated downstream 
signaling of OTR with respect to MAPK signaling, the related transcription factor family 
MEF2 as well as synaptic-plasticity and anxiety-related factors like the CRFR2α and its 
soluble splice variant sCRFR2α. 
 
 
2.1. Effects on MAPK and MEF2 signaling 
First, I assessed the activity of MEK1/2 in the PVN affected by chronic OT. Phosphorylation 
levels were increased in both treatment groups compared to VEH. Treatment with 1 ng/h 
chronic OT increased pMEK1/2 by 4.9-fold (± 1.5), MEK1/2 phosphorylation levels 
increased 3.8-fold (± 1.0) induced by 10 ng/h chronic OT (Fig. 14A). Also, phosphorylation 
of ERK1/2 was upregulated but notably only in the high dose of chronic OT (pERK1: 2.5 ± 
0.2, pERK2: 2.2 ± 0.2). ERK1/2 activity remained unchanged in the 1 ng/h group (pERK: 
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1.0 ± 0.2, pERK2: 1.0 ± 0.2, Fig. 14B). This suggests an involvement of the MAPK pathway 
in the molecular effects of chronic OT similar to its activation seen in pregnancy and 
lactation or acute OT (Jurek et al., 2012; van den Burg et al., 2015). Total protein levels of 
MEK1/2 and ERK1/2 remained unchanged (Fig. 14C) Another MAPK signaling kinase 
ERK5 was phosphorylated in the 1 ng/h group but dephosphorylated in the 10 ng/h group 
(Fig. 14C). Furthermore, the MAPK-activated transcription factor CREB was significantly 
increased and activated in both treatment groups whereas MAPK-activated transcription 
factor ELK-1 remained unchanged (Fig. 14C). Although activated by chronic OT, the 
involvement of the alternative MAPK pathways p90RSK1 and MSK1/2 in the anxiogenic 
effect of chronic OT is unlikely, due to unspecific activation in both treatment groups (Fig. 
14C). p38 MAP kinase activity remained unchanged in both treatment groups (Fig. 14C). 
 
 
 
 
 
 
 
Figure 14. cOT-induced MAPK signaling. 
Western blot data is represented as mean fold changes (+SEM) relative to VEH groups. 
(A) MEK1/2 protein phosphorylation levels in PVN samples taken from male rats treated with VEH or cOT (1 
ng/h or 10 ng/h); number of animals: VEH/treatment groups = 7. One Way ANOVA on Ranks H = 8.396 with 2 
MEK1/2 ERK1 ERK2 pERK5 CREB pCREB p90RSK1 pp90RSK1 ELK-1 MSK pp38
1 ng/h cOT
10 ng/h cOT
One way ANOVA ns ns ns ns p < 0.001 p = 0.041 ns p < 0.05 ns p = 0.008 ns
(p-value vs. VEH) ns ns ns ns p = 0.025 p = 0.012 ns ns ns ns ns
Protein expression and phosphorylation: 0 1 2 3 4 5
(fold change)
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degrees of freedom p = 0.015, multiple comparisons versus control group (Dunn’s Method), * p < 0.05 1 ng/h 
and 10 ng/h vs VEH. (B) ERK1/2 protein phosphorylation levels in PVN samples taken from male rats treated 
with VEH or cOT (1 ng/h or 10 ng/h); number of animals: VEH/treatment groups = 7; pERK1: One way ANOVA 
F(2;20) = 9.672, p = 0.001, Holm-Sidak post hoc test, * p = 0.001 10 ng/h vs VEH and 1 ng/h; pERK2: One Way 
ANOVA on Ranks H = 10.293 with 2 degrees of freedom p = 0.006. All Pairwise Multiple Comparison Procedures 
(Tukey Test) * p < 0.05 10 ng/h vs VEH, * p < 0.05 10 ng/h vs 1 ng/h. (C) Heat map representing expression 
and phosphorylation levels of MAPK signaling related kinases. 
 
 
Focusing on the anxiogenic 10 ng/h chronic OT group, the next question was whether the 
activation of MAPK pathways culminates in the activation of transcription factors such as 
MEF2. DNA binding capacity, i.e. transcriptional activity of two isoforms, MEF2A and 
MEF2C was assessed in both male and female rats treated with chronic OT. In the PVN of 
male rats, MEF2A was activated in all treatment groups, independent of stress levels. The 
increase ranked between a fold change of 1.6 ± 0.1 (1 ng/h), and 1.5 ± 0.1 (10 ng/h and 10 
ng/h – stress, indicated as -s). Significant activation of MEF2C was only detectable in the 1 
ng/h (1.1 ± 0.03) group, shifting the focus of research towards MEF2A (Fig. 15A). Chronic 
OT seems to activate alternative pathways in females, as they displayed no significant 
changes in MEF2A and MEF2C activity (Fig.15B). 
 
 
 
Figure 15. cOT-dependent MEF2A/C activity in PVN of male and female rats. 
Analysis of cOT-dependent MEF2A and C activity in PVN samples from both male and female rats treated with 
VEH or cOT (1 ng/h and 10 ng/h) for 14 d. DNA binding was assesed using the TransAM® MEF2 transcription 
factor activation assay (Active Motif, Rixensart, Belgium). Results are shown as fold changes (+SEM) in binding 
activity compared to VEH. (A) Binding of MEF2A in males was significantly increased in all treatment groups: 
One way ANOVA, F(3;39) = 6.732, p = 0.001, Holm-Sidak post hoc test * p < 0.05 vs VEH; number of animals: 
                                                                                                                                   Results 
82 
 
VEH = 7; 1 ng/h cOT = 7, 10 ng/h cOT = 16, 10 ng/h cOT –s = 10. Binding of MEF2C in males was only increased 
in the 1 ng/h group: One way ANOVA F(2;17) = 5.633, p=0.015, Holm-Sidak post hoc test * p=0.015 vs VEH; 
number of animals: VEH/treatment groups = 6. (B) No significant changes in MEF2A and MEF2C DNA binding 
could be detected in females. Binding MEF2A females: One way ANOVA F(2;22) = 0.177; p = 0.839; number of 
animals: VEH/1 ng/h cOT = 8, 10 ng/h cOT = 7. Binding MEF2C females: One way ANOVA F(2;22) = 3.186; p = 
0.063; number of animals: VEH/ 1 ng/h cOT = 8, 10 ng/h cOT = 7. 
 
 
Next, I investigated whether the effect of chronic OT-induced MEF2 activation was region-
specific for the PVN. In hippocampal tissue of rats treated with chronic OT no changes in 
MEF2A or MEF2C activity were detectable (Fig 16A). Consistent with the behavioral 
observations, activation of MEF2A and MEF2C by chronic OT was of transient nature. 
Chronic OT affected MEF2A/C activity only during ongoing infusion, whereas 5 days after 
the infusion ended, both MEF2A and MEF2C activity in the PVN returned to basal (Fig. 
16B). 
 
 
Figure 16. cOT-dependent MEF2A/C activity in hippocampus (HPC) and after recovery. 
(A) MEF2A and MEF2C binding activity in HPC tissue of male rats after VEH or cOT (1 ng/h and 10 ng/h) 
treatment. Shown are fold changes in binding activity compared to VEH. MEF2A: One way ANOVA F(2,20) = 
0.632, p = 0.543; number of animals: VEH/treatment groups = 7. MEF2C: One way ANOVA F(2,20) = 0.347, p = 
0.712; number of animals: VEH/treatment groups = 7. (B) After a 5-days recovery period after cOT, binding of 
the two MEF2 isoforms was assessed again. No changes could be detected, indicating a transient effect also 
on a molecular level. MEF2A: One way ANOVA F(2,14) = 2.316, p = 0.141; number of animals: VEH/treatment 
groups = 5. MEF2C: One way ANOVA F(2;14) = 0.803, p = 0.471; number of animals: VEH/treatment groups = 
5. 
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Having proven that both MEF2A and MEF2C are activated by chronic OT (Fig. 17A), I was 
focused on a detailed analysis of the different phosphorylation sites. Parallel to the rise in 
activity, total MEF2 protein levels increased in PVN tissue lysates. In detail, MEF2A total 
protein levels increased 1.8-fold (± 0.3, 1 ng/h) and 1.6-fold (± 0.1, 10 ng/h) in the OT 
treatment groups compared to VEH. However, the effect in the 1 ng/h failed to reach 
significance (Fig. 17A). For MEF2C total protein levels, a significant increase (2.1 fold 
change ± 0.2) in the 10 ng/h chronic OT group was detected, whereas in the 1 ng/h group 
(1.6 fold change ± 0.1) significance was not reached (Fig. 17A). 
MEF2A activity appeared to be orchestrated by three different phosphorylation sites as 
shown by further analysis of MEF2 phosphorylation patterns. The phosphorylation of the 
transcription activating site Thr312 increased 2.2-fold (± 0.4) in the PVN by 1 ng/h chronic 
OT, whilst 10 ng/h chronic OT increased phosphorylation by 1.7-fold (±0.1, Fig. 17B). A 
second transcription activating site, Thr319 was significantly activated in both treatment 
groups (4.1 fold change ± 0.3 for 1 ng/h and 3.3 fold change ± 0.2 for 10 ng/h). Analysis of 
the transcription inhibitory site S408 revealed a significant 0.5-fold (± 0.1) 
dephosphorylation exclusively in the PVN of rats treated with the high dose of chronic OT 
(Fig. 17B). As this phosphorylation pattern corresponded to the increased anxiety-like 
behavior in the 10 ng/h chronic OT group, the S408 phosphorylation is likely to be the main 
driver of the chronic OT-induced molecular effects leading to the anxiogenic effect. 
Despite the analysis of several phosphorylation sites on MEF2C, its activity could not be 
linked to the observed behavioral changes induced by the high dose of chronic OT. 
Phosphorylation at S58 was only increased in the 1 ng/h group (1.8 fold change ± 0.2), 
whereas phosphorylation at S396 was increased in both treatment groups, 4.1-fold (± 0.3) 
induced by 1 ng/h and 2.0-fold (± 0.2) by 10 ng/h chronic OT (Fig. 17C). Phosphorylation 
levels at S387 remained unaffected in both treatment groups compared to VEH (1 ng/h: 1.3 
± 0.2; 10 ng/h: 1.7 ± 0.1, Fig. 17C). 
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Figure 17. PVN MEF2A and C signaling after cOT in males. 
Western blot data is represented as mean fold changes (+SEM) relative to VEH groups. 
(A) Both MEF2A and MEF2C total protein expression in PVN were significantly increased after 10 ng/h cOT 
treatment in male rats. MEF2A: One Way ANOVA on Ranks; H = 7.156 with 2 degrees of freedom, p = 0.028, 
All Pairwise Multiple Comparison Procedures (Dunn’s Method): * p < 0.05 10 ng/h vs VEH; number of animals: 
VEH/1 ng/h = 6, 10 ng/h = 7. MEF2C: One way ANOVA F(2;19) = 10.189 p < 0.001, Holm-Sidak post hoc test *p 
< 0.001 10 ng/h vs VEH, VEH = 6, treatment groups = 7. (B) Fold changes in phosphorylation levels of MEF2A 
at several amino acid residues in PVN after VEH or cOT (1 ng/h and 10 ng/h) treatment in male rats. pMEF2A 
Thr312: One Way ANOVA on Ranks, H = 9.106 with 2 degrees of freedom, p = 0.011. All Pairwise Multiple 
Comparison Procedures (Tukey Test): * p < 0.05 1 ng/h vs VEH; number of animals: VEH/treatment groups = 
7. pMEF2A Thr319: One way ANOVA F(2,17) = 41.139 p < 0.001, Holm-Sidak post hoc test overall significance 
level p = 0.05; * p < 0.001 1 ng/h vs VEH, * p < 0.001 10 ng/h vs VEH, p = 0.041 1 ng/h vs 10 ng/h; number of 
animals: VEH/treatment groups = 6. pMEF2A S408: One way ANOVA F(2;23) = 4.614, p = 0.022, Student-
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Newman-Keuls post hoc test * p = 0.022 10 ng/h vs 1 ng/h, * p = 0.033 10 ng/h vs VEH; number of animals: 
VEH/1 ng/h = 7, 10 ng/h = 10. (C) Fold changes in phosphorylation levels of MEF2C in PVN after cOT (1 ng/h 
and 10 ng/h) in male rats compared to VEH treatment. pMEF2C S59: One way ANOVA F(2,20) = 14.718, p < 
0.001, Holm-Sidak post hoc test, * p < 0.001 1 ng/h vs VEH, p = 0.988 10 ng/h vs VEH, p < 0.001 1 ng/h vs 10 
ng/h; number of animals: VEH/treatment groups = 7. pMEF2C S396: One way ANOVA F(2,17) = 48.277, p < 
0.001, Holm-Sidak post hoc test, * p < 0.001 1 ng/h vs VEH, * p = 0.011 10 ng/h vs VEH, p < 0.001 1 ng/h vs 
10 ng/h; number of animals: VEH/1 ng/h = 7, 10 ng/h = 6. pMEF2C S387: One way ANOVA F(2,20) = 1.762, p = 
0.200; VEH/treatment groups = 7, cOT treatment did not induce statistically significant differences. (D) 
Representative western blots of MEF2A and C protein expression as well as the corresponding phosphorylation 
sites. 
 
 
Despite the effect of the low dose of chronic OT on anxiety in female rats, MEF2A and 
MEF2C DNA binding activity remained unchanged (Fig. 15B), indicating sexually dimorphic 
downstream signaling. Further analysis of MEF2A and C phosphorylation sites 
substantiated these observations. The corresponding phosphorylation sites Thr319 and 
S408 of MEF2A were both not affected by chronic OT treatment in female rats (Fig. 18A). 
Also, no activation of MEF2C, represented by phosphorylation at the amino acid residue 
S396 was detectable (Fig. 18A). 
 
Figure 18. PVN MEF2A and C signaling after cOT in females. 
(A) Mean fold changes in protein phosphorylation induced by cOT (1 ng/h and 10 ng/h) treatment compared to 
VEH. Treatment did not lead to significant differences in female rats. pMEF2A Thr312: One way ANOVA F(2;11) 
= 3.287, p = 0.085; number of animals: VEH/treatment groups = 4. pMEF2A S408: One way ANOVA F(2;11) = 
0.8637, p = 0.454; number of animals: VEH/treatment groups = 4. pMEF2C S396: One way ANOVA F(2;11) = 
0.995, p = 0.407; number of animals: VEH/treatment groups = 4. (B) Representative western blots of MEF2A 
and C protein phosphorylation. 
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To exclude the ability of an acute bolus of OT to increase the transcriptional activity of 
MEF2A or MEF2C, both total protein expression and DNA binding activity were assessed. 
Neither an infusion directly into the PVN (Fig. 19A and B), nor an i.c.v. infusion (Fig. 19C) 
had effects on these parameters. This indicated again the transient and late-onset nature 
of the effect of chronic OT with regard to MEF2A and MEF2C activation. 
 
 
 
Figure 19. MEF2A/C signaling after acOT treatment. 
(A) MEF2A and C total protein levels were assessed after acute treatment with either VEH or OT. For both 
MEF2A and C, acOT did not lead to altered total protein levels. Data are represented as mean fold changes 
(+SEM) relative to VEH groups. MEF2A: t = 0.616 with 11 degrees of freedom, one-tailed p-value = 0.275; 
number of animals: VEH = 6; OT = 7. MEF2C: Rank Sum Test, Mann-Whitney U Statistic= 20.000, p = 0.945; 
number of animals: VEH = 6; OT = 7. (B) acOT-induced MEF2A binding activity in PVN of male rats was 
analyzed, treatment did not lead to altered MEF2A activity. Data are represented as mean fold changes (+SEM) 
of DNA binding activity compared to VEH. t = 0.0938 with 11 degrees of freedom, one-tailed p-value = 0.463; 
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number of animals: VEH = 6, OT = 7. (C) MEF2A and MEF2C binding in PVN after i.c.v. VEH or acOT treatment. 
Data are represented as mean fold changes (+SEM) of DNA binding activity compared to VEH. MEF2A: Rank 
Sum Test; Mann-Whitney U Statistic = 8.000, p = 0.247; number of animals: VEH = 5, OT = 6. MEF2C: Rank 
Sum Test; Mann-Whitney U Statistic = 11.000, p = 0.537; number of animals: VEH = 5, OT = 6. i.c.v. infused 
acOT has also no effects on MEF2A and MEF2C activity. 
 
 
In summary, the high dose of chronic OT (10 ng/h) is anxiogenic and, on a molecular level, 
activates the MAPK pathway via phosphorylation of MEK1/2 and ERK1/2. This causes the 
subsequent dephosphorylation of the transcriptional inhibitory residue S408 at MEF2A. 
These effects are transient and of late-onset, as after recovery of 5 days as well as after 
acute OT treatment none of the effects were detectable. 
 
 
2.2. MEF2A activity induced by chronic oxytocin shifts the expression of mCRFR2α 
to sCRFR2α 
The specific activation of the MAPK pathway and MEF2A signaling in the PVN led to the 
hypothesis that the hypothalamic PVN is the main target brain region where chronic OT 
treatment might act. To assess further downstream targets of chronic OT signaling, a PCR 
array for several stress-, anxiety-, and neuroplasticity-related genes associated with MEF2 
was conducted. 
PCR array analysis with PVN tissue samples revealed increased sCrfr2α (1.3 fold change) 
and decreased mCrfr2α (0.7 fold change) mRNA levels in rats treated with the high dose of 
OT compared to VEH (Fig. 20A). Furthermore, the transcription factor paired box 3 (Pax3) 
was 0.2-fold downregulated, whereas the closely related Pax2 was 2-fold upregulated. 
Despite the behavioral differences, a similar pattern could be observed in the low dose of 
OT. Pax2 was 1.5-fold upregulated as well as sCrfr2α (1.9 fold change). Additionally, a 
significant increase in tyrosine hydroxylase (Th, 1.7 fold change) mRNA levels and a 
decrease in Ucn (0.4 fold change) mRNA levels appeared. Similar to the 10 ng/h group, 
Pax3 (0.3 fold change) and mCrfr2α (0.7 fold change) mRNA expression was reduced (Fig. 
20B). 
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Figure 20. cOT-induced effects on stress-, anxiety-, and neuroplasticity-related genes. 
(A) PCR array analysis of PVN samples after 10 ng/h cOT compared to VEH. The ΔΔCT method was used for 
calculations; number of animals: VEH = 5, 10 ng/h = 6. The following p-values were acquired for statistical 
significant differences: Pax3 * p = 0.021, mCrfr2α * p = 0.02, sCrfr2α # p = 0.09, Pax2 * p = 0.05. (B) PCR array 
analysis of PVN samples after 1 ng/h cOT compared to VEH. The ΔΔCT method was used for calculations; 
number of animals: VEH = 5, 1 ng/h = 6. The following p-values were acquired for statistical significant 
differences: Pax3 * p = 0.043, Ucn * p = 0.029, mCrfr2α * p = 0.022, sCrfr2α # p = 0.09, Th # p = 0.080. 
Data in (A) and (B) being shown as mean fold changes compared to VEH, values > 1 represent upregulation, 
values < 1 represent downregulation in mRNA expression. 
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With the in silico detection of a MEF2A responsive element within Exon 6 of the Crfr2 gene 
(Winter et al., in preparation) and the data obtained from the PCR array, the CRFR2 was a 
promising target for chronic OT-mediated MEF2A signaling. 
The differential regulation in mCrfr2α/sCrfr2α mRNA expression was also reflected on 
protein levels. The behaviorally relevant 10 ng/h group expressed significantly more 
sCRFR2α protein in the PVN (fold change 4.2 ± 0.6), mCRFR2 levels remained unchanged 
(fold change 2.4 ± 0.5, Fig. 21A and B). In the 1 ng/h group, OT had no significant impact 
on mCRFR2α (fold change 2.0 ± 0.3) and sCRFR2α (fold change 2.3 ± 0.3) protein 
expression (Fig. 21A and B). Despite the regulation of mCrfr2α/sCrfr2α mRNA in both 
groups as seen in the PCR array (Fig.20A and B), and the trend to an overall increase in 
mCRFR2α/sCRFR2α protein levels (Fig. 21A and B), only the high dose of OT caused a 
significant shift in mCRFR2α/sCRFR2α protein ratio (Fig. 21C lower panel and 21D). The 
ratio shifted from 79.0 % mCRFR2α in the VEH to 88.3 % in the 10 ng/h OT group, 
respectively, the sCRFR2α portion halved from 21.1 % (VEH) to 11.8 % (10 ng/h, Fig. 21D). 
As this shift occurred exclusively in the 10 ng/h chronic OT group, the ration between 
membrane-bound and soluble receptors appears to be a crucial factor in the regulation of 
anxiety-related behavior by chronic OT. In line with the absence of MEF2 activation in the 
PVN of female rats after chronic OT infusions as well as after an acute bolus of OT in males, 
neither treatment had an impact on mCRFR2α/sCRFR2α protein ratio (Fig. 21E and F). In 
females, the ratio of mCRFR2α and sCRFR2α ranked between 30.2 % to 69.8 % and 48.0 
% to 52.0 % (Fig. 21E). In males treated with acute OT, the percentage of both splice 
variants was around 50 % and remained unaffected by treatment (Fig. 21F). 
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Figure 21. mCRFR2α and sCRFR2α protein expression. 
Changes in protein expression levels of mCRFR2α (A) and sCRFR2α (B) induced by cOT (1 ng/h and 10 ng/h) 
treatment. Data are shown as mean fold changes (+SEM) compared to VEH. mCRFR2α: One way ANOVA 
F(2,16) = 3.416, p = 0.062; number of animals: VEH = 5, treatment groups = 6. sCRFR2α: One way ANOVA F(2,16) 
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= 10.630, p = 0.002, Holm-Sidak post hoc test, * p = 0.001 10 ng/h vs VEH, p = 0.025 1 ng/h vs 10 ng/h; number 
of animals: VEH = 5, treatment groups = 6. (C) Upper panel: Representative bands of mCrfr2α (400bp)/sCrfr2α 
(300bp) mRNA after VEH and cOT (1 ng/h and 10 ng/h) treatment. Lower panel: Representative western blot 
image of mCRFR2α (~ 50kDa) and sCRFR2α (~ 30kDa) levels after chronic treatment with either VEH or cOT 
(1 ng/h and 10 ng/h). The antibody used recognizes both mCRFR2α and sCRFR2α (EMD Millipore, ABN433). 
(D) 10 ng/h cOT led to an increased level of sCRFR2α in relation to mCRFR2α. Data are shown as ratio of 
mCRFR2α and sCRFR2α protein expression in % after chronic treatment with VEH or cOT (1 ng/h and 10 ng/h) 
in male rats. One way ANOVA F(2;15) = 5.311, p = 0.021, Holm-Sidak post hoc test * p = 0.019 10 ng/h vs VEH; 
number of animals: VEH = 6, 1 ng/h = 5, 10 ng/h = 6. (E) Analysis of the ratio of mCRFR2α/sCRFR2α protein 
expression in % revealed no changes induced by cOT (1 ng/h and 10 ng/h) in female rats. One way ANOVA 
F(2;16) = 1.801, p = 0.201; number of animals: VEH/10 ng/h cOT = 5, 1 ng/h cOT = 7. (F) Treatment with acOT 
had also no effects on the ratio of mCRFR2α/sCRFR2α protein expression in %; t = 0.784 with 11 degrees of 
freedom, two-tailed p-value = 0.450; number of animals: VEH = 6, OT = 7. 
 
 
After the importance of the ratio between mCRFR2α and sCRFR2α was proven, the impact 
of CRFR2 expression but also activity in the PVN on anxiety-like behavior was assessed. 
Therefore, the highly CRFR2-selective antagonist ASV or the agonist SCP were infused 
locally into the PVN. Infusion of ASV increased anxiety-like behavior in the LDB from 29.1 
% (± 2.4 %) time spent in the LB to 20.9 % (± 1.9 %), whereas SCP acted anxiolytic and 
increased the time treated animals spent in the LB to 46.2 % (± 7.4 %, Fig 22A). This data 
provides evidence for the anxiolytic role of CRFR2 activity in the PVN of male rats. To further 
specify the role of CRFR2α and the soluble splice variant, ASOs targeting either the 
sCRFR2α (GapmeRs) or the mCRFR2α (TSB) were injected locally into the PVN. Diffusion 
of locally injected ASOs was representatively analyzed by confocal microscopy of the 5’-
FAM label (Fig. 22B; green) in the corresponding brain areas (OT neurons in magenta); 
ASOs were mostly found in hypothalamic areas with particularly prominent labeling in the 
PVN target region (Fig. 22B). 
Specific KD of the sCRFR2α splice variant in the hypothalamus using GapmeRs, led to 
decreased anxiety-related behavior both in the LDB (increased time spent in LB from 36.3 
% ± 10.8 % to 55.1 % ± 8.6 %; Fig. 22C; left panel) and the OFT (increased time spent in 
inner zone from 3.9 % ± 1.2 % to 8.0 % ± 2.1 %; Fig. 22C; right panel). On the other hand, 
blocking of the splice sites flanking exon 6 which are responsible for the inclusion of exon 
6 in the mature mRNA by TSBs increased anxiety in the LDB from 53.8 % (± 9.3 %) time 
spent in the LB to 28.0 % (± 10.5 %) time spent in the LB after TSB treatment (Fig. 22D). 
Knocking down the alternative splice variant, thereby leaving the regular form unaltered, 
yielded in the formerly unknown anxiogenic effect of the splice variant for anxiety-related 
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behavior. This is supported by increased anxiety levels due to enhanced alternative splicing 
induced by TSB treatment. 
Anxiety and social behaviors are closely linked (Menon et al., 2018), therefore, social 
preference was assessed after both GapmeR and TSB applications. All animals displayed 
social preference as they spent 2 to 3 times more time investigating a conspecific compared 
to a non-social stimulus (empty cage, Fig. 22E), excluding a social component of the 
sCRFR2α. 
 
 
 
Figure 22. Manipulation of mCRFR2α and sCRFR2α expression in the PVN alters anxiety-related 
behavior. 
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(A) Effects of agonism and antagonism of the CRFR2 in the PVN on anxiety-like behavior in male rats. Intra-
PVN administration of the CRFR2 antagonist ASV (280 µM, corresponding to 0.14nmol/0.5µl per side) increased 
anxiety in the LDB 10 min after infusions. On the other hand, administration of CRFR2 agonist SCP (1.4 mM, 
corresponding to 3µg/0.5 µl per side) led to decreased anxiety-like behavior. Data shown as mean percentage 
of time spent in the LB. One way ANOVA, F(2;51) = 12.099; p < 0.001, Holm-Sidak post hoc test * p = 0.03 ASV 
vs VEH, * p = 0.003 SCP vs VEH, p < 0.001 ASV vs SCP; number of animals: VEH = 23, ASV = 21, SCP = 8. 
(B) Representative distribution of 5’-FAM-labelled ASOs in the hypothalamic area after microinfusions 
(1nmol/0.5µl per animal). Direct infusions into the PVN resulted in mostly PVN, but also dorsal hypothalamus 
staining. Magenta: OT-Neurophysin positive neurons, green: ASOs. (C) Left panel: The anxiolytic effect of 
sCRFR2α KD on anxiety-like behavior was assessed in the LDB (7 days after GapmeR infusion) and the OFT 
(8 days after GapmeR infusion). Data are shown as mean percentage of time spent in the LB (t = -1.762 with 
16 degrees of freedom, one-tailed t-test * p = 0.0486), and the mean percentage of time in the inner zone (IZ) 
of the OFT (Rank Sum Test, Mann-Whitney U Statistic = 16.000, * p = 0.037); animal numbers for both tests: 
VEH = 10, GapmeR = 8. Right panel: Representative heat maps showing the location of a VEH and GapmeR 
treated rat in LB and DB of the LDB or the inner and outer zone of the OFT over the testing period. (D) Increasing 
the availability of the splice variant with TSBs had contrary effects on anxiety-like behavior compared to GapmeR 
treatment. Rats showed increased anxiety-like behavior in the LDB 7 days after TSB administration. t = 1.843 
with 18 degrees of freedom, one-tailed p-value * p = 0.0409; number of animals: VEH/TSB = 10. Right panel: 
Representative heat maps showing the location of a VEH and TSB treated rat in LB and DB of the LDB over the 
testing period. (E) The impact of sCRFR2α expression on social preference was measured by the percentage 
of time an animal spent investigating (sniffing) a non-social stimulus (empty cage) versus a social stimulus (cage 
with a conspecific) for 5 min each. All rats displayed social preference (VEH/scr, * p = 0.001 non-social vs social, 
GapmeR, * p = 0.033 non-social vs social, TSB, * p < 0.01 non-social vs social; Bonferroni’s post hoc analysis; 
number of animals: VEH/treatment groups = 10) with no significant effect of treatment, indicating an exclusive 
anxiety-related effect of the splice variant and excludes a social component of the sCRFR2α. 
 
 
2.3. Chronic oxytocin promotes the release of sCRFR2α and leads to increased 
anxiety 
Release of the sCRFR2α from cells into the culture medium has already been shown, 
although no secretory properties could be proven (Chen et al., 2005; Evans and Seasholtz, 
2009). CSF taken from urethan-anesthetized rats contained detectable amounts of 
sCRFR2α. Dot blot analysis after GapmeR treatment confirmed the decrease in sCRFR2α 
levels (Fig. 23A). GapmeR-treated rats had a significantly lower load (fold change 0.5 ± 0.1) 
of the splice variant in the CSF compared to VEH treated rats. To ensure the specificity of 
the antibody, several control samples were analyzed (Fig. 23B). Cerebellum tissue served 
as negative control, with minimal sCRFR2α expression, whereas PVN tissue expressed 
higher levels of the splice variant (Fig. 23B). A correlation between anxiety levels and 
sCRFR2α abundance in CSF shed further light on the impact of sCRFR2α on anxiety-like 
behavior. High sCRFR2α levels significantly correlated with high anxiety levels. The more 
splice variant was found in the CSF, the less time the animals spent in the LB, indicating 
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higher anxiety levels (Fig. 23C). Due to the observed interplay between the anxiogenic 
effect of chronic OT and a previous mild stressor, the impact of stress and OT, respectively, 
on CSF-sCRFR2α levels was assessed. Unstressed rats had a lower abundance of 
sCRFR2α in the CSF compared to stressed rats (Fig. 23D). Additional treatment with the 
high dose of chronic OT even caused doubling of sCRFR2α levels compared to unstressed 
rats (Fig. 23D), indicating a combinatorial effect of stress and chronic OT on anxiety as well 
as on sCRFR2α release. 
 
 
Figure 23. sCRFR2α release into CSF and anxiety. 
(A) sCRFR2α levels in the CSF of GapmeR-infused rats were quantified by dot blot analysis. Reduced signal 
intensity represents reduced release of sCRFR2α, indicating an efficient KD and overall reduced sCRFR2α 
expression in the brain. Data are shown as fold changes in protein occurrence compared to VEH, t = 1.828 with 
12 degrees of freedom, one-tailed t-test, * p = 0.046; number of animals: VEH =8, GapmeR = 6. (B) 
Representative picture of dot blot analysis of CSF (VEH and GapmeR) and control tissue protein lysates 
(cerebellum = CB as negative control, PVN as positive control, H2O). (C) Significant correlation between CSF 
levels of sCRFR2α and anxiety-like behavior (% time spent in LB) as shown by linear regression (R = -0.54, one 
way ANOVA F(1;13) = 4.946, p = 0.046). (D) The effect of stress on sCRFR2α release into CSF of rats treated 
with VEH and 10ng/h cOT and an unstressed control was analyzed by dot blot. Both stress and cOT treatment 
increased sCRFR2α release compared to unstressed animals. However, the effect did not reach significance, 
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one way ANOVA F(2,13) = 3.849, p = 0.053; number of animals: no stress = 4, VEH (stress) = 7, 10 ng/h (stress) 
= 3. 
 
 
As the mild stress had profound effects on anxiety-related behavior and also influenced 
release of the sCRFR2α, both mCRFR2α and sCRFR2α protein levels as well as MEF2A 
activation were determined in animals that underwent LDB with and without prior stress 
exposure. This experiment aimed to separate the effects of the mild stress from the chronic 
OT infusion on the CRFR2α and MEF2A. Therefore, it is important to note, that in the graphs 
shown in Fig. 24, all animals received 10ng/h chronic OT, the difference between the groups 
being the exposure to stress (+s) or no stress. sCRFR2α protein levels remained unaffected 
by stress exposure (Fig. 24A). However, there was a slight yet significant increase of 1.4-
fold (± 0.2) in mCRFR2α expression after elevated platform stress 24 h before LDB testing. 
The high dose of chronic OT had no differing effects on MEF2A phosphorylation levels at 
S408 (Fig. 24B), which suggests stress-independent activation of MEF2A signaling. 
 
 
 
Figure 24. Stress has no effects on protein expression of sCRFR2α and the phosphorylation of MEF2A. 
A separate group of animals treated with 10 ng/h cOT was analyzed with and without the mild elevated platform 
stress on day 13. (A) No effects on sCRFR2α expression were detected, but a slight yet significant upregulation 
of the mCRFR2α was caused by the stressor. Data shown as mean fold change compared to VEH treatment. 
sCRFR2α: t = -0.0214 with 18 degrees of freedom, one-tailed p-value = 0.492; number of animals: all treatment 
groups = 10. mCRFR2α: Rank Sum Test, Mann-Whitney U Statistic = 23.000, * p = 0.045 10 ng/h +s vs 10 ng/h; 
number of animals: all treatment groups = 10. (B) The mild stressor had no effect on the previously observed 
decrease in protein phosphorylation of MEF2A S408, t = -0.717 with 18 degrees of freedom, one-tailed p-value 
= 0.241; number of animals: all treatment groups = 10. 
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The lateral septum and the hypothalamus are closely related in the regulation of anxiety, 
e.g. via outputs from the lateral septum to the hypothalamus. CRFR2 activity in the lateral 
septum differentially affects anxiety, depending on cell type and severity of stress, as 
antagonism of the CRFR2 was shown to be anxiolytic under high-stress conditions (Bale et 
al., 2002a). As shown in the results above, the hypothalamic PVN was the main brain region 
where chronic OT exhibited its effects. Several control regions including the hippocampus 
remained unaffected by chronic OT. The lateral septum as a region of high CRFR2 
expression displayed increased mCrfr2α mRNA levels upon chronic OT administration. The 
low dose of chronic OT caused a 13.3-fold (± 0.7) significant increase in mCRFR2α 
expression, the high dose led to an increase of 5.0-fold (± 0.4, Fig. 25A). sCRFR2α mRNA 
levels were increased in both treatment groups, 5.4-fold (± 0.4) by 1 ng/h and 8.9-fold (± 
0.4) by 10 ng/h, despite the profound elevation, only an overall statistical effect of p = 0.062 
could be reached (Fig. 25A). Analysis of the upstream signaling pathway excluded an 
involvement of MEF2A, no changes in MEF2A mRNA levels could be detected (Fig. 25A). 
To deepen the understanding of an involvement of the lateral septum in the anxiogenic 
phenotype of chronic OT, more analysis will be necessary, regarding protein expression 
and ratio as well as activation of transcription factors. Due to the impact of intra-PVN 
infusions of TSB and GapmeRs, the lateral septum was not investigated in more depth, 
however, it will be subject of further studies. 
 
 
Figure 25. Effects of cOT treatment on mCrfr2α, sCrfr2α, and Mef2a mRNA expression in the lateral 
septum. 
(A) mRNA levels of mCrfr2α, sCrfr2α and Mef2a were analyzed in the lateral septum, as cOT led to a slight 
reduction of OT binding there (Winter et al., in preparation). Both Crfr2α variants were upregulated in the septum 
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by the low dose of chronic OT, whereas Mef2a levels remained unchanged. mCrfr2α: One way ANOVA on 
Ranks, H = 9.773 with 2 degrees of freedom. All pairwise multiple comparison procedure (Tukey test), * p = 
0.006 1 ng/h cOT vs VEH; number of animals: VEH = 5, treatment groups = 6. sCrfr2α: One way ANOVA on 
Ranks, H = 5.577 with 2 degrees of freedom, # p = 0.062; VEH = 5, treatment groups = 6. Mef2a one way 
ANOVA on Ranks, H = 3.228 with 2 degrees of freedom, p = 0.199. VEH = 5, treatment groups = 6. (B) 
Localization of the septum within the rodent brain marked with red dots (Paxinos, 1998). 
 
 
To determine the intracellular reallocation of mCRFR2α and sCRFR2α, the intact 
transmembrane receptor was labeled using CRISPR-mediated HiBiT tagging. This 
technique consists of the genomic insertion of a tag-sequence into the target gene, which, 
once expressed as protein, labels the membrane-bound target protein on the cell surface. 
In this case, I inserted the HiBiT donor sequence into the Exon 6 of the CRFR2 gene, which 
resulted in the expression of the HiBiT in an extracellular domain of the CRFR2. By 
application of the corresponding LgBiT protein (spoken as “large BiT”), the mCRFR2α was 
made visible in live cells by the fluorescent reaction of the HiBiT-LgBiT-complex (Fig. 26A). 
As this is no “end-point” assay, in theory, multiple cycles of membrane incorporation and 
internalization of the receptor can be visualized. However, to prove my point it was sufficient 
to assess just on time point after OT stimulation. Luminescence measurements revealed a 
decrease in membrane-bound CRFR2α after long-term stimulation (24 h) using a 
concentration of 100nM OT, corresponding to the high dose chronic OT treatment in vivo 
(Fig. 26B). Mean luminescence decreased from 1521 (± 79) to 1186 (± 28, Fig. 26B). 
However, the HiBiT system only allowed the detection and analysis of the intact membrane-
bound mCRFR2α. Assessment of sCRFR2α release into the extracellular space was 
determined by dot blot analysis of sCRFR2-content in the cell culture medium. In line with 
previous publications, I detected sCRFR2α release into the extracellular medium under 
basal conditions, however, OT stimulation significantly increased sCRFR2 release into the 
medium, supporting our in vivo data (Fig. 26C and Fig. 23D). In untreated cells the mean 
gray intensity, reflecting sCRFR2α in the medium, averaged 5811 (± 798), whereas the 
release increased to 62499 (± 20380) after chronic OT treatment (Fig. 26C). 
In addition, the distribution of the sCRFR2α was also detectable in immunocytochemical 
stainings of rat hypothalamic primary cells (Fig. 26D). The sCRFR2α signal (Fig. 26D; 
green) was diffuse and detectable within the entire cytoplasm (Fig. 26D, upper panel). Co-
stainings with GFAP (Fig. 26D; magenta) demonstrated both neuronal and glial expression 
of the sCRFR2α, and its distributed expression in the cell soma, neurites, and especially 
the end-boutons of the neurites (Fig. 26D, lower panel). 
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Figure 26. in vitro sCRFR2α release and membrane expression of the mCFRFR2α. 
(A) Schematic representation of HiBiT-mediated signaling in H32 cells stimulated with either VEH or OT for 24 
h. (B) mCRFR2α membrane expression was assessed by luminescence caused by the interaction of the 
extracellular HiBiT-tag and the corresponding substrate (LgBiT) that was applied to the cells before 
measurements. Treatment with 100 nM OT for 24 h decreased the luminescent signal, indicative of alternative 
splicing of Exon 6 and the subsequent reduction in membrane expression of mCRFR2α. Data are shown as 
absolute values of mean luminescence. Rank Sum Test, Mann-Whitney U Statistic = 32.000, * p ≤ 0.001; n-
number: VEH = 20, OT = 12. (C) In HiBiT-expressing cells, OT treatment (100 nM for 24 h) also led to a 10-fold 
increased release of sCRFR2a into the medium. Data are shown as average gray intensity relative to area; 
Rank Sum Test, Mann-Whitney U Statistic < 0.001, * p = 0.029; n-number: VEH/OT = 4. (D) Rat hypothalamic 
mixed primary cultures were stained for DAPI (blue), anti-sCRFR2α (green), and GFAP (magenta), illustrating 
cytoplasmic distribution of sCRFR2α in neuronal cells (GFAP negative) and astrocytes (GFAP positive). 
Biorender.com 
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To specify the role of the transcription factor MEF2A on mCRFR2α expression and 
alternative splicing, RNA interference was used to generate a transient KD of MEF2A 
(Mef2a_KD). To exclude an effect of siRNA treatment per se, control cells were also treated 
with a non-targeting scrambled control RNA (scrRNA) and compared to mCRFR2α and 
sCRFR2α levels of Mef2a_KD cells. First, the efficiency of the KD was verified via western 
blot, revealing a decrease to 0.1-fold (± 0.03) of MEF2A protein levels by siRNA treatment 
for 72 h (Fig. 27A). Both mCRFR2α (0.2 fold change ± 0.02) and sCRFR2α (0.5 fold change 
± 0.05) protein levels were significantly decreased by the KD of Mef2a, supporting the 
hypothesis of a direct link between MEF2A and CRFR2α (Fig. 27B). Furthermore, in silico 
analysis revealed a MEF2A responsive element within Exon 6 of the CRFR2 gene. A 
mechanistic proof for MEF2A binding to the CRFR2 gene has been provided by a 
Chromatin-Immunoprecipitation experiment (data not shown), as described in my 
manuscript (Winter et al., in preparation). 
 
 
 
 
 
 
Figure 27. mCRFR2α and sCRFR2α expression are MEF2A-dependent. 
mCRFR2α and sCRFR2α expression depend on MEF2A, as revealed by siRNA-mediated KD of MEF2A. 
Reduced MEF2A availability decreased both mCRFR2α and sCRFR2α protein expression levels in otherwise 
untreated H32 cells. (A) Treatment with siRNA (5µg) targeting Mef2a mRNA for 72 h led to a significant reduction 
in MEF2A protein levels, t = 8.301 with 10 degrees of freedom, two-tailed p-value = 0,00000851, * p < 0.01. (B) 
mCRFR2α and sCRFR2α protein levels were significantly downregulated after siRNA treatment. mCRFR2α: 
Rank Sum Test, Mann-Whitney U Statistic < 0.001, * p = 0.002. sCRFR2α: t = 2.574 with 10 degrees of freedom; 
one-tailed p-value = 0.0138; n-number: scrRNA/Mef2a_KD = 6 for all targets. 
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So far only expression patterns in whole-cell protein lysates, containing membrane-, 
cytoplasmic-, and nuclear proteins, were assessed. As a next step, to determine 
internalized receptor proteins, cytoplasmic proteins were separately isolated and analyzed 
for OT-induced changes in mCRFR2α and sCRFR2α protein expression levels. 24 h of 
stimulation with 100nM OT caused a significant increase in cytoplasmic sCRFR2α levels 
(1.5 fold change ± 0.1). The mCRFR2 levels in the cytoplasm, which represent vesicular 
stored receptors, ready for membrane incorporation, remained constant (Fig. 28A). This 
result confirms in vivo data and the hypothesis of an increase in the soluble, cytoplasmic 
splice variant sCRFR2α upon OT stimulation. 
 
 
Figure 28. mCRFR2α and sCRFR2α expression in cytoplasm. 
(A) Specific isolation of cytoplasmic proteins revealed an increase of sCRFR2α protein levels induced by OT 
treatment (100 nM OT, 24 h) in H32 cells. Data are shown as mean fold changes of protein expression compared 
to VEH. mCRFR2α: t = -0.742 with 18 degrees of freedom; one-tailed p-value = 0.234. sCRFR2α: t = -3.071 
with 18 degrees of freedom, one-tailed p-value = 0.00329; n-number: VEH/OT = 10. (B) Representative western 
blot images of mCRFR2α and sCRFR2α antibody staining. 
 
 
Next, as also shown in vivo, the in vitro effects of a 100 nM acute OT stimulation (10 and 
30 min) on CRFR2α expression and alternative splicing in H32 cells were investigated. No 
statistically significant changes were induced by acute OT treatment, confirming my 
hypothesis of a CRFR2-system that is only responsive to a chronic OT stimulus. However, 
the mCRFR2α was slightly reduced by 30 min of OT stimulation (0.3 fold change ± 0.2), 
whereas sCRFR2α levels remained constant (Fig. 29A). As only a very weak signal of 
mCRFR2α could be detected in western blot analysis, results should be interpreted carefully 
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(Fig. 29B). Preliminary analysis of phosphorylation levels of MEF2A S408 revealed a 0.4-
fold reduction (± 0.1) after 30 min (data not shown). 
 
 
Figure 29. mCRFR2α and sCRFR2α expression induced by acute OT in H32 cells. 
(A) Acute treatment with OT (100 nM, 10 and 30 min) had differential effects on mCRFR2α and sCRFR2α 
expression. mCRFR2α: Two way ANOVA main effect of treatment F(1,15) = 5.384, p = 0.039, there is no main 
effect of time F(1,15) = 0.284, p = 0.604. There is a statistically significant interaction between treatment and time 
point F(1,15) = 7.631, p = 0.017; n-number: VEH/OT 10/30 min = 4. sCRFR2α: Two way ANOVA revealed no 
main effect of treatment F(1,15) = 0.000545, p = 0.982, also treatment had no statistically significant effect F(1,15) 
= 0.0853, p = 0.775. There is also no statistically significant interaction between treatment and time point F(1,15) 
= 0.499, p = 0.493; n-number: VEH/OT 10/30 min = 4. (B) Representative western blot images of mCRFR2α 
and sCRFR2α antibody staining. 
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3. Effects of chronic oxytocin on neuronal morphology and signaling in vitro 
 
Further analysis of OT effects on downstream signaling and neuronal morphology was 
transferred from in vivo experiments to in vitro studies in several neuronal cell lines. Cell 
lines are a powerful tool in studying molecular signaling cascades, furthermore, changes in 
neuronal morphology become easily accessible. Morphological analysis assesses 
parameters like the size and shape of a cell (Delarue et al., 2017; Meyer et al., 2018), neurite 
length (Lestanova et al., 2016b; Lestanova et al., 2017; Meyer et al., 2018; Zatkova et al., 
2018a) and nucleus size (Hara and Merten, 2015; Kim et al., 2015), providing important 
information about cellular function, activity and health of a cell. Also, the use of cell culture 
contributes to the reduction of experimental animals needed. 
 
 
3.1. Characterization of Be(2)-M17, H32, and N2a cells 
As a first step, the expression profile of several factors of interest was assessed in Be(2)-
M17, H32 and N2a cells (see table 8) by means of qPCR analysis. The expression of both 
the OTR and the CRFR2 was essential for the reproducibility of the data obtained from the 
in vivo experiments described above. All cell lines express the OTR and the CRFR2, 
whereas only Be(2)-M17 cells express the CRF-BP, the CRFR1 was expressed by neither 
of the cell lines. The expression of a ligand of the CRFR2, UCN has only be determined in 
Be(2)M17 cells. The transcription factors MEF2A and MEF2B are present in all cell lines, 
N2a cells lack the MEF2C isoform. H32 cells express the AVP receptor 1a and lack the 
AVP receptor 1b, Be(2)-M17 and N2a express the 1b, but not 1a subform. The MAPK 
signaling kinase ERK5, which is one potential upstream kinase of MEF2, is expressed by 
all cell lines used here. 
 
Table 8. Characterization of the expression profile in Be(2)-M17, H32 and N2a cells via qPCR analysis. 
+, ++, +++ indicates expression intensity, n.d. = not determined. 
 H32 Be(2)-M17 N2a 
CRFR1 - - n.d. 
CRFR2 + + +++ 
CRF n.d. + + 
CRF-BP - + - 
UCN n.d. + n.d. 
OTR + + +++ 
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3.2. Chronic oxytocin induces neurite retraction 
Previous studies have shed light on OT-induced morphological changes in neurites. 
However, the effect is not only time-, dose- and treatment dependent but also varies in 
different cell types (Lestanova et al., 2016b; Lestanova et al., 2017; Meyer et al., 2018; 
Zatkova et al., 2018a). In the murine N2a cell line, chronic treatment with OT for 10 h at a 
concentration of 100 nM induced neurite retraction. The mean neurite length decreased 
from 85.7 µm in VEH treated cells to 70.0 µm (Fig. 30A and B). Unlike in rat H32 cells 
(Meyer et al., 2018), this effect was exclusively mediated by OT, no effect of TGOT (88.5 
µm) or AVP (87.0 µm) appeared. This indicates that a combined effect of the OTR and AVP 
receptor results in morphological alterations, which is achieved by the promiscuous binding 
of OT to both receptor types. 
 
 
Figure 30. OT-induced morphological changes in murine N2a cells. 
(A) Mean neurite length in murine N2a cells decreased after 10 h of OT treatment. TGOT and AVP stimulations 
had no effect on mean neurite length. One way ANOVA on Ranks, H = 33.809 with 3 degrees of freedom. 
Dunn’s Method * p < 0.001 100 nM OT vs VEH; n-number: VEH = 585, OT = 199, TGOT = 200, AVP = 200. 
AVPR1a + - - 
AVPR1b - + + 
MEF2A + + +++ 
MEF2B + ++ + 
MEF2C (+) (+)? - 
MEF2D ++ ++ n.d. 
ERK5 ++ ++ ++ 
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(B) Representative images of VEH and OT treated cells (unstained). Pictures were taken with a fluorescent cell 
imager (ZOE™, Bio-Rad, Munich, Germany). 
 
 
3.3. CRISPR-mediated knockout of the oxytocin receptor impairs MAPK signaling and 
affects neuronal morphology 
The establishment of the CRISPR-Cas9 system in vitro was another important part of the 
thesis presented here. For the generation of OTR KO cells, a plasmid-mediated approach 
was conducted. After transfection with Oxytocin-R Double Nickase Plasmids (h, sc-400641-
NIC, Santa Cruz Biotechnology, USA) and antibiotic pre-selection with puromycin, Be(2)-
M17 cells were isolated at a single-cell level and grown back to full confluence. Expression 
of a GFP control gene on the plasmid allowed immediate visual confirmation of transfection 
(Fig. 31A). After single-cell isolation, cells were monitored daily for several weeks for cell 
division and shape/size of the cells, which indicates their health status (Fig. 31B). 
 
A       B 
 
Figure 31. CRISPR transfection. 
(A) Representative image of Be(2)-M17 cells after transfection with Oxytocin-R Double Nickase Plasmids (h, 
sc-400641-NIC, Santa Cruz Biotechnology, Dallas, USA). Visual confirmation of transfection efficiency was 
enabled by the expression of a GFP control protein (green). (B) Successfully isolated BeJ(1) cell after single-
cell isolation and first cell division. 
 
 
Approximately 10 single-cells were re-cultured after single-cell isolation and analyzed by 
means of western blot, qPCR, PCR and Sanger Sequencing. In figure 32, the representative 
analysis of one newly obtained OTR KO cell line is depicted. This cell line was named 
BeJ(1), all further experiments were performed using this cell line. 
PCR analysis with primers flanking the CRISPR cutting sites revealed a disruption of the 
Otr gene in BeJ(1) cells, as the expected PCR product with ~ 550 bp could not be amplified 
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(Otr-/-). In contrast, amplification of the Otr product in wildtype Be(2)-M17 (Otr+/+) cells 
carrying the intact Otr was possible (Fig. 32A). On the protein level, western blot analysis 
using the anti-OTR antibody provided by Abcam substantiated the previous PCR results 
(Fig. 32B). No OTR protein band was detectable in the KO cell line compared to wildtype 
cells (expected band height ~ 45 kDa). For the final confirmation of the Otr-/- genotype, 
Sanger Sequencing was performed at Macrogen with both bands obtained from PCR 
amplification (Fig. 32A). Sequence alignment using Serial Cloner software revealed 100 % 
conformity between the Otr whole gene sequence obtained from whole-genome 
sequencing (StarSEQ, Mainz, Germany) and the Otr+/+ band (Fig. 32C). Alignment with the 
lower band from both cell types (Fig. 32A) showed no conformity with the Otr whole gene 
sequence, indicating an unspecific PCR product (data not shown). 
For the generation of a second KO cell line, the Alt-R® CRISPR-Cas9 system (IDT, 
Germany) was used. The transcription factor MEF2A was knocked out in H32 cells, in order 
to gain more insight into the functional relevance of MEF2A for cellular signaling and 
morphology. Here, single-cell isolation was performed using FACS. Transfected cells 
containing the fluorescently labeled tracrRNA ATTO 550 were sorted individually into single 
wells of a 96-well plate. Untransfected cells served as negative control for gating during 
FACS analysis. After re-culturing, all single-cells were so far analyzed by means of western 
blot using the Acris MEF2A antibody (see method section table 10). Figure 32D represents 
protein levels of a successful KO (Mef2a-/-) compared to wildtype H32 cells (Mef2a+/+). No 
protein expression was detectable in Mef2a-/- cells, however further analysis on mRNA level 
as well as Sanger Sequencing are necessary. Once validated, the newly created cell line 
will serve as cellular model to study MEF2A-related effects in future studies. 
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Figure 32. Sequencing and western blot analysis of BeJ(1) cells and H32 Mef2a-/- cells compared to 
respective wildtype cells. 
(A) Representative image of PCR analysis of the Otr gene. CRISPR-mediated KO of the Otr gene leads to the 
loss of the respective band in BeJ(1) cells compared to Be(2) cells. (B) Representative image of western blot 
analysis of OTR expression in wildtype and KO cells. BeJ(1) KO cells lack the OTR band at 55 kDa compared 
to Be(2)-M17 wildtype cells. The OTR [EPR12789] rabbit antibody provided by Abcam (Cambridge, UK) was 
used. (C) Sanger Sequencing analysis of the purified Otr+/+ band, obtained by PCR, confirmed the loss of the 
corresponding gene fragment containing the CRISPR cutting sites in BeJ(1) cells. These data confirmed the 
successful KO. (D) Representative image of western blot analysis of MEF2A protein expression in H32 wildtype 
and KO cells. MEF2A KO cells lack the MEF2A band at 50 kDa compared to H32 wildtype cells. The anti-MEF2A 
rabbit (AP06372PU-N) antibody provided from Acris (Distributor Germany: Acris; Manufacturer: OriGene 
Technologies, Rockville, USA) was used. 
 
 
Unlike N2a cells, the human Be(2)-M17 cell line and consequently also the BeJ(1) cells are 
undifferentiated neurons. To enable an analysis of morphology in Be(2)-M17 and BeJ(1) 
cells, a differentiation protocol of 5 days with either forskolin and retinoic acid, or dbcAMP 
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was performed, resulting in the formation of distinct, measurable neurites (Fig. 33). 
Differentiation protocols significantly increased neurite length in these cells. 
 
 
 
Figure 33. Differentiation of Be(2)-M17 cells. 
Representative image of differentiated Be(2)-M17 cells. Differentiation was induced by treatment with forskolin 
and retinoic acid. Cellular membranes were stained with Green CellMask (Thermo Fisher Scientific, Waltham, 
USA) and nuclei were stained with Hoechst 33342 (Thermo Fisher Scientific, Waltham, USA). 
 
 
Comparative signaling studies in Be(2)-M17 and BeJ(1) cells revealed the impact of the 
loss of the OTR. Firstly, the impact of OT treatment on neuronal morphology was diminished 
(Fig. 34A) and MAPK and MEF2 signaling were impaired (Fig. 34B). OT caused neurite 
retraction in Be(2)-M17 cells from 57.9 µm (± 1.9) to 49.5 µm (± 1.4), whereas BeJ(1) cells 
retained a length between 52.5 µm (± 2.2) and 56.3 µm (± 2.5, Fig. 34A). In the same 
passage of BeJ(1) cells, OT-induced MAPK signaling, represented by ERK1/2 
phosphorylation, remained unchanged (fold change of 1.1 ± 0.2 and 1.1 ± 0.3 compared to 
VEH). Plasmid-driven OTR overexpression in BeJ(1) cells restored OT-induced ERK1 
phosphorylation (fold change of 1.3 ± 0.3 compared to VEH), however, ERK2 
phosphorylation levels were still unaltered (fold change 1.1 ± 0.1, Fig. 34B). This lack of 
ERK2 phosphorylation is likely to be caused by suboptimal transfection efficiency, and 
would reach significance once ~100% cells express the OTR construct. Due to the minor, 
but significant, impact on ERK1 phosphorylation, MEF2A S408 phosphorylation levels were 
assessed. BeJ(1) cells transfected with the empty vector displayed no changes in MEF2A 
phosphorylation at S408, OTR overexpression and the subsequent activation of ERK1 led 
to an increase in MEF2A S408 protein phosphorylation (fold change 1.3 ± 0.1, Fig. 34C). 
However, as expected, overall phosphorylation levels of pMEF2A S408 were relatively low 
in BeJ(1) cells (Fig. 34D). 
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Figure 34. Effects of OT treatment on morphology and MAPK signaling in BeJ(1) cells. 
(A) Mean neurite length in human Be(2)-M17 decreased after 24 h of OT treatment (100 nM). Rank Sum Test, 
Mann-Whitney U Statistic = 9243.500, * p = 0.002; n-number: VEH = 135, OT = 173. OT had no effect on 
neuronal morphology in BeJ(1) cells. Rank Sum Test, Mann-Whitney U Statistic = 8498.500; n-number: VEH = 
134, OT = 136. Data shown as mean +SEM. (B) Analysis of ERK1/2 protein phosphorylation after VEH and OT 
treatment in BeJ(1) cells. Cells were either pretreated with an empty control vector or an OTR overexpression 
vector. Data shown as mean fold change compared to VEH +SEM. pERK1 (empty vector): t = -0.307 with 4 
degrees of freedom, one-tailed p-value = 0.387; n-number: VEH = 3, OT = 3. pERK1 (OTR vector): t = -1.772 
with 4 degrees of freedom, # one-tailed p-value = 0.0756; n-number: VEH = 3, OT = 3. pERK2 (empty vector): 
t = -0.233 with 4 degrees of freedom, one-tailed p-value = 0.414; n-number: VEH = 3, OT = 3. pERK2 (OTR 
vector): t = -0.884 with 4 degrees of freedom, one-tailed p-value = 0.213; n-number: VEH = 3, OT = 3. (C) 
Analysis of MEF2A S408 protein phosphorylation after VEH and OT treatment in BeJ(1) cells. Cells were either 
pretreated with an empty control vector or an OTR overexpression vector. Data shown as mean fold change 
compared to VEH +SEM. Empty vector: t = 0.397 with 4 degrees of freedom, one-tailed p-value = 0.356; n-
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number: VEH = 3, OT = 3. OTR vector: t = -2.557 with 4 degrees of freedom, * one-tailed p-value = 0.0314; n-
number: VEH = 3, OT = 3. (D) Representative western blot images of pERK1/2 and pMEF2A S408 antibody 
staining. 
 
 
3.4. Optimizing the in vitro model for oxytocin receptor signaling with cholesterol 
The cholesterol content of cell membranes has profound effects on signal transduction and 
functional activity of the OTR (for detailed references see Introduction part 2.4.). In order to 
create a solid cellular model of the intracellular OTR pathway with reproducible outcomes 
my aim was to optimize the cellular machinery by cholesterol enrichment. Cholesterol is 
typically not a supplement in cell culture medium, so all cell line based models suffer from 
those artificial conditions. Therefore, Be(2)-M17 cells were enriched with cholesterol as 
described in the methods section and MAPK signaling, represented by ERK1/2 
phosphorylation levels, was assessed. To exclude a basal impact of higher cholesterol 
contents in the membrane on signaling, pERK1/2 levels were measured in untreated (0 or 
VEH) and cholesterol enriched (+ or +chol) cells. Without prior OT stimulation, ERK1/2 
phosphorylation levels remained unchanged in both untreated and enriched cells (fold 
change pERK1: cytoplasm 0.7 ± 0.1, nucleus 0.7 ± 0.2; pERK2: cytoplasm 0.7 ± 0.1, 
nucleus 0.8 ± 0.2, Fig. 35A and B). Cytoplasmic and nuclear proteins were analyzed 
separately, in order to detect nuclear translocation of either pERK1 or pERK2. However, 
nuclear translocation was also unaffected by cholesterol enrichment (Fig. 35A and B). 
 
Figure 35. Western blot analysis of cholesterol effects on ERK1/2 phosphorylation in Be(2)-M17 cells. 
To study the effects of OT treatment on MAPK signaling of cells enriched with cholesterol, the basal effect of 
cholesterol enrichment was assessed. Cholesterol enrichment had no statistically significant effects on ERK1/2 
phosphorylation in Be(2)-M17 cells. Both protein samples from cytoplasmic and nuclear fractions were analyzed. 
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Data shown as mean fold changes (+SEM) compared to respective VEH groups. (A) Cytoplasm: pERK1 vs 
pERK1 + chol. t = 1.865 with 13 degrees of freedom, two-tailed p-value = 0.0849; n-number: VEH = 8, + chol. 
= 7. pERK2 vs pERK2 + chol. t = 1.855 with 14 degrees of freedom, two-tailed p-value = 0.0848; n-number:  
VEH/+ chol. = 8. Nucleus: pERK1 vs pERK1 + chol. t = 1.335 with 8 degrees of freedom, two-tailed p-value = 
0.218; n-number: VEH/+ chol. = 5. pERK2 vs pERK2 + chol. t = 1.111 with 8 degrees of freedom, two-tailed p-
value = 0.299; n-number: VEH/+ chol. = 5. (B) Representative image of pERK1/2 western blot analysis. 0 
represents in blot pictures no cholesterol treatment, + represents cholesterol treatment. 
 
 
As the increased membrane content of cholesterol had no significant effects on ERK1/2 
protein phosphorylation, the next step was to assess the effect of OT treatment on ERK1/2 
phosphorylation. Two concentrations of OT were used (10 nM and 100 nM) for 5, 10 and 
20 min after enrichment with a cholesterol-MßCD solution. Cytoplasmic and nuclear 
proteins were assessed separately, as activated (phosphorylated) ERK translocates to the 
nucleus. As a control, all OT stimulations were also conducted without cholesterol 
enrichment. The lower concentration of OT (10 nM) had no time-dependent impact on 
ERK1/2 phosphorylation, neither in the cytoplasmic nor in the nuclear fraction (Fig. 36A and 
B, Table 9). However, there was a significant effect of cholesterol enrichment on pERK2 
expression in the cytoplasm (Fig. 36A, table 9). In the nucleus, both pERK1 and pERK2 
were altered by cholesterol pre-treatment (Fig. 36B, table 9). Despite some exceptions, the 
overall impact of cholesterol points towards a reduction in ERK1/2 phosphorylation induced 
by cholesterol treatment. Stimulations with a higher dose of OT (100 nM) had no significant 
time-dependent effects (Fig. 36C and D, table 9). Also, the stabilization of the OTR with 
cholesterol pre-treatment was not able to increase ERK1/2 phosphorylation levels 
significantly in a two way ANOVA analysis (Fig. 36C and D, table 9). However, the 
expression patterns of pERK1/2 after cholesterol enrichment displayed an increase in 
phosphorylation compared to non-enriched cells, pointing towards positive effects of 
cholesterol enrichment on MAPK signaling (Fig. 36C and D). 
 
Table 9. Summary of effects of cholesterol enrichment and OT stimulation on pERK1/2 in Be(2)-M17 
cells. 
Statistical significant differences are indicated with check marks. For statistical details see legend (Fig. 36). 
 
pERK1 pERK2 Effect of:
- - Time
-  Cholesterol treatment
- - Time
  Cholesterol treatment
- - Time
- - Cholesterol treatment
- - Time
- - Cholesterol treatment
Cytoplasma
Nucleus
Cytoplasma
Nucleus
10 nM
100 nM
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Figure 36. Western blot analysis of cholesterol effects on OT-induced pERK1/2 expression in Be(2)-M17 
cells. 
Effects of cholesterol on the impact of OT treatment on ERK1/2 phosphorylation over a time course of 20 min. 
Data are shown as fold change (+SEM) compared to respective VEH set to 1. 0 represents in blot pictures no 
cholesterol treatment, + represents cholesterol treatment. n-number per time point was 2, overall n-number per 
+ chol and- chol was 6. 
(A) Cytoplasm [10 nM OT]: pERK1, no time dependent effect, two way ANOVA F(2,11) = 0.509, p = 0.625. No 
effect of cholesterol treatment, two way ANOVA F(1,11) = 5.253, p = 0.062. pERK2, No time dependent effect, 
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two way ANOVA F(2,11) = 1.251, p = 0.351. Effect of cholesterol treatment, two way ANOVA F(1,11) = 18.081, p = 
0.005, Holm-Sidak post hoc test, * p < 0.05 - chol vs + chol. (B) Nucleus [10 nM]: pERK1, no time dependent 
effect, two way ANOVA F(2,11) = 1.225, p = 0.358. Effect of cholesterol treatment, two way ANOVA F(1,11) = 
20.794, p = 0.004, Holm-Sidak post hoc test, * p < 0.05 - chol vs + chol. pERK2, no time dependent effect, two 
way ANOVA F(2,11) = 1.452, p = 0.306. Effect of cholesterol treatment, two way ANOVA F(3,13) = 17.919, p = 
0.005, Holm-Sidak post hoc test, * p < 0.05 - chol vs + chol. (C) Cytoplasm [100 nM]: pERK1, no time dependent 
effect, two way ANOVA F(2,11) = 0.00828, p = 0.992. No effect of cholesterol treatment, two way ANOVA F(1,11) 
= 1.413, p = 0.279. pERK2, no time dependent effect, two way ANOVA F(2,11) = 0.108, p = 0.899. No effect of 
cholesterol treatment, two way ANOVA F(1,11) = 0.209, p = 0.663. (D) Nucleus [100 nM]: pERK1, no time 
dependent effect, two way ANOVA F(2,11) = 0.0836, p = 0.921. No effect of cholesterol treatment, two way 
ANOVA F(1,11) = 0.293, p = 0.608. pERK2, no time dependent effect, two way ANOVA F(2,11) = 0.244, p = 0.791. 
No effect of cholesterol treatment, two way ANOVA F(1,11) = 0.643, p = 0.453. 
 
 
Evidence for the success and efficiency of cholesterol enrichment was provided by Filipin 
III staining. Filipin III specifically binds to cholesterol in membranes and can be visualized 
via blue fluorescence. VEH treated cells displayed moderate intensities (Fig. 37A) in 
comparison to cells after 30 min of cholesterol depletion (Fig. 37B). Both 15 min and 30 min 
of enrichment clearly enhanced the cholesterol content in the treated cells as shown by 
increased fluorescence (Fig. 37C and D), confirming the efficiency of the protocol used for 
enrichment. 
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Figure 37. Representative fluorescent microscopic images of Be(2)-M17 cells with Filipin III staining. 
(A) Cells after 30 min of incubation with MßCD. (B) Cells after 15 min of incubation with cholesterol-MßCD. (C) 
Cells after 30 min of incubation with cholesterol-MßCD (D). Images were taken at the SP8 Leica confocal 
microscope with a x20 objective, Filipin III was visualized under DAPI filter. 
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Parts of the Discussion have been taken and adapted from the following publication: 
Chronic oxytocin signaling reveals alternative splice variant of CRFR2 as biomarker 
for anxiety (in preparation). 
Julia Winter1, Magdalena Meyer1, Ilona Berger2, Sebastian Peters3, Melanie Royer1, Julia 
Kunze4, Stefan O. Reber4, Kerstin Kuffner5, Anna K. Schmidtner1, Anna Bludau1, Marta 
Bianchi1, Simone Stang1, Oliver J. Bosch1, Erwin van den Burg6, #, Inga D. Neumann1, 7, *, #, 
and Benjamin Jurek1, #, * 
 
1Department of Behavioural and Molecular Neurobiology, Institute of Zoology, University of Regensburg, 
Regensburg, Germany; ²Technische Universität Dresden, University Hospital, Department of Internal Medicine 
III, Dresden, Germany; 3Department of Neurology, University Hospital Regensburg, Regensburg, Germany; 
4Laboratory for Molecular Psychosomatics, Clinic for Psychosomatic Medicine and Psychotherapy, University 
Ulm, Ulm, Germany; 5Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg; 
6Centre de neurosciences psychiatriques, Lausanne, Switzerland; 7lead contact, *corresponding author, #these 
authors contributed equally 
 
Contributions as following: 
Conceptualization, B.J., S.P., E.H.vdB., and I.D.N.; Methodology, J.W., M.M., I.B., B.J.; Validation, J.W., M.M., 
I.B., K.K., M.B., M.R., A.B., Investigation, J.W., M.M., I.B., S.P., M.R., J.K., K.K., O.J.B, A.B., M.B., A.K.S.; 
Writing – Original Draft, J.W. and B.J.; Writing – Review & Editing, S.P., S.R., O.J.B., E.H.vdB., I.D.N., B.J.; 
Funding Acquisition, I.D.N. and B.J.; Resources, I.D.N; Supervision, B.J., S.P., E.H.vdB., and I.D.N. 
 
 
Data from this publication will be discussed in this thesis, however, as some of the 
experiments conducted have not been performed by myself, they are not part of 
the Results section of this thesis, indicated as Winter et al, in preparation. 
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Discussion 
 
 
In this thesis, the molecular mechanism underlying the anxiogenic phenotype resulting from 
chronic OT delivery was assessed. With numerous clinical and preclinical studies on OT as 
a potential treatment option for psychiatric disorders like ASD (Guastella and Hickie, 2016; 
Parker et al., 2017), schizophrenia (Feifel et al., 2010; Macdonald and Feifel, 2012), 
depression (Domes et al., 2016), and anxiety disorders (Neumann and Slattery, 2016), 
fundamental knowledge on OT’s mode of action and in particular on long-term effects 
remains relatively sparse (reviewed in(Jurek and Neumann, 2018). Here, chronic OT 
treatment for 14 days increased anxiety in male and female rats in a dose-dependent 
manner. When compared to an anxiolytic bolus of acute OT, substantial differences were 
discovered with regard to activation of intracellular signaling cascades and target gene 
expression, specifically the transcription factor MEF2 and alternative splicing of the 
CRFR2α. MEF2A-mediated alternative splicing increased the cytoplasmic, soluble 
sCRFR2α variant shifting the ratio between mCRFR2α and sCRFR2α towards sCRFR2α in 
the PVN and even led to a release into the CSF, ultimately increasing anxiety-like behavior. 
 
 
1. The two faces of oxytocin in anxiety – effects of chronic vs acute oxytocin 
 
Acute and short term applications of OT have well-known positive effects in rodents and 
humans. Infusions of synthetic OT into the lateral ventricle, PVN, hippocampus, septum, 
amygdala, as well as intranasal delivery revealed improved anxiety, sociability, or stress 
coping (Jurek and Neumann, 2018; Neumann and Landgraf, 2012)and references therein). 
The PVN was confirmed as the region of action of OT-mediated anxiolysis (this 
thesis,(Blume et al., 2008; Jurek et al., 2012), as only local-intra PVN infusions were able 
to alter anxiety-like behavior in contrast to i.c.v. infusions. To date, only very few studies 
have addressed the behavioral and molecular effects of chronic OT (Calcagnoli et al., 2014; 
Du et al., 2017; Havranek et al., 2015; Peters et al., 2014; Slattery and Neumann, 2010; 
Windle et al., 2004; Windle et al., 1997). In the present thesis, I found a transient, dose-
dependent anxiogenic effect of i.c.v. chronic OT treatment in male and female rats and 
investigated the underlying molecular mechanism. Interestingly, the anxiogenic effect 
depended on a mild stressor 24 h before the LDB test, corroborating previous findings that 
OT requires a second stimulus like stress to be effective (Blume et al., 2008; Jurek and 
Neumann, 2018; Jurek et al., 2015). This accounts not only for rats but was also recently 
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shown in mandarin voles, where a dose of i.c.v. chronic OT (10 ng/h) had no effect on 
anxiety-like behavior. Yet, a mechanism in mandarin voles that is distinct from rats has to 
be considered (Du et al., 2017). Chronic OT caused a sexual dimorphic phenotype, as 
female rats display increased anxiety already after the low dose of OT (1 ng/h) and appear 
to be more sensitive to chronic treatment than males. Although the effect in the high dose 
ceased to reach significance, this lack of effect has to be taken with caution since the 
experiment was statistically underpowered. As the level of anxiety also tended to increase 
in the high dose group, it is possible that it might reach significance when the experiment is 
repeated. Sex differences with regard to OT treatment have been reported previously. OT 
has anxiolytic properties in males and more prosocial effects in females (Li et al., 2016). 
Therefore, the underlying molecular mechanism of chronic OT-induced behavioral changes 
in females represents a fundamental research question worth investigating in further 
studies. 
In males, an intrinsic brain mechanism, rather than a peripheral stress response seems to 
be responsible for the anxious phenotype, as plasma corticosterone and ACTH levels were 
not changed (Winter et al., in preparation). Chronic activation of the HPA axis can lead to 
increased anxiety-like behavior in rats (Reber and Neumann, 2008), however, I found no 
evidence for this mechanism in my study. In fact, there was no peripheral parameter altered 
after 14 days of chronic i.c.v. OT, although the exogenous OT we infused could be detected 
in the plasma (described in Master thesis Serena Gusmerini 2015). 
OT has a half-life of 3 to 6 min in plasma (Rydén and Sjöholm, 1969) and is degraded 20 
min after i.c.v. application in CSF (Mens et al., 1983), the activated OTR is recycled to the 
cell surface within about 4 hours (Conti et al., 2009). Nevertheless, the anxiolytic effect of 
intra-PVN infusions vanished after 3 hours after local infusions. A recovery or wash-out 
period of 5 days after chronic infusions also restored anxiety levels back to basal, confirming 
a reversible and slow onset molecular mechanism within the brain. The mechanism behind 
does not consist of altered OTR expression or binding in the PVN, as both parameters were 
not affected by chronic OT treatment (Winter et al., in preparation). In addition to the PVN, 
the septum potentially contributes to the observed phenotype, as both mCrfr2α and sCrfr2α 
mRNA levels were affected by chronic OT. No effects on any parameter measured were 
detected in other stress/OT-related brain regions, such as the hippocampus or prefrontal 
cortex, though, highlighting the important role of the hypothalamic PVN as a central 
regulator of the OT system and anxiety-like behavior. 
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2. MAPK and MEF2 signaling induced by chronic oxytocin 
 
Parallel to intracellular signaling induced by acute OT administration (this study and(Blume 
et al., 2008; Jurek et al., 2015; Jurek et al., 2012), chronic OT also activated the MAPK 
pathway, represented by phosphorylation of MEK1/2, ERK1/2, and further downstream the 
transcription factors MEF2A, MEF2C and CREB. As CREB was equally activated by the 
low and the high dose of chronic OT, an exclusive involvement in the differential anxiogenic 
effect of the high dose can be excluded. However, MEF2A and MEF2C are known to be 
part of a larger transcriptional complex, including CREB and its cofactors CRTC, and each 
factor is related to OT signaling (Devost et al., 2008; Jurek et al., 2015; Meyer et al., 2018; 
Tomizawa et al., 2003). Here, the low and the high dose of chronic OT caused a differential 
activation of MEF2A and MEF2C, as MEF2C DNA binding activity was only increased by 
the low dose of chronic OT. Since no behavioral parameters were changed in the low dose 
OT group, MEF2C activity seems to be irrelevant for the anxiogenic effect of OT. 
DNA binding is a feasible parameter to assess activity of a target transcription factor, but, 
more importantly, the downstream inhibitory or activating nature has to be determined. The 
three phosphorylation sites in MEF2A (S408, Thr312, Thr319) directed the factor towards 
transcriptional activation, especially in the high dose OT group, where S408 
dephosphorylation drives gene transcription. Phosphorylation of MEF2A at S408 is known 
to inhibit transcription, potentially influenced by cyclin-dependent kinase 5 (Gong et al., 
2003; Shalizi et al., 2006). MEF2A-induced gene transcription via S408 was exclusive for 
the high dose OT group, providing a solid link between the phosphorylation status of MEF2A 
and anxiety-like behavior. Upstream factors regulating the phosphorylation status, in 
addition to MEK1/2-ERK1/2, might include ERK5 (kinase activity,(Devost et al., 2008) and 
calcineurin (phosphatase activity,(Lynch et al., 2005; Mao and Wiedmann, 1999). ERK1/2 
and ERK5 contain several similarities with regard to signaling, however, ERK5 might exhibit 
differential effects on MEF2 activation by the phosphorylation of distinct amino acid residues 
of different isoforms (Nishimoto and Nishida, 2006). Also, previous in vitro experiments 
revealed the prominent activation of MEF2C by ERK5 (Kato et al., 1997). However, 
providing definitive evidence for an OT-induced physical binding of those factors was 
beyond the scope of this thesis. To assess the molecular underpinnings of the anxiogenic 
effect of chronic OT it is important to identify the downstream targets of activated MEF2A. 
Among the many possible target genes, the CRFR2 represents a central factor that might 
mediate observed changes in anxiety-like behavior, which I will discuss in more detail 
below. The pathway described, starting from the activated OTR to nuclear MEF2A via the 
MAPK pathway and the transcription of target genes like the CRFR2 might underlie the 
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anxiogenic effect of chronic OT. Yet, the question remains why this only occurs in 
chronically treated rats. What is the difference between an acute bolus of OT, directly 
infused into a brain region like the PVN or i.c.v., and the chronic treatment paradigm that I 
applied over the course of 14 days? One major factor is the availability and activity of 
MEF2A. Only after 14 days of treatment, I could detect an increase in MEF2A total protein 
levels, and this higher amount of MEF2A in the brain showed greater activity. Acute OT 
infusions failed to reach a certain threshold that initiates the transcription, translation, and 
post-translational modification of MEF2A within a certain time frame. If the high level and 
activity of this central factor is missing, OT acts via the TRPV2-Ca2+- PKC- MAPK-, 
CREB/CRTC pathway (Jurek and Neumann, 2018), to orchestrate a relatively rapid 
anxiolytic response. 
In addition to the differences between chronic and acute OT in male rats, the behavioral 
response of female rats that received chronic OT treatment differed slightly from that of 
males, which raises the interesting question whether the underlying molecular pathway is 
also sex-specific. Indeed, DNA binding activity of MEF2A and MEF2C remained at basal 
levels after 14 days of the chronic OT treatment. Consistent with the missing effect on 
MEF2A and MEF2C DNA binding activity, phosphorylation levels at activating or inhibitory 
residues remained unchanged. Although it is beyond the scope of this thesis to investigate 
the alternative pathway responsible for the anxiogenic effect of the low dose of chronic OT 
in female rats, I can exclude the MAPK-MEF2A-centered pathway in the PVN that is 
responsible in male rats. Sex-specific activation of MAPK or equivalent pathways has been 
shown previously in related contexts, e.g. learning and memory formation (Mizuno and 
Giese, 2010), neurite outgrowth (Kumar et al., 2018), as well as anxiety (Jurek et al., 2012) 
and could be involved here as well. Whatever the nature of the alternative pathway in female 
rats is, it is likely to be located within the PVN, as this region is close to the ventricular 
system, expresses OT, OTR, MEF2A/C and CRF receptors, and, when manipulated is 
known to influence anxiety-like behavior (Jurek and Neumann, 2018; Neumann et al., 
2000c; Smith et al., 2016). In fact, other brain regions that have been associated with 
anxiety and fear, like the hippocampus with its high levels of OTR expression (Grinevich et 
al., 2014) displayed no chronic OT-induced alterations of MEF2A or C expression or activity, 
and no changes in CRFR2 expression are therefore to be expected. 
By means of an additional experimental design, I was able to test the permanence of the 
chronic OT-induced effects in males. The osmotic minipumps I implanted have a defined 
pumping rate and reservoir volume, resulting in a clear-cut pumping time, after which the 
pumps stop delivering their content. I utilized this effect to leave the pumps implanted after 
the flow stopped for a “wash-out-period” of 5 days. This resulted in a 14+5 days-time frame 
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from surgery to final behavioral test and tissue collection. Intriguingly, all effects seen on 
day 14, i.e. anxiogenesis, MEF2A activation, or CRFR2α transcription, recovered to basal 
levels, suggesting only transient effects of the neuromodulator OT. 
Taken together, this data obtained from rats treated with chronic OT might explain the 
transient and slow onset characteristics of the anxiogenic effect of chronic OT. Acute OT is 
not enough to alter protein levels and activity of MEF2A, and the downstream transcriptional 
activity of MEF2A, as discussed in the following paragraph, requires additional time to take 
effect. 
 
 
 
3. CRFR2α alternative splicing increases anxiety induced by chronic 
oxytocin 
 
To shed further light on the molecular pathway behind increased anxiety caused by chronic 
OTR activation, potential MEF2A downstream targets were analyzed. In order to do so in 
the most efficient way possible, I pre-selected genes that have been associated with 
anxiety, stress, neuronal morphology, synaptic plasticity, and carry a MEF2 binding 
sequence within their promoters or gene. While the MEF2 binding sequence is non-
selective between the A and C subform of MEF2, I already have proven that MEF2A is the 
main driving force of the anxiogenic effect in the high dose OT group, and so all regulatory 
effects on those genes can be attributed to MEF2A activity. 
A central factor for this thesis is the CRFR2α, that carries multiple MEF2 binding sequences 
in its promoter and throughout the gene, and has been associated with anxiety and stress 
in a multitude of publications (Deussing and Chen, 2018)and references therein). 
The CRFR2α is almost exclusively expressed in the brain (Lovenberg et al., 1995; Van Pett 
et al., 2000), and an alternative splice variant lacking the trans-membrane domain has been 
identified. This shorter sCRFR2α form is unable to incorporate into the cellular membrane; 
instead, it diffuses randomly into the cytoplasm and is released into the extracellular space 
(Chen et al., 2005; Evans and Seasholtz, 2009). With an antibody that detects both the full-
length mCRFR2α and the splice variant sCRFR2α, protein levels in the PVN of rats after 
chronic OT treatment were analyzed. Chronic OT promoted sCRFR2α expression, whereas 
mCRFR2α levels remained unchanged, which resulted in a shift of the sCRFR2 to mCRFR2 
ratio. On mRNA level, even a decrease in mCrfr2α mRNA could be detected, as both the 
full-length receptor and the splice variant derive from the same mRNA. Regulation of full-
length mRNA availability is thought to be one of the functions of alternative splicing of the 
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CRFR2α (Evans and Seasholtz, 2009; Markovic and Grammatopoulos, 2009). Also, mRNA 
processing and alternative splicing are common ways to regulate class B GPCR availability 
and function (Deussing and Chen, 2018; Furness et al., 2012). This might account for the 
effects of chronic OT on alternative splicing as well, as a shifted protein ratio towards 
sCRFR2α promotes the anxious phenotype that was exclusively observed in male rats that 
received the high dose of chronic OT.  
The question how OT induces the process of alternative splicing might conveniently be 
answered already, i.e. by the activity of MEF2A. MEF2A as a transcription factor is not 
intuitively linked to the process of alternative splicing. However, recent findings support the 
hypothesis that transcription and alternative splicing are two processes closely working in 
conjunction and depend on each other. MEF2A is part of a large complex of transcription 
and splicing-regulating factors, such as Brg1/Brm, BAF47, BAF170, BAF155, MyoD, and a 
histone acetyl transferase. These factors contribute to the correct transcription and 
immediate splicing of the transcript (Proudfoot et al., 2002; Zhang et al., 2016). It is therefore 
perfectly feasible to infer a parallel role for MEF2A in the transcription and alternative 
splicing of the CRFR2α gene. This might also explain how the sexual dimorphic anxiety-like 
behavior of chronically treated male rats persists on a molecular level. No changes in the 
mCRFR2α/sCRFR2α ratio could be detected in females and in males treated with acute 
OT, as in both circumstances substantial MEF2A activity was missing. 
To elucidate the so far unknown effects of CRFR2α activity in the PVN on anxiety, I 
conducted behavioral experiments to assess both agonism (SCP) and antagonism (ASV) 
of the CRFR2, and confirmed the anxiolytic properties of the mCRFR2α in the PVN. The 
dosage of ASV was chosen at a concentration that mostly excludes CRFR1 activation 
(Tebbe et al., 2005; Zorrilla et al., 2013) and considered carefully, as contradictory effects 
of ASV in other brain regions that have been reported in literature are mainly due to the use 
of supra-maximal doses (Zorrilla et al., 2013). On the contrary, stimulation of PVN-CRFR2α 
with the specific CRFR2 agonist SCP acted anxiolytic, in favor of my hypothesis. 
I have so far in this discussion assumed that the ratio between the regular mCRFR2α and 
the intra- or extracellular sCRFR2α was the main cause of the chronic OT-induced 
anxiogenesis. However, a second scenario is equally possible, that involves the short splice 
variant as an independent behavioral effector either by intracellular actions or by acting as 
a decoy receptor in the extracellular space. 
The second scenario is supported by the use of locked nucleic ASOs, in more detail 
GapmeRs or TSBs to either increase mCRFR2α or sCRFR2α expression. The elegance of 
this experiment lies in the mechanism to manipulate either variant. While the GapmeRs are 
designed to target the Exon 5-7 boundary, which only exists in the sCRFR2α splice variant, 
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and therefore eliminates all sCRFR2α without alterations of the mCRFR2α expression, the 
TSBs, in turn, prevent the formation of the regular mCrfr2α mRNA, which results in the 
exclusive translation of sCRFR2α. This design allowed me to study the behavioral effects 
of each variant independently. Low levels of sCRFR2α protein expression led to low anxiety 
levels, whereas increased expression of sCRFR2α, in consequence, enhanced anxiety-
related behaviors. This data led me to conclude, with all the scientific rigor and carefulness, 
that the above described scenario of an independent anxiogenic effect of the sCRFR2α 
variant is the most likely hypothesis. 
In addition, high CSF-sCRFR2α levels negatively correlated with anxiety, supporting the 
anxiogenic effect as well as the supposed release into the extracellular space (Chen et al., 
2005; Evans and Seasholtz, 2009). Here, the sCRFR2α is supposedly cleared from the 
parenchyma into the ventricular system and the peripheral circulation to be either degraded 
or taken up. The exact fate, however, is so far subject to speculation. 
Taken these results into account, the extracellular sCRFR2α might serve as a biomarker 
that is easily detectable in various tissues and body fluids (CSF, plasma, urine, saliva; 
personal communication with Dr. Benjamin Jurek) and represents a potential treatment 
target for anxiety disorders. 
A potential treatment option for human anxiety patients includes the use of the above-
described GapmeRs. In vivo application of ASOs is a viable approach for the manipulation 
of mRNA translation, due to their efficacy, stability, and cell penetrating properties , i.e. no 
need for any transfection reagent (Aartsma-Rus and van Ommen, 2007). Additionally, 
changes in mCRFR2α and sCRFR2α expression had no effect on social behavior or general 
arousal, suggesting that the effects might be specific for anxiety-related behaviors. 
The great impact of stress on CRFR2 activity and behavioral outcomes has been addressed 
in the Introduction section of this thesis (also see(Anthony et al., 2014; Issler et al., 2014). 
In addition, stress also induces synthesis of CRFR2 and membrane integration (Reyes et 
al., 2008). The high dose of chronic OT in combination with a mild stressor caused a 
moderate increase in mCRFR2α expression compared to unstressed animals. The 
induction of mCRFR2α expression under chronic OT-stress-conditions could be interpreted 
as a stress-coping and compensatory mechanism of the animal in order to dampen the 
stress experienced. This should not be confused with the overall effect of the chronic OT 
treatment compared to stressed VEH treated animals, which led to increased sCRFR2α 
expression and stable mCRFR2α levels, ultimately resulting in a shifted 
sCRFR2α/mCRFR2α ratio and anxiogenesis. 
When summarized, my data reveal the paramount importance of the cellular localization of 
the CRFR2α, i.e. either membrane-bound (mCRFR2α) or intra/extracellularly (sCRFR2α). 
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Specific detection of the splice variant is enabled by an antibody against the sCRFR2α, 
whose specificity has been tested and published previously (Chen et al., 2005). However, 
antibody specificity and their use in semi-quantitative methods like western blotting or dot 
blots is a recurrent topic in the scientific literature, and has been proposed as one of many 
reasons for the “reproducibility-crisis” in science (Baker, 2015; Bradbury and Pluckthun, 
2015; Simpson and Browning, 2017). In consequence, a detection system that only relies 
on antibody detection can be risky and prone to bias. To test my hypothesis with scrutiny 
and scientific rigor, I developed an antibody-independent method to clearly distinguish 
between membrane-bound mCRFR2α and intracellular sCRFR2α in a live-cell setting. 
I established a CRISPR-based detection system, where I inserted a tag (HiBiT) into the 
extracellular domain of the CRFR2α by means of genome editing. The extracellular domain 
is the part of the protein that is removed by alternative splicing, thereby removing the tag 
from the final protein. The HiBiT-tag itself is visualized by its cognate substrate, the so-
called “LgBiT”, which is simply added to the cell culture medium. Once bound, the HiBiT-
LgBiT-complex produces a fluorescent signal, whose intensity can be recorded from living 
cells. This allows to clearly distinguish between the two receptor variants, independent of 
antibodies. To detect changes in membrane expression of CRFR2α, I mimicked in vivo 
chronic OT treatment in cell culture experiments by stimulating H32 cells for 24 h with 100 
nM OT. Analysis of the HiBiT-labelled membrane-bound receptor confirmed my hypothesis, 
as OT reduced membrane expression of the CRFR2α. 
Furthermore, extracellular release of the splice variant was not only detectable under basal 
conditions, as described by(Chen et al., 2005)in CosM6 cells, but was stimulated by OT in 
cell culture, which supports H32 cells as an ideal model for the analysis of signaling 
cascades activated by chronic OT. Additionally, the cytoplasmic content of sCRFR2α in OT 
stimulated H32 cells was analyzed and revealed an intracellular accumulation of the 
sCRFR2α. In primary hypothalamic neurons a mainly perinuclear distribution along the 
neurites of neurons and glial cells with an accumulation at the end-boutons of neurites 
became visible. Those accumulations at the end-boutons of neurites could facilitate the 
secretion of the sCRFR2α into the extracellular space and CSF. The in vitro effects were 
again limited to chronic OT treatment, acute applications between 10 and 30 min had no 
effect on either mCRFR2α or sCRFR2α protein expression. However, 30 min after the onset 
of OT stimulation, phosphorylation of MEF2A at S408 was decreased. MEF2A as a 
transcription factor undergoes rapid activation, whereas detectable levels of alternative 
splicing apparently require more time. This indicates 30 min as the starting point of chronic 
OT effects in vitro. 
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Once secreted, the sCRFR2α is able to bind its ligand with nanomolar affinity (Chen et al., 
2005) and could act as a ligand decoy receptor to prevent the activation of the anxiolytic 
(PVN)-membrane-bound CRFR2α. A possible future experiment to test this hypothesis 
could involve a co-immunoprecipitation pulldown experiment, to prove physical coupling of 
the sCRFR2α with its ligand, and a reporter-protein being coupled to the mCRFR2α to 
reveal reduced activation by the trapped ligand. 
However, the origin of ligand inputs into the PVN involved in chronic OT-induced anxiety 
remains an open question. Regions of high UCN2 and UCN3 expression include the 
supraoptic nucleus, arcuate nucleus, locus coeruleus, the brain stem, median preoptic area, 
medial amygdala, and the BNST (Deussing and Chen, 2018). Retrograde tracing studies 
would reveal whether it is a rather intrinsic circuit within the PVN or whether innervation 
from distinct brain regions like the amygdala or the BNST plays a role (Bale et al., 2002a). 
In the discussion above I focused on MEF2A and its target CRFR2α as the main factors 
regulating chronic OT-induced anxiogenesis. However, the complexity of the human brain 
is unrivaled in biology, and to assume that only one transcription factor (MEF2A), regulating 
one downstream target (CRFR2α) is sufficient to orchestrate a complex emotional behavior 
such as anxiety would be naïve. However, the complexity of the system only allows to 
investigate a finite set of factors in great detail. Consequently, especially within the time 
frame of a PhD thesis, other factors that might be equally involved can only be discussed 
superficially. 
Two of those candidate factors that are MEF2-dependently regulated within the PVN are 
the transcription factors Pax2 and Pax3. In PVN tissue-lysates of male rats treated with the 
high dose of OT, Pax2 mRNA was increased, whereas Pax3 was decreased. Pax2 is one 
of the earliest Pax genes to be expressed during development and is critically involved in 
the formation of the midbrain-hindbrain boundary, which controls midbrain and cerebellar 
development. Also, it was shown to recruit histone methyltransferase complexes to the 
promoter regions of target genes (Blake and Ziman, 2014). Pax3 mostly acts as a 
transcriptional activator, only rare cases of transcriptional repression have been reported. 
The most common downstream targets of Pax3 include factors like NCAM, MyoD or cMET 
which are involved in cell adhesion, differentiation, proliferation and cell survival (Mayanil et 
al., 2001; Stuart and Gruss, 1996). In summary, additive to the morphological effects of 
chronic OT in vitro that will be discussed in the next chapter, changes in neuronal 
morphology in the brain of rats treated with chronic OT are very likely and are potentially 
mediated via OTR-MEF2-Pax signaling. However, the exact interplay and the role of Pax in 
the OT pathway has to be determined in future studies. 
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Another gene affected by chronic OT was the tyrosine hydroxylase (Th), which suggests a 
potential involvement of chronic OT in depression-like symptoms. As Th is involved in 
dopamine synthesis (Molinoff and Axelrod, 1971) and dysregulations have been shown to 
be associated with depression in humans (Zhu et al., 1999) or depressive-like symptoms in 
rats (Nestler et al., 1990), there might be a yet undetermined effect of chronic OT on the 
dopamine system and subsequently a depression-like phenotype. 
 
Overall, from the in vivo and in vitro results I obtained regarding mCRFR2α and sCRFR2α 
expression, the following conclusions can be drawn: a permanent “overdose” of OT causes 
a switch in intracellular signaling by the activation of MEF2A and the subsequent alternative 
splicing of the CRFR2α. The alternative splice variant sCRFR2α is anxiogenic and can be 
released into the periphery due to its soluble properties (Fig. 38). 
The evolutionary background of such alterations in both intracellular signaling and behavior 
remains an open question. A shifted equilibrium between activation and degradation that 
was also shown in other cases of chronic receptor activation (Zhou et al., 2018) could be 
responsible for the activation of the MEF2A-CRFR2α-pathway by chronic OT treatment. 
However, an escalation of the OT system by the extremely high doses of exogenous OT 
could also be responsible for the negative behavioral effects and the changes in signaling. 
Based on these speculations, the final answer to this question has to be subjected to further 
studies. 
 
 
Figure. 38. Signaling scheme of chronic OT via MEF2A and alternative splicing of the CRFR2α. 
Biorender.com 
                                                                                                                              Discussion 
127 
 
4. Bridging the gap between intracellular genomic effects and behavior: 
oxytocin-induced morphological alterations 
 
Having established the intracellular pathway leading from the activated OTR to nuclear 
MEF2A and stimulated gene transcription/alternative splicing, the question remains how 
those molecular changes translate into subtle shifts in the emotional behavior of an animal. 
In other words, which mechanism transports the OT message from a single neuron to the 
level of conscious behavior? The answer might again lie in the function of MEF2A: MEF2A 
has previously been described as a regulator of excitatory synapse number, neuronal 
plasticity and cellular morphology (Fiore et al., 2009; Flavell et al., 2006; Flavell and 
Greenberg, 2008; Flavell et al., 2008). Dysregulations in connectivity between neurons, 
such as hyperconnectivity cause severe psychiatric disorders like ASD (Tang et al., 2014; 
Zaslavsky et al., 2019). The neuronal connectome depends on the regulation of cellular 
morphology, i.e. neurite retraction and outgrowth, to form new-, or prune redundant synaptic 
connections (Tang et al., 2014). Intriguingly, various studies have shown that OT is involved 
in neurogenesis and neural differentiation both in vivo and in vitro (Jafarzadeh et al., 2014; 
Lestanova et al., 2016b; Leuner et al., 2012; Meyer et al., 2018). Not only neuronal 
morphology, but also glial coverage of neuronal circuits is modulated by OT (Theodosis, 
2002). 
 
 
4.1. Chronic oxytocin induces neurite retraction in vitro in various cell lines 
In our group we have focused on the morphological alterations of neuronal cells that follow 
exposure to OT. OT-induced neurite retraction is not only observable in rat H32 or human 
SH-SY5Y cells but also in murine N2a cells. Using the protocol that was recently established 
in our laboratory (Meyer et al., 2018), I could show that N2a cells displayed similar OT-
induced neurite retraction as H32 cells. OT treated cells had significantly shorter neurites 
compared to cells after VEH, TGOT or AVP treatment. The OTR-specific agonist TGOT as 
well as AVP were used to investigate receptor specificity of the observed phenotype. 
Neurite retraction in N2a cells appears to be not exclusively mediated by the OTR, as TGOT 
failed to induce neurite retraction. A combinatorial effect of OTR and the AVP receptor 1a 
is likely, also due to the missing impact of AVP alone. In H32 cells, not only OT but also 
TGOT and AVP impaired neurite outgrowth, indicating a strong involvement of the OTR and 
a slow onset of AVP-mediated morphological effects (Meyer et al., 2018).This supports a 
differential signaling pathway of neuronal morphology in N2a cells, however, an involvement 
of MEF2 is likely as previous studies confirmed MAPK-MEF2-mediated morphological 
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changes. In more detail, stimulation with β-hydroxy-β-methylbutyrate induces MAPK/ERK-
dependent neurite outgrowth in N2a cells (Salto et al., 2015). Also, KD of the long non-
coding RNA Malat1 promotes neurite outgrowth in N2a cells ERK/MAPK-dependently 
(Chen et al., 2016). However, more detailed analysis of OT-induced signaling in N2a cells 
is required. 
With regard to the in vivo data presented in this thesis, the parallel activation of OTR and 
AVP receptors by chronic OT is very likely. As both receptors exert similar downstream 
effects (Jurek and Neumann, 2018) this is not an issue for the interpretation of the 
behavioral results. 
 
 
4.2. CRISPR-Cas9-mediated gene knockout 
Alongside with extensive knowledge in vivo, the intracellular effects of OTR activation are 
well studied in cell culture (Jurek and Neumann, 2018). The CRISPR-Cas9 system provides 
the perfect tool for the generation of specific KO cell lines. The human neuroblastoma cell 
line Be(2)-M17 which expresses the OTR was used to create a neuronal OTR KO cell line, 
named BeJ(1). In a second approach, the transcription factor MEF2A was knocked out in 
the rat hypothalamic cell line H32. Both cell lines can be employed in a variety of further 
studies, like signaling and morphological studies, as well as for the generation of spheroids 
to assess cellular interactions. During the creation of genetically modified cell lines with 
CRISPR-Cas9, several issues had to be addressed that I will discuss briefly in the following. 
First, the transfection protocol for either vector-based constructs or RNP complexes had to 
be optimized for the corresponding cell line. For Be(2)-M17 and H32 cells, cationic lipid-
mediated delivery yielded the highest transfection rates with great cell survival. Cationic 
lipid delivery also displays a viable method for in vivo delivery of CRISPR-Cas components 
(Zuris et al., 2015) and is equally suitable for vector and RNP-based gene editing (Ewert et 
al., 2010). After the generation of monoclonal cell lines by single-cell isolation, the 
phenotype of the newly created BeJ(1) and H32 MEF2A KO cells was assessed by means 
of western blot. In both cases a clear reduction in antibody signal could be detected in the 
KO cells compared to WT cells. For MEF2A KO cells further analysis is missing and will be 
addressed in a separate project. Positive results for BeJ(1) cells had to be interpreted 
carefully due to the assumed lack of specificity of OTR antibodies (Yoshida et al., 2009). 
However, these results were confirmed with PCR and Sanger sequencing. As the gene 
fragment flanked by the CRISPR cutting sites could not be amplified via PCR for Sanger 
Sequencing, deletion of this part of the OTR gene is granted. The sequencing of the WT 
fragment revealed an intact Otr gene. The second band obtained by PCR was likely due to 
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unspecific primer annealing, as there was no corresponding sequence within the Otr. So far 
no off-target analysis was performed via whole-genome sequencing. Taken together, KO 
cell lines created by means of CRISPR-Cas9 are the perfect control for comparative 
signaling and morphological studies, and further analysis of OT-induced neuronal 
connectivity. 
 
 
4.3. Oxytocin receptor-mediated signaling and neuronal morphology 
Wildtype Be(2)-M17 cell and BeJ(1) KO cells were now used to investigate the link between 
OTR signaling cascades, alternative splicing, morphology and behavior. 
First, loss of the OTR caused impaired MAPK signaling and subsequent MEF2A S408 
phosphorylation. This defect could be restored with transient plasmid-mediated OTR 
expression in BeJ(1) cells, excluding an impact of potential off-target effects. Furthermore, 
BeJ(1) cells lacked the characteristic retraction of neurites upon long-term OT treatment, 
indicating a mainly OTR-mediated morphological effect. These data qualify the Be(2)-M17 
cell line and the corresponding OTR KO line, BeJ(1), for further investigation of the link 
between alternative splicing and morphology. This approach is supported by the known 
importance of splicing factors for the regulation of neuronal morphology (Raj and Blencowe, 
2015). Moreover, in vitro studies on the interaction of OT-induced MEF2 activity, splicing 
factors, alternative splicing, and potential morphological alterations could be improved by 
the use of fluorescently-tagged human induced pluripotent stem cells (hiPSCs), which 
simplify morphological analyses. These cell lines are available in the Allen Cell Catalogue 
(allencell.org) and contain the potential for various applications including CRISPR-Ca9-
mediated genomic manipulations. 
Additionally, BeJ(1) cells can be employed for advanced receptor studies by the introduction 
of modified receptors. The impact of single nucleotide polymorphisms, alternative 
internalization patterns, like β-arrestin independent internalization (Passoni et al., 2016) or 
constitutive receptor activity (Holliday et al., 2007) can be addressed. Especially the 
investigation of internalization could provide more detailed insights into receptor recycling 
dynamics upon chronic OTR stimulation. 
In contrast to the KO of the Otr gene, receptor stability was increased using a model of 
manipulation of cholesterol content in the cell membrane. As already mentioned, cholesterol 
content and receptor location within the membrane play a crucial role in OTR-mediated 
signaling (Gimpl and Fahrenholz, 2000; Klein et al., 1995). Also, membrane cholesterol 
contents are involved in the functional activity of several other GPCRs as shown for the 
galanin receptor (Pang et al., 1999), the µ-opioid receptor (Lagane et al., 2000), and the 
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somatostatin receptor (Pucadyil and Chattopadhyay, 2004). Formation and stabilization of 
lipid rafts and caveolae in the membrane require high levels of cholesterol hence, around 
80-90 % of total cellular cholesterol can be found in the plasma membrane (Prinz, 2002). 
Consequently, depletion of cholesterol destabilizes these structures and impairs receptor-
mediated signal transduction (Simons and Toomre, 2000). The human Be(2)-M17 cell line 
expresses the OTR and MAPK signaling occurs upon OT stimulation (this thesis and(Jurek 
et al., 2015). Here, cholesterol enrichment itself had no effect on MAPK signaling, excluding 
constitutive activity of the OTR (Reversi et al., 2006; Seifert and Wenzel-Seifert, 2002) in 
Be(2)-M17 cells and confirming an exclusive OT effect in the following experiments. 
However, to completely rule out overall cellular effects of cholesterol enrichment, cell 
viability should be addressed in further studies. Stimulations with 100 nM OT caused 
increasingly higher phosphorylation levels for both ERK1 and ERK2 in cholesterol-enriched 
cells. This effect failed to reach significance and requires potentially longer stimulation with 
OT, also at higher concentrations. Possibly, 30 min enrichment with 0.3 mM cholesterol-
MßCD were not sufficient to force enough OTRs into lipid rafts and caveolae (Reversi et al., 
2006) and extended enrichment is required. However, cholesterol was successfully 
introduced into membranes of Be(2)-M17 cells using the described protocol as Filipin III 
staining revealed increased fluorescence in cholesterol treated cells and a reduced signal 
due to cholesterol depletion (Beknke et al., 1984). Furthermore, manipulation of cholesterol 
in membranes with the MßCD method is very well established and has produced reliable 
results in several previous studies (Gimpl et al., 1997; Klein et al., 1995; Reversi et al., 
2006). Due to the changes in membrane fluidity by cholesterol, higher cholesterol levels 
increase the stiffness of the membrane, extension of the enrichment has to be performed 
carefully, as cholesterol concentrations over a threshold value of 60 % has no beneficial 
effects on OTR binding anymore (Gimpl et al., 1997; Gimpl and Fahrenholz, 2000). As 
cholesterol extraction and analysis have been described previously (Bligh and Dyer, 1959; 
Borroni et al., 2007; Gimpl and Fahrenholz, 2000), more profound knowledge on the 
possible impact of cholesterol enrichment and depletion on OTR signaling Be(2)-M17 cells 
could be achieved by analysis of exact cholesterol contents in untreated cells. 
In summary, cell culture systems like the ones presented here, are reliable tools for the 
investigation of OTR-mediated effects on signaling cascades, alternative splicing and 
neuronal morphology. I established an approach for the manipulation of OTR expression 
using CRISPR-Cas9, accompanied by increased receptor stability due to cholesterol 
enrichment. This is the basis for the investigation of the definite connection between chronic 
OT-induced changes in signaling, as well as morphological changes. Future steps might 
include the investigation of OT-induced changes in neuronal morphology in vivo. 
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7. Conclusion 
 
The present study provides insight into the molecular mechanism that causes increased 
anxiety-like behavior following chronic OT treatment. I showed that chronic OT promoted 
alternative splicing of the CRFR2α via activated MAPK pathway and MEF2A signaling, 
which led to a proportional increase of the soluble splice variant sCRFR2α. This shift from 
membrane-associated CRFR2α towards cytoplasmic distribution and extracellular release 
of sCRFR2α underlies the anxiogenic effect of chronic OT, as activity of the regular 
mCRFR2α acted anxiolytic in the PVN. Elevation or reduction of sCRFR2α mRNA levels 
revealed a direct correlation between high sCRFR2α levels in the PVN and increased 
anxiety-like behavior. However, this mechanism seems to be sexually dimorphic as the 
anxiogenic effect of chronic OT in female rats was not mediated by MEF2A activity and the 
subsequent shift in mCRFR2α/sCRFR2α ratio. Unmasking the anxiogenic properties of 
chronic OT required an additional mild stressor that activated the Crfr2 gene. This reflects 
the situation in real life with human patients where stressors are omnipresent, so adverse 
side effects of an otherwise helpful OT treatment have to be considered. However, any 
molecular and behavioral alterations seem to be reversible after termination of the 
treatment, and long-term consequences are not be expected in adult brains and periphery. 
The impact on developing brains in children and juveniles, however, is an important aspect 
requiring further investigation. Furthermore, mechanistic details could be reproduced in the 
hypothalamic rat cell line H32, proving cell culture as a suitable model to study the 
intracellular, molecular mechanism of chronic OTR activation. 
In addition to detrimental behavioral effects and the activation of the alternative splicing 
machinery, chronic OT also induced changes in neuronal morphology. Neurite retraction 
was confirmed in the murine cell line N2a as well as in human Be(2)-M17 cells. The impact 
on the morphology of Be(2)-M17 cells was exclusively OTR-dependent as a CRISPR-
mediated KO abolished neurite retraction. Also, OT-induced MAPK signaling in the OTR 
KO cells BeJ(1) was impaired, whereas enrichment with cholesterol in the membrane had 
beneficial effects on ERK1/2 phosphorylation. I was able to establish the in vitro use of the 
CRISPR-Cas9 system in our laboratory, paving the way for further extensive cellular studies 
including the use of hiPSCs and potentially the cultivation of 3D-organoids. 
The presented results extend the understanding of OT’s molecular downstream signaling 
(Fig. 39) and challenge its status as a treatment option for psychiatric disorders, potentially 
representing a prerequisite for a translation into clinical application. Treatment with chronic 
or repetitive OT requires careful consideration of dosage, treatment duration and sex of the 
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patients. Additionally, the discovery of the anxiogenic splice variant sCRFR2α in this context 
bears promising potential as an alternative marker that might serve as a viable target for 
the anamnesis and treatment of anxiety disorders. 
 
 
 
Figure 39. Signaling scheme of known (bold arrows) and hypothetical (dashed arrows) interactions of 
OTR signaling upon chronic stimulation. 
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Perspectives 
 
The identification of sCRFR2α as a key player in anxiety and its detectability in CSF and 
serum provides a powerful new approach to the diagnosis of psychiatric disorders and could 
be combined with simple detection platforms like CRISPR-based diagnostic. This technique 
is based on the rapid detection of RNA and DNA with attomolar sensitivity and provides a 
portable detection platform (Gootenberg et al., 2017). In addition, to get a more translational 
insight into the brain mechanisms after chronic OT treatment, the use of programmable 
minipumps should be considered, as treatment in humans rather occurs in a repeated than 
a chronic fashion. These data can be compared to the extensive data I obtained with regard 
to the chronic administration of OT. For the medication of human patients suffering from 
anxiety disorders or ASD, knowledge on uncritical dosage and treatment duration is 
indispensable. This knowledge will also help to assess the underlying mechanism in 
animals that are unresponsive to OT, as treatment resilience complicates the successful 
medication of psychiatric disorders. Moreover, as a clear sexual dimorphic effect of 
prolonged OT application became apparent, extended studies on downstream signaling 
cascades in females are required. With regard to ASD, the inclusion of juveniles in the 
paradigm should be considered. Taken together, these approaches will contribute to 
provide more personalized and effective treatment options. 
On a molecular level, the development of an additional CRISPR-based HiBiT system to 
directly detect and trace the splice variant will provide more detailed knowledge on the 
release and expression dynamics of the sCRFR2α. Manipulation of the splice variant within 
OTR Cre mice enables the assessment of further behavioral paradigms, including social 
fear conditioning, and allows the investigation of spatial interactions between the OTR and 
sCRFR2α-positive neurons or astrocytes. 
To fully understand the effects of chronic OT it is crucial to further investigate the interplay 
of the PVN system described here, with other brain regions like the septum. Techniques 
including optogenetic stimulation and retrograde tracing could help to elucidate interactions 
of brain regions involved in the anxiogenic phenotype and determine ligand origin. 
Furthermore, with the great advances in the use of viral approaches in vivo, direct GapmeR-
based manipulation of sCRFR2α expression could be achieved by OTR-cell specific, 
optogenetic activation of GapmeR expression. 
The identification of several factors involved in the anxiogenic phenotype (MEF2A, 
CRFR2α) is the basis for the creation of new disease models, exploiting state-of-the-art 
techniques like CRISPR-Cas9. The establishment of the CRISPR-Cas9 system for the 
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manipulation of the OTR and MEF2A in vitro paved the way for the application in vivo, 
enabling targeted modification in one or more brain regions to finally answer the question 
of the interaction between morphological changes and anxiety-related behavior. 
In summary, the data presented here provide an outline or tentative general strategy on 
how to address temporal and dosage-related issues when studying neuropeptides with 
regard to potential medical use. Addressing these open questions will broaden the 
understanding of how prolonged administration of high doses of OT and in more general 
neuropeptides take effects. 
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